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    1. INTRODUCTION 
1.1 Motivation 
1.1.1 Minor depression in the spectrum of psychiatric disorders 
Depressive disorders belong to the most debilitating psychiatric disorders both for 
patients and for the healthcare system1, 2. As for many psychiatric disorders, the spectrum 
of depressive disorders is broad, starting from few subthreshold symptoms up to a full-
blown major depression with suicidal thoughts or psychotic features3, 4. The prevalence of 
depressive disorders changes with gender, age and somatic status. In particular, 
depression more often affects females1, 5. With aging and accumulation of somatic 
diseases the incidence of minor depression prevails over major depressive disorder6. 
The American Psychiatric Association (APA) proposed a critical threshold of five 
depressive symptoms in order to distinguish between minor and major depressive 
episode3, 4 (Figure 1, 2). 
 
Figure 1 Depressive symptoms according to DSM-IV  
 
1
According to the fourth edition of the Diagnostic and Statistical Manual of mental 
disorders (DSM-IV) minor depressive episode is diagnosed when two to four depressive 
symptoms (including at least one core symptom, see Figure 1) disturb a patient for at least 
two weeks. Exclusion of depression history is required for the diagnosis of minor 
depressive disorder. In DSM-IV minor depressive disorder is listed under a category 
Depressive Disorder Not Otherwise Specified (NOS, code 311)3. 
The DSM-5 does not use the term “minor depression” anymore. A similar condition, 
where only one core symptom - depressed mood - is combined with up to three other 
depressive symptoms,  is placed at the category “Other specified depressive disorders” 
(code 3114).  
According to the 10th edition of the International Classification of Diseases (ICD-10) 
persons suffering from two core symptoms and two additional symptoms should be 
diagnosed with mild depressive episode (F32.0). Those having less than four symptoms 
qualify for F32.8 (Other depressive episodes) or F32.9 (Depressive episode, unspecified). 
The criteria for these categories are vague though. The beta-draft of ICD-11 
(https://icd.who.int/dev11) tends to avoid counting the depressive symptoms focusing more 




Figure 2. Minor depression in the categorization of depressive disorders 
according to international classifications, Diagnostic and Statistical Manual for 
psychiatric disorders (DSM)3, 4 and International Classification of Diseases (ICD)7.  
 
 
Overall classification systems disagree on thresholds and diagnostic criteria for major 
and minor depression. Nevertheless, all of them leave space for a diagnosis of some kind 
of subthreshold depression with different number of symptoms per category. The need for 
such a category is clear due to high prevalence of subthreshold depressive symptoms, 
especially in the elderly population. 
 
 1.1.2 Minor depression is prevalent but unrecognized 
When patients are examined thoroughly by the psychiatrist, it becomes obvious that 
minor depression is not rare. The majority of studies assessing prevalence of minor 
depression show that this condition is very prevalent especially in late life. Nevertheless, 
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the point prevalence ranges widely: from 0 % in community settings8 to 26.5 % in patients 
with mild cognitive impairment9. Likely due to the high variation in the assessment 
methods, the prevalence of minor depression, its’ clinical correlates and the most 
vulnerable groups were never systematically reviewed.  
Insufficient information and inconsistencies in the classification systems reflect lack of 
understanding of the nature of minor depression. It is viewed either as an independent 
depressive disorder or as a prodrome of major depression10. The first view is supported by 
a single episode and relatively low conversion rates11. On the other hand, the conversion 
into major depressive disorder in some patients suggests that minor depression might be a 
first episode in the development of more severe depressive disorder12, 13. Both courses are 
possible and are likely orchestrated by, to date, unknown biological mechanisms. 
Identification of these mechanisms is crucial for understanding the nature and course of 
the disorder.  
Despite two neuroimaging studies investigating cortical thickness14 and volume15 in 
minor depression, pathophysiology of this disorder is largely unexplored. In the course of 
this thesis, prevalence rates and biological correlates were systematically reviewed, and 
blood and imaging biomarkers of minor depression investigated.   
 
1.2 Theoretical background 
1.2.1 Overview of depression hypotheses 
The spectrum of depressive disorders is broad and pathophysiological alterations of 
depression are even broader. The heritability of depression is estimated at 36-37%16. No 
single gene responsible for development of depression was found17. Rather depression is 
viewed as a polygenic disorder, sharing some genes with other psychiatric disorders18 and 
having an "own" group of genes19. 
A large number of involved genes results in a number of altered biochemical pathways. 
Among the most studied ones are serotoninergic20, neurotrophic21 and glial22 hypotheses 
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of depression (Figure 3). These hypotheses are grounded on animal and biomarker 
studies 23-25. Human neuroimaging analyses in patients with major depression revealed 
reductions in gray matter density and cortical thickness (Figures 4, 5), white matter 
lesions26, and alterations in structural and functional connectivity27, 28. The attempts to 
combine several levels of analysis are challenging and, therefore, still rare29, 30. Such 
combinations, however, build a promising link between imaging and biochemical theories. 
 
Figure 3. Overview of depression hypotheses based on the level of analysis. 
  
 
1.2.2 Neurotrophic hypothesis of depressive disorders 
The neurotrophic hypothesis of mood disorders relies on a number of observations 
related to Brain Derived Neurotrophic Factor (BDNF), a protein responsible for synaptic 
plasticity and long-term potentiation. In animal models, increased cortisol levels due to 
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stress lead to reduced BDNF levels in the brain and induced depressive-like behavior in 
rodents31, 32. On the other hand, peripheral BDNF levels were consistently reduced in 
serum of patients with major depression21, 33-36. Together these findings gave rise to the 
neurotrophic hypothesis of depression21. This hypothesis postulates that in mood disorders 
reduced levels of neurotrophic factors due to the chronic stress result in diminished 
neuronal plasticity, loss of neuronal connections and apoptosis21. 
  
1.2.3 Glial hypothesis of depressive disorders 
The glial hypothesis of depressive disorders is originally based on histopathological 
postmortem findings showing reductions in glial cell density or glial cell numbers in the 
subgenual anterior cingulate cortex, the orbitofrontal cortex, and dorsolateral prefrontal 
cortex37, 38.  These reductions were mainly attributed to astrocytes and oligodendrocytes 
and preceded neuronal pathology in depression39. Furthermore, in vivo studies show that a 
marker of glial activation and injury - the calcium-binding protein S100B - is consistently 
elevated in serum and cerebrospinal fluid of patients with acute depression40, 41. At the 
same time a marker of neuronal injury, neuron-specific enolase, remains unchanged in 
patients with major depression41. 
 
1.2.4 Structural neuroimaging changes in major depression 
In vivo human neuroimaging evidence has linked major depressive disorder to white 
matter lesions42 of, presumably, vascular genesis and to alterations in gray matter density 
and cortical thickness.  
Gray matter density is consistently reduced in orbitofrontal and anterior cingulate cortex, 
hippocampus and amygdala across several meta-analytic studies43-47. The map of 
alterations in major depression as compared to healthy controls obtained by the most 
recent meta-analysis is presented in Figure 443. 
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 Figure 4. Map showing alterations (orange – decrease, blue - increase) of gray 
matter density in major depression relative to control subjects, obtained by the 




The cortical thickness has also been measured in a number of studies investigating 
major depression. The evidence was recently summarized by a large scale meta-analysis 
by the ENIGMA consortium48. Its results are depicted in Figure 5. The cortical thickness 
did not correlate with symptom severity48, while hippocampal gray matter density was 
positively related to depression severity at the meta-regression analyses. 
Figure 5. Map of cortical thinning in major depression, obtained by meta-analysis 
of Schmaal et al.48 
 
 
Several neuroimaging findings related subthreshold depression to smaller medial 
prefrontal cortex49 and (manually traced) amygdala50. One study has, surprisingly, shown 
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that gray matter volume in left operculum and superior temporal gyrus, and bilateral 
postcentral gyrus correlated positively with subclinical depressive symptoms (at 
FDR<0.05)51. These studies have diagnosed patients based on self-rating depression 
scales.  Finally, one group selected patients with minor depression using the Structured 
Clinical Interview for DSM-IV (SCID). This group observed cortical thinning in the right 
cingulate cortex14 and a negative association of the normalized prefrontal volume and the 
severity of depression15. This group, however, included only 18 patients and used 1.5 
Tesla MRI-scans in the study. Therefore, their findings still need replication. 
 
 
1.3 Rationale and hypotheses of the empirical studies 
Due to high prevalence of minor depression in late life and absence of any data on 
pathophysiology of this disorder the rationale of the current thesis is to increase interest to 
the problem and understand whether there are any detectable pathophysiological 
alterations underlying this disorder. 
  
1.3.1 Research questions:  
   In this thesis, we focused on the following research questions: 
- What is the prevalence of late life minor depression in different populations? 
- What are the biological correlates of minor depression? 
- Is minor depression sufficiently detected by the medical personnel? 
- Can serum BDNF serve as a biomarker for major depressive disorder? 
- Are serum BDNF, S100B and NSE levels altered in minor depression, similarly to 
major depression? 
- Are there any structural brain alterations in minor depression? 
 
1.3.2 Research hypotheses 
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The systematic review on the prevalence rates and biological correlates of minor 
depression was performed in order to summarize the existing epidemiological data.  
In order to develop hypotheses for the BDNF biomarker study in minor depression we 
performed a series of meta-analyses including studies assessing serum BDNF changes in 
major depression. These meta-analyses were based on the following hypotheses: 
- We expected reduced peripheral BDNF concentrations in acute state of mood 
disorders as compared to healthy controls, and as compared to the euthymic state; 
- Serum BDNF measurements were expected to be more consistent as compared to 
plasma measurements; 
- We expected that serum BDNF concentrations are related to the response to the 
antidepressive treatment in depression; 
- Central BDNF expression in rodents and peripheral BDNF concentrations in both 
rodents and humans were expected to increase in response to electro-convulsive 
treatment. 
 
Based on the biomarker and imaging meta-analytical findings in major depression we 
developed further hypotheses for our studies in minor depression: 
- We expected decreased serum BDNF, increased serum S100B levels and unaltered 
serum NSE levels in minor depression as compared to healthy subjects. 
- In the whole brain analysis, we hypothesized a disease-specific decrease of gray 
matter density in bilateral anterior cingulate cortex (ACC), hippocampus, amygdalae 
and right dorsomedial frontal cortex. 
- In the region of interest (ROI) analysis, we expected decreased gray matter density 
within the meta-analytically-derived mask (the largest cluster: left insula, temporal 
pole, inferior frontal, superior temporal gyrus) and  cortical thinning in bilateral medial 
orbitofrontal cortex, fusiform gyrus, insula, rostral anterior and posterior cingulate 
9
cortex, unilaterally in the left middle temporal, right inferior temporal gyrus and right 
posterior part of  ACC. 
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2. EMPIRICAL STUDIES 
         2.1 The prevalence of minor depression in the late life 
2.2 The Meta-analysis of BDNF changes in mood disorders 
2.3 The Meta-analysis of BDNF changes following ECT in depression 
2.4 Serum markers in minor depression 
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a b s t r a c t
Background: Minor depression (MinD) and mild cognitive impairment (MCI) are common disorders in
late life that often coexist. The aim of the present review is to demonstrate prevalence rates of minor
depression in older patients with and without MCI.
Methods: Electronic database searches were performed through Medline, ISI Web of Knowledge,
Psycinfo, and Cochrane library. Two independent reviewers extracted the original studies based on
inclusion criteria: representative study population aged 55 and older, diagnostics of MinD according to
DSM. Data on prevalence rates, risk factors, comorbidity and health care usage were analyzed.
Results: Point prevalence for MinD is higher in medical settings (median 14.4%) than in the community-
based settings (median 10.4%) and primary care patients (median 7.7%). Although minor depression is
rarely investigated in elderly persons with MCI, nearly 20% of patients with MCI seem to suffer from
MinD. No data was found on the prevalence of MCI in patients with MinD. Risk factors associated with
MinD include female gender, history of cerebrovascular diseases, generalized anxiety disorder, loneliness,
and long-term institutional care.
Limitations: Methodological differences of included studies resulted in a broad range of prevalence rates.
No data is shown regarding the prevalence of MCI in MinD group due to insufficient evidence.
Conclusions: Our review indicates that MinD is frequent in elderly population. MCI among those subjects
has not been sufficiently investigated. Future studies based on clinical structured interviews should be
performed in longitudinal design in order to differentiate late-life depression from progressive MCI or
early manifestation of Alzheimer's disease.
& 2013 Elsevier B.V. All rights reserved.
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1. Introduction
Depression and dementia are among the most common psy-
chiatric disorders in late life (Olivera et al., 2008; Rabins et al.,
1996; Wancata et al., 2000). Due to the growth of the elderly
population these conditions have recently become a focus of
research. Most studies on depressive disorders in the elderly refer
to major depressive disorder (MDD) although minor depression
(MinD) was found to be the most prevalent mental disorder in
primary care settings (Helmchen, 2001).
MinD includes clinically relevant symptoms of MDD without
meeting the full criteria for this disorder. Approximately 1 in 10
patients seen in primary care has symptoms of MinD (Banazak,
2000) and prevalence seems to be highest in late life (Beekman
et al., 1995; Newman, 1989). The prevalence has been estimated to
be between 10% and 20% (Tannock and Katona, 1995). Never-
theless, older adults are significantly less likely than younger
adults to receive specialized mental health care (Unutzer, 2002).
Indeed, recognition of MinD in older adults is difficult due to their
increased tendency to demonstrate alexithymia and somatisation
which may mask depression (Tannock and Katona, 1995; Watts
et al., 2002). Insufficient clinical diagnostics are also observed in
most available studies—only a few of them used structural clinical
interviews and applied a classification according to Diagnostic and
statistical manual of mental disorders (DSM). Patients often fail to
meet criteria for MinD because symptoms are not present for most
of the day, nearly every day. That makes clinical interviews based
on DSM-criteria essential. Clinical diagnostics based solely on self-
administered questionnaires is not sufficient. All these factors
contribute to the underestimation of the disorder by medical staff.
Evidence suggests that patients fulfilling criteria for MinD have
an increased risk of developing MDD (Lyness et al., 2006) or other
adverse outcomes such as substance abuse or dependence
(Lewinsohn et al., 2000). About 25% of patients suffering from
MinD will develop MDD within 2 years (Lyness et al., 1999). Eaton
et al. (1995) regarded MinD as part of the prodromal phase of MDD
and about 13% of MinD patients have attempted suicide at least
once (Angst, 1995). These results show that MinD cannot be
regarded as a “minor” condition at all.
The concept of mild cognitive impairment (MCI) is developed
to describe subjective and neuropsychologically confirmed cogni-
tive deficit in persons whose daily living is not altered. It is usually
subdivided into amnestic (aMCI) and non-amnestic MCI subtypes
(non-aMCI), also with respect to single or multi-domain deficits
(Winblad, 2004). However, depending on the neuropsychological
protocol used, aMCI is frequently discovered as multi-domain MCI
when episodic memory tests are used. To this end, the aging-
associated cognitive decline (AACD) (Levy, 1994) concept was first
introduced to cover a broad range of cognitive deficits and
nowadays is replaced by Petersen's multi-domain MCI concept
(Schönknecht et al., 2005).
MCI is the transitional phase between unimpaired cognition
and dementia and 10–15% of patients progress to dementia per
year compared to 1–2% of healthy controls (Petersen et al., 1999;
Petersen et al., 2001). Population-based studies document that
with respect to different age ranges, 10–25% of the elderly suffer
from MCI (Schönknecht et al., 2005). In general hospitals the
prevalence may increase to about 36% (Bickel et al., 2006).
Compared to the prevalence of dementia it is twice as high.
The common co-existence of depression and MCI in older
persons is likely to increase the rate of adverse outcomes for
physical health, functional status, and mortality and represents the
most compelling reason for decreased quality of life (Bickel et al.,
2006). In particular, in older adults co-existence is associated with
an increased risk of dementia as 20–60% develop Alzheimer's
disease (AD) within a few years after the onset of depression
(Berger et al., 1999; Houde et al., 2008; Li et al., 2001; Modrego
and Ferrandez, 2004; Paterniti et al., 2002; Teng et al., 2007). In
their Italian Longitudinal Study on Aging (ILSA) Solfrizzi et al.
(2007) found a 63.3% prevalence rate of depressive symptoms
among people with MCI. Depressive symptoms included mild
(49.3%) and severe (14.0%) forms. Houde et al. (2008) found a
52% prevalence of depression among the 60 MCI patients in a
clinical sample. Sixty percent of these MCI patients progressed to
AD within a mean period of 4.3 years resulting in an annual
conversion rate of 14%. In another clinical sample Feldman et al.
(2004) reported a 50% prevalence rate of depression in MCI.
Paterniti et al. (2002) found that high baseline levels of depressive
symptoms predicted cognitive decline because MMSE score was
more likely to fall below 26 and to remain below the MMSE score
of those without depressive symptoms. In a study by Starkstein
et al. (2005), prevalence of MinD increased from 21% in the
moderate stage of AD to 45% in the severe stage of AD.
A deep systematic review was published regarding the pre-
valence and risk factors of subthreshold by Meeks et al. (2011).
However, the authors noted that studies assessing more than one
type of subthreshold depression tend to show higher than median
prevalence rates (Meeks et al., 2011). To date, studies on the
co-existence of MinD and MCI are still rare. Depressive patients
have often been excluded from MCI studies and vice versa. In a
population-based epidemiological study by Lyketsos et al. (2002)
20% of the 320 MCI patients exhibited depression. A number of
studies show that about half of the patients with MCI report
depressive symptoms (Feldman et al., 2004; Forsell et al., 2003;
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Houde et al., 2008; Solfrizzi et al., 2007). In contrast, in studies
on MDD in MCI, prevalence rates were consistently low and in
the range of 3.4–11.2% (Forsell et al., 2003; Levy, 1994). Two types
of MinD were hypothesized by Park et al. (2010); MinD as
a subsyndromal stage for recurrent MDD or an independent
subsyndromal disorder in late life. Li et al. (2001) suggest that
early depressive symptoms in patients with MCI may constitute a
preclinical sign of dementia and predict the conversion to AD or
vascular dementia (VaD). The main aim of this review is to
summarize the findings concerning MinD in older patients with
and without MCI and to look for the prevalence rates, factors, and
comorbid disorders associated with them.
2. Methods
2.1. Systematic literature search
Two independent reviewers (NS, MP) performed the literature
search using the electronic databases Medline, ISI Web of Knowl-
edge, Psycinfo, and Cochrane library (last date 15/07/2013)
with the following keywords: minor depression, minor depressive
disorder, subsyndromal depression, subthreshold depression, cog-
nitive impairment, mild cognitive impairment, cognitive impair-
ment no dementia, MCI, and CIND in combination with elderly,
older adults, geriatric, and late life. Searches were categorized by
topic, title, title and abstract, keyword, or text word where
applicable. We identified 2028 potentially relevant articles. All of
them were independently screened by two reviewers (NS, MP)
using title, abstract and—when available—full text to meet the
inclusion criteria (see Fig. 1). References from the original articles
were screened to reveal omitted papers. Whenever there was any
doubt regarding inclusion of the paper a third reviewer (PS) was
consulted. Studies reporting prevalence of other than MinD types
of subsyndromal depression as well as those reporting combined
rates were not included in the review. If two or more studies were
performed on the same cohort of patients one of themwas chosen.
One exception was accepted: The studies by Mechakra-Tahiri et al.
(2009) and Preville et al. (2008) used the same sample but covered
different aspects in the data analysis. Mechakra-Tahiri studied the
point prevalence, whereas Preville concentrated on the 12-month
prevalence and comorbidity. In total, 23 original research publica-
tions were retrieved and included in the review.
2.2. Methodological quality assessment
The quality of included studies was assessed by the adapted
criteria for methodological quality assessment published else-
where (Luppa et al., 2012). Each criterion was rated from 0
to 2 points (see Table 1). Studies scoring 75% or more of the
maximum score (Z14 points) were rated as ‘high quality’, studies
scoring between 50% and 75% (9–13 points) were considered
‘moderate quality’, and studies with lower than 50% (9 points)
were considered ‘low quality’.
2.3. Definition of minor depression (MinD)
According to DSM-IV research criteria (APA, 2000), MinD
requires less than five, but at least two depressive symptoms
during a two-week period with either depressed mood or loss of
interest or pleasure being one of them. A history of MDD excludes
the person from this category. Other studies use terms such as
subsyndromal (Judd et al., 1994) or subthreshold (Heun et al.,
2000) depression. Therefore, at least two depressive symptoms are
decisive. It is necessary to distinguish other forms of depression
(e.g., recurrent brief depression, atypical depression, seasonal
 2028 records are screened 
according to the preset 
inclusion criteria
Records screened 
 1.English language 
 2. Original study 
 3. DSM-III or DSM-IV criteria of MinD 
 4. Elderly population, age 55 and  
older 
 5.Representative population-based 
     sample 
Inclusion 
criteria 
 MinD in patients without MCI (21) 
MinD in patients with MCI (2) 
Included studies 
 1. Age under 55 years 
 2. Diagnosis does not meet DSM criteria for  
     MinD  or MinD is not distinguished from 
     other types 
 3. Literature review 
 4. Intervention assessment 
 5. Study is focussed on specific group of 
     patients(one gender, group at risk)  




  References from original 
articles (25) 
Manual search 
 - MedLine (475) 
 - PsycInfo (193) 
 - Web of Knowledge (1259) 
 - Cochrane library (76) 
Computerized search 
Fig. 1. Selection of the studies.
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affective disorder, premenstrual dysphoric disorder, etc.), which do
not meet criteria for MDD. In DSM-IV (APA, 2000) MinD was
included in the depressive disorder NOS (Not Otherwise Specified)
category where any depressive disorder not meeting criteria for a
specific disorder can be found. The recently published DSM-V
(APA, 2013) assigned MinD a new name ‘Depressive episode with
insufficient symptoms’ under the category 311 ‘Other Specified
Depressive Disorder’. This diagnosis requires the following criteria:
depressed affect and at least one of the other eight symptoms of a
major depressive episode associated with distress or dysfunction
that persists for at least 2 weeks in an individual who has never
met criteria for any other mood disorder, does not currently
meet active or residual criteria for any psychotic disorder, and
does not meet criteria for ‘mixed subsyndromal anxiety–depres-
sive disorder’.
2.4. Definition of mild cognitive impairment (MCI)
Predementia syndromes arising in elderly persons have
received a multitude of descriptions: mild cognitive impairment
(Petersen et al., 1999), late-life forgetfulness, age-consistent mem-
ory impairment (Blackford and Larue, 1989), cognitive impairment
—no dementia (Graham et al., 1997), and age-associated memory
impairment (Crook et al., 1986). Prevalence of the different
predementia syndromes varies as a result of different diagnostic
criteria (Schönknecht et al., 2005; Schroder et al., 1998; Toro et al.,
2009). MCI began to gain popularity as it is thought to be
a prodromal phase of Alzheimer's Disease (AD) (Petersen, 2000).
Criteria for MCI suggested by the American Academy of
Neurology in 2001 correspond to the aMCI: (1) an individual's
report of his or her own memory problems, preferably confirmed
by another person, (2) measurable, greater-than-normal memory
impairment detected with standard memory assessment tests
(1.5 SD below age norms), (3) normal general thinking and
reasoning skills, (4) ability to perform normal daily activities.
Criteria used in different studies mostly include the above-
mentioned features (Petersen, 2004; Petersen et al., 2001).
Most recently, the First Key Symposium held in Stockholm in
2003 adopted the following recommendations for MCI general
diagnostic criteria: (i) a person is not normal but not demented,
(ii) cognitive decline reported and impairment of objective cogni-
tive tasks—not only amnestic—or there is evidence of cognitive
decline with time, (iii) preserved activities of daily living (Winblad,
2004). MCI is divided into four subtypes and is attended by an
increased risk of developing dementia:
(1) Amnestic MCI-single cognitive domain (memory
impairment only).
(2) Amnestic MCI-multiple domain (memory impairment plus
nonmemory deficits, such as in language, executive function,
or visuospatial function)—corresponding to AACD.
(3) Non-amnestic MCI-single domain (nonmemory deficit).
(4) Non-amnestic MCI-multiple domain (impairment in at least
two cognitive domains other than memory).
3. Results
3.1. Characteristics of the sample
The literature search described above revealed 2028 original
articles. Of these, 2005 papers were disregarded because they met
the exclusion criteria (see Fig. 1). For the subsequent analysis 23
original research articles were chosen (Tables 2 and 3). Among
them, 13 studies were designed to be community-based, three
were medical inpatient studies, three studies assessed patients in
nursing homes, three assessed primary care patients, and another
assessed home care patients. Only two studies were designed to
assess depressive symptoms including MinD in patients with MCI.
In total 19,876 patients of both sexes were included, aged 55 and
older. They represented 10 countries (Australia, Austria, Brazil,
Canada, Germany, Finland, Netherlands, South Korea, Spain, and
USA). DSM-III or DSM-IV criteria were used for assessment of
MinD, MDD, and subthreshold depressive disorder. Cognitive
status was diagnosed using neuropsychological tools such as
MMSE (Jongenelis et al., 2004), Clinical Dementia Rating (CDR);
(Gabryelewicz et al., 2004; Teresi et al., 2001), global deterioration
scale (Gabryelewicz et al., 2004) and others (Tables 2 and 3). MCI
diagnosis was made according to Mayo Clinic diagnostic criteria.
3.2. Methodological quality
According to the methodological quality criteria assessment
described above, the 23 previously selected original research
articles were given a total score ranging from 9 to 18. Among
them, eight studies were rated as “high quality” (scores 14–18), the
rest of the studies were rated as “moderate” methodological
quality, two of which got a borderline score (9 points).
3.3. Prevalence of minor depression in the elderly
The point prevalence of late life MinD ranged from 0 to 18.6%
depending on the study design. The prevalence was higher in the
Table 1
Criteria for methodological quality assessment of epidemiologic studies.
Criteria Not met Partially met Fully met
Socio-demographic and medical data is described (e.g., age, race, educational status, etc.) 0 1 2
Age groups are differentiated * 0 1 2
Inclusion and/or exclusion criteria are formulated 0 1 2
Detailed description of methods and instruments is given 0 1 2
Participation and response rates are described ** 0 1 2
Information about cognitive status is given 0 1 2
Mean, SD, CI are reported for the most important outcome measures 0 1 2
Diagnostic procedure is described: 0 1 2
a) For categorical diagnosis: diagnostic algorithm, diagnostician.
b) For dimensional diagnosis: valid cut-off score.
The missing values are described 0 1 2
Total 0–18 points
Annotations:
n Age groups: only one age group (0 points), two or more age groups (1 point), three and more groups described (2 points).
nn Participation and response rates: below 50% or not described (0 points); 50–75% (1 point); more than 75% (2 points).
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Table 2
Studies on prevalence of MinD in older adults without MCI.
Reference Study design, subjects Diagnostic criteria





Depressive Symptoms; risk factors, comments Methodological
Quality score







Only 48.5% of the patients are identified by nurses. 20.6% of




Primary care patients, New
York, US N¼745; AgeZ65





MinD and MDD were associated with poorer outcome in Trails B
and ΔTrails time (but not in other cognitive tasks).
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MMSE 18.15% showed MinD
at baseline, 17.5%—at
1 year follow-up
Patients with MinD at baseline showed 1 point lower
performance in MMSE at 1 year follow-up.
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65–79 y. 17.7%; 80–
99 y. 11.0%
63% of the population had mild dysfunction MMSE (15–23);
prevalence highest for men 65–79 y. (26.7%); MinD was
associated with presence of loneliness (OR¼4.52) and age below




GP attendees, 58 GPs in
Netherlands, rural and




Not included Point prevalence:
10.2% 65–74 y. rural
7.8%; urban 12.1%;
475 y. rural 13.5%;
urban 15.5%
Prevalence increases with age. Prevalence is higher in urban
areas.
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46.2% of MinD patients were prescribed antidepressants. 9
Kramer et al. 2009 Nursing home's residents,
Munich, Germany N¼97;
Age Z65
DSM-IV criteria SCID Not specified Point prevalence:
14.4%
42.9% of the subjects with acute MDD were diagnosed as
depressive by their attending physicians, and only half of them
received an antidepressant; 17.5% received antidepressants












History of depression, cognitive impairment, less tangible and
emotional support, fewer friends seen are associated with MinD.































depression in the old
age
FOME, TMT Point prevalence:




Troubles with relatives—a significant variable for the onset of
MinD (p¼0.02) FOME showed significant influence on the newly
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MinD at baseline was
14.8%
Individuals with prior MinD episodes had significantly higher
incidence rates of MD (23 per 1000 risk-years) than those with
no prior episodes. Incidence of any depression increased when


















Ostbye et al. (2005) Community-based
þmedical inpatients;












Prevalence was higher for females; increased with age for males;
prevalence for women highest in youngest age group 65–74
years; little difference in prevalence rates among hospitalized
subjects and those in the community (5.0% and 4.0%,
respectively) slight difference between subjects with and
















sum of MMSE score
was 22.375 for all
MinD persons
Oldest-old; no differences between genders, MinD associated
with long-term institutional care, frequent feelings of loneliness,
poor physical health, poor ability to walk, poor functional
abilities.
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Depression as a single episode 57.6%, Late-onset (78.0% of MinD)
depression was more prevalent than early onset. Prior MDD
episodes, female gender, history of stroke or TIA are associated
with MinD. MMSE scores were lower in MinD group than in

















MinD is the most prevalent mental disorder in the studied
population. Prevalence of psychiatric disorders the most
frequent comorbidity is observed with specific phobia (4.3%),
generalized anxiety disorder (4.3%), obsessive-compulsive
disorder (3.7%) and mania (1.3%) Used self-reported information,














Depression prevalence progressively increased with worsening
cognitive impairment; 8% of the sample received medication for
depression those cognitively intact reported less treatment than
individuals with cognitive impairment.
13







HAMD, SCID , DIW
MMSE Point prevalence:
16.8%
Patients with cognitive impairment included 37–45% of cases














MinD is not associated with higher mortality risk. 14












Small sample, all MinD subjects are female; lower life
satisfaction, worse life quality; presence of generalized anxiety




AGEGAT—Automated Geriatric Examination for Computer Assisted Taxonomy; CAMDEX—Cambridge Examination for mental disorders in elderly; CES-D—Centre of Epidemiologic studies depression scale; CIDI-SF—Composite
International Diagnostic Interview—Short form; DIS—Diagnostic Interview Schedule; DIW—Diagnostic Impression Worksheet; DSI—Depression Status Inventory; FTQ—Feeling Tone Questionnaire; GDS—Geriatric Depression Scale;
GMS—Geriatric Mental State; HAMD—Hamilton Depression Rating Scale; MADRS—Montgomery–Asberg Depression Rating Scale; MINI—Mini International Neuropsychiatric Interview; NPI—Neuropsychiatric Inventory; PRIME-MD
—Primary Care Evaluation of Mental Disorders; SCAN—Schedule of clinical Assessment in Neuropsychiatry; SCID—Structured Clinical Interview.
Dementia diagnostic tools:
CERAD-K-C—Clinical assessment battery (Korean Version); CDR—Clinical Dementia Rating; FAB—Frontal Assessment Battery; FCSRT—Free and Cued Selective Reminding test; FOME—Fuld Object memory evaluation; GDS—Global
Deterioration Scale; MAC-Q—Memory Complaint Questionnaire; MMSE—Mini Mental State Examination; SIDAM—Structured Interview for the diagnosis of Dementias; TMT—Trail Making Test part B.
Others:
ADL—Assessment Instrument for measuring instrumental Activities of Daily Living; ARIC—Atherosclerosis Risk in Communities; CCI—Charlson Comorbidity Index; GAF—Global Assessment of Functioning; HRQOL—Health related

















medical settings (median 14.4%) than in the community-based
settings (median 10.4%) and primary care patients (median 7.7).
Paivarinta et al. (1999) report association of MinD with long-term
institutional care. In a community-based study in Canada (Preville
et al., 2008) MinD was found to be the most prevalent mental
disorder in old age. Table 2 summarizes the findings for the
prevalence of MinD in the elderly without MCI.
3.4. Co-occurrence of MinD and MCI
Though depressive symptoms are a common observation in
patients with MCI and preclinical dementia (Berger et al., 1999;
Li et al., 2001; McCusker et al., 2005; Paterniti et al., 2002), MinD
in elderly persons with MCI is rarely investigated. We found only
two studies that focused on MinD in patients with MCI and made a
clinical diagnosis according to DSM. Both studies defined MCI
according to Mayo Clinic group diagnostic criteria published by
Petersen et al. (1999). Gabryelewicz et al. (2004) found a MinD
prevalence of 26.5% in MCI patients. Kumar et al. (2006) revealed
that 17.2% of patients with MCI suffered from MinD. In a study
by Jongenelis et al. (2004), 22% of patients with MinD showed
cognitive impairment. Xavier et al. (2002) observed worse perfor-
mance in the memory task measured by the CDR scale. However in
this study, patients with MinD reported worse self-evaluation of
the memory function, scoring equally to the healthy controls.
Steffens et al. (2009) corroborate the hypothesis that the preva-
lence of depression progressively increases with worsening cog-
nitive impairment. Paivarinta et al. (1999) showed slight decreases
in MMSE scores in patients with MinD compared to control
groups (22.375 and 23.974, respectively, p¼0.046). McCusker
(McCusker et al., 2005) demonstrated an association between
cognitive impairment and MinD. On the other hand, Jongenelis
et al. (2004) found no association between MinD and mild or
moderate cognitive impairment.
3.5. Risk factors for minor depression in the elderly
3.5.1. Gender
The influence of gender data on the development of MinD
is heterogeneous. Licht-Strunk et al. (2005), Ostbye et al. (2005),
Xavier et al. (2002), Mechakra-Tahiri et al. (2009), as well as Park
et al. (2010) revealed higher prevalence rates of MinD for women
in late life. In studies by Heun et al. (2000), McCusker et al. (2005)
and Gabryelewicz et al. (2004) no significant gender differences in
the prevalence of MinD were found.
3.5.2. Age
As with gender, evidence for an impact of age on the develop-
ment of MinD in late life is sparse. In most of the studies
(Gabryelewicz et al., 2004; Heun et al., 2000; Jongenelis et al.,
2004; McCusker et al., 2005) prevalence of MinD is not related to
age. Nevertheless, Licht-Strunk et al. (2005) reported a continuous
increase of MinD prevalence with growing age (in rural areas:
55–64 years 7.5%; 65–74 years 7.8%; 475 years 13.5%, in urban
areas: 13.1%, 12.1%, 15.5%). In this study patients over the age of 55
years were included, whereas subjects in the other studies were
mostly 65 years or older. A continuous rise with age was also
found by Ostbye et al. (2005), but only for men. Jongenelis et al.
(2004) found that the prevalence of MinD was higher in the group
aged below 80 years (OR¼1.95, CI¼1.02–3.70). In the study by
Mechakra-Tahiri et al. (2009), MinD prevalence was higher in the
younger age group (65–69 years)—18.4% compared to 11.4—12.9%
in older age groups—(70–75 years, 75–79 years, 80–84 years,
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rather on the study design and cannot be considered an indepen-
dent risk factor over the age of 65.
3.5.3. Other risk factors
A number of other risk factors were revealed in the reviewed
studies. Loneliness and lack of tangible support were reported by
Jongenelis (Jongenelis et al., 2004) and McCusker (McCusker et al.,
2005) to accompany MinD. To this group of factors one can add
long-term institutionalization reported by Ostbye et al. (2005).
Mechakra-Tahiri et al. (2009) showed that the lack of conflict
in intimate relationships was associated with lower prevalence of
depression.
Licht-Strunk et al. (2005) included territorial factors in their
research and revealed higher prevalence of MinD in urban areas.
In contrast, during the ESA study in Canada (Mechakra-Tahiri et al.,
2009), three types of locations were included and the finding was
that the prevalence of depression was higher in the rural (17.0%)
and urban areas (15.1%) than in the metropolitan areas (10.3%).
Paivarinta et al. (1999) found a group of physical health factors
to be of significant influence: poor physical health, history of
myocardial infarction for men, poor ability to walk, and smoking in
women. Park et al. (2010) found an association between a history
of stroke or transitory ischemic attack (TIA) with MinD. In contrast,
Jongenelis et al. (2004) did not find any association between
health-related factors and MinD, and Vilalta-Franch et al. did not
reveal an association with higher mortality risk (Vilalta-Franch
et al., 2012).
3.6. Comorbidity
In the reviewed studies, Xavier et al. (2002) and Preville et al.
(2008) reported comorbidity with generalized anxiety disorder.
Heun et al. (2000) showed a trend towards comorbidity with
subthreshold anxiety disorder diagnosed during lifetime. Lyness
et al. (2006) stated that MinD is a risk factor for MDD in itself, as
patients with minor or subsyndromal depression had a 5.5-fold
risk of developing MDD in the 12 subsequent months. Moreover,
according to McCusker et al. (2005) and Park et al. (2010) MinD
and MDD may be similar disorders but different in severity. Other
possible comorbid disorders, one should mention, are specific
phobias, obsessive compulsive disorder, and mania (Preville
et al., 2008).
3.7. Usage of health care services and medication
Health care services usage for the patient's psychological
distress varies between 8% and 39% in the studied populations
(McCusker et al., 2005; Preville et al., 2008; Steffens et al., 2009).
Though, MinD is associated with institutionalization of patients
(Ostbye et al., 2005), Preville et al. (2008) revealed that 85% of
health care attendees consulted a general practitioner for their
probable active cases of psychological distress syndromes, 4.8%
visited another general practitioner, only 11.5% visited a specialist,
9.8% first visited a psychologist, and 4.4% visited a social worker.
McCusker et al. (2005) showed that almost all of those receiving
treatment take antidepressants. Interestingly, Steffens et al. (2009)
states that patients with cognitive impairment are more likely to
receive antidepressive treatment than those without.
3.8. Recognition of minor depression by nonpsychiatric staff
Though MinD is associated with institutionalization of patients
(Ostbye et al., 2005), only 37–45% of patients diagnosed by psychia-
trists are recognized as depressed by nursing home staff (Teresi et al.,
2001). For the home care nurses the sensitivity of recognition was
48.5% and the accuracy of recognition was higher in the nurses with
geriatric experience (Brown et al., 2003). Among the treating physi-
cians in two Montreal hospitals, the sensitivity of recognition was
31.1%. Herein, patients with a history of depression, low comorbidity
(Charlson Comorbidity Index o1), long duration of hospitalization,
and higher severity were more likely to be recognized as depressed
(Cepoiu et al., 2007).
4. Discussion
The aim of the current review was to summarize the preva-
lence rates and risk factors of MinD in elderly patients with or
without MCI. We have shown a great variation in the reported
prevalence rates ranging from 0 up to 18.6% of the elderly
population. Prevalence rates for MinD in the elderly population
are higher than those reported for MDD—usually below 10%—
(Boyle et al., 2010; Cole and Dendukuri, 2003; Heun et al., 2000;
Meeks et al., 2011) and higher in medical settings than in
community settings, that is consistent with finding of Meeks for
all the subthreshold types of depression (Meeks et al., 2011).
Though patients with cognitive impairment are often excluded
from the studies of MinD, available studies show that 17.2% and
26.5% of patients with MCI suffer from MinD (Gabryelewicz et al.,
2004; Kumar et al., 2006). It was outlined that female gender
tends to be associated with MinD, while data on age impact seems
to be insufficient and contradicting. Risk factors for MinD in late
life include (i) physical health problems (such as myocardial
infarction, history of stroke, or TIA); (ii) mental health disorders
(generalized anxiety disorder, specific phobia, and obsessive com-
pulsive disorder); (iii) psychological factors (loneliness, lack of
tangible support, and conflict in intimate relationships). Medical
service usage analysis revealed that about a half of the patients get
medical help for their condition but most of them only visit
general practitioner with their complaints. The recognition rates
of MinD in the primary care services are below 50%, which
decreases the amount of sufficient mental help to this group of
patients.
The prevalence rate may depend on the number of factors:
the coverage of studied population, its age, physical health, and to
a large extent the diagnostic approach. A number of those
included to review studies used a single diagnostic instrument
(Grabovich et al., 2010; Heun et al., 2000; Kramer et al., 2009;
Ostbye et al., 2005; Vilalta-Franch et al., 2012). Among them are
SCID, CIDI, AGECAT, CAMDEX, ESA computer questionnaire (see
Table 2 for abbreviations) and a single clinical examination. The
range of prevalence rates across these studies is quite large (0–
16.8%). However, the median prevalence is only 6.5%. In the studies
using two or three diagnostic instruments the median prevalence
rate is 10.7% (range 5.2–18.6%). This suggests that number and
quality of tools may influence the revealed prevalence rate.
Structured clinical interviews may be less efficient compared to
self-administered questionnaires, but provide more accurate find-
ings. Since generalizations are hard to make across the variety of
included populations we looked at the most frequently used
diagnostic instruments. Studies using structured clinical tools
(DIS, SCID) and depression rating scales (HAMD, MADRS) report
higher prevalence rates for MinD. For DIS median prevalence rate
is 12.1% (7.9–18.15%), for SCID median is 10.1% (5.2–16.8%),
for HAMD median is 11.4% (5.2–18.15%), overall median prevalence
rate for studies using one of abovementioned instruments is 10.7%.
(5.2–18.15%). However, two studies that used CIDI reported the
lowest prevalence rates—Heun (Heun et al., 2000) has shown 0%
point prevalence and Steffens (Steffens et al., 2009) 1.35% lifetime
prevalence. Composite International Diagnostic Interview (CIDI) is
a tool developed by the world health organization according to the
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definitions and criteria of ICD-10 and DSM-IV. One of the possible
reasons for such low rates could be that ICD-10 does not contain
the diagnostic category for MinD and such criteria are not taken
into consideration in the interview. Similar low rates were shown
using only clinical interview based on DSM criteria or automated
geriatric examination (3.6–5.2%). Among the screening tools the
most used was GDS and median prevalence rate estimated in these
studies was 10.7% (5.52–14.1%) which is similar to the median in
the elderly population.
An alternative explanation could also be considered: differ-
ences in the representativeness of the samples. To a large extent
representativeness is achieved by the way patients are recruited.
For example, Licht-Strunk et al. (2005) (point prevalence of 10.2%)
cooperated with general practitioners (GPs) who invited the
elderly to participate in the study, whereas Heun et al. (2000))
(point prevalence of 0%) selected a random sample of elderly
subjects with the support of the city census office and contacted
all subjects at home. When contacted via GP the participants
suffering from MinD succeeded in overcoming the first barrier
(seeking help) and were perhaps persuaded more easily to
participate than the subjects who were contacted at home.
Newman et al. (1998) obtained a point prevalence of 3.6% for
MinD based on a random sample of subjects from a health
insurance database. Their participants and the subjects from
Ostbye et al. (2005) were contacted at home and conducted their
study in conjunction with the same national prevalence study
Canadian Study of Health and Aging (CSHA) and achieved similar
point prevalence rates for MinD (4.0%). Considering those findings,
one could conclude that point prevalence rates for MinD vary
between 0 and 4.0% using representative community samples (in
cooperation with city census offices or other population registers).
As an argument for our previous explanation we would like to
point out that the last two studies did not use standard diagnostic
tools, but automated questionnaires and a clinical examination.
For example, Norton et al. (2006) included the subjects Medicare
enrollee list and Paivarinta et al. (1999) included all persons from
one town born before 1906. Using DIS they achieved prevalence
rates of 14.8% and 18.6%.
Demographical factors associated with MinD allowed us to
identify only the female gender. Although this factor does not
always show significant association (Heun et al., 2000; Jongenelis
et al., 2004; McCusker et al., 2005), an association with MinD
tends to be shown in a number of studies (Licht-Strunk et al.,
2005; Meeks et al., 2011; Ostbye et al., 2005; Xavier et al., 2002).
Association with female gender is controversial and not well
understood so far, especially in late life. However, this tendency
is also observed for MDD (Cole and Dendukuri, 2003; Meeks et al.,
2011). The age difference in the prevalence rates of MinD seems to
be inconsistent, confirming the previous findings (Buechtemann
et al., 2012).
Symptoms of MinD are present in every fourth to fifth patient
with MCI (Gabryelewicz et al., 2004; Jongenelis et al., 2004; Kumar
et al., 2006), but so far this field has not been well investigated. A
number of studies published on depression in MCI patients, either
did not specify depressive symptoms or did not separate the
severeness of MCI (Boyle et al., 2010; Forsell et al., 2003; Jessen
et al., 2010; Solfrizzi et al., 2007). In the included MCI studies only
aMCI criteria were used. Therefore patients suffering from non-aMCI
were automatically excluded from the studies. That could lower the
prevalence rates and alter the comorbidity with MinD rates.
According to Teng et al. (2007), who found depression to be the
most prevalent predictor for a progression to AD, future long-
itudinal analyses should determine if depressive symptoms are a
risk factor for developing AD from MCI or represent a part of the
prodromal phase of AD. Berger et al. (1999) showed that the
presence of depression with motivational and not mood-
associated features predicted progression to dementia within
3 years. Interestingly, Jessen et al. (2010) demonstrated that
subjective memory impairment was associated with a higher risk
of conversion to any type of dementia. Hence, future studies are
warranted to investigate the association between subjective
memory or cognitive impairment and MinD.
Finally, the recognition rates of MinD among non-psychiatric
staff remain pretty low (under 50%). That comes in agreement
with Kramer et al. (2009) who demonstrated recognition levels for
MDD at only 49%. They also demonstrated that only half of the
patients receive treatment with antidepressant. As 85% of patients
with MinD consult a GP with their complaints, the recognition of
depressive symptoms in primary care services remains a problem
for the elderly group of patients.
4.1. Limitations of the present review
No comparison with other types of depression in the elderly was
made because we focused only on comorbidity with MCI. Addition-
ally, we did not show the actual prevalence rate of MCI in patients
with MinD as we were not able to find literature on this problem.
Though all included studies are based on DSM criteria of MinD, they
use different diagnostic tools and time frames. Here we decided
to accumulate as much data as possible about this disorder in late
life. Therefore, the presence of different sample settings makes meta-
analysis not applicable for this review. Geographical and cultural
differences were not included in the current analysis, though they
may have an impact on prevalence rates.
5. Conclusion
MinD is the most prevalent mental disorder in old age (Preville
et al., 2008). It is found to be a risk factor for MDD and MCI in late
life. A number of factors are associated with MinD such as female
gender, presence of somatic (stroke, myocardial infarction) and
mental health disturbances (generalized anxiety disorder, history
of MDD), and psychological problems. Our review, aiming to
elucidate MinD, may enable easier recognition, treatment, and
prevention of possible complications of this disorder in the future.
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a b s t r a c t
Background: Peripheral brain-derived neurotrophic factor (BDNF) is decreased in acute major depressive
disorder (MDD) and bipolar disorder (BD) and recovered after treatment. Here we validated on a meta-
analytical level whether BDNF restores differentially according to treatment response and whose
measurements could be used as a biomarker, plasma or serum.
Methods: Using strict inclusion criteria, we compared BDNF in healthy controls and patients with MDD
(38 studies, n¼6619), and BD (17 studies, n¼1447). Pre- and post-treatment BDNF levels were meta-
analyzed according to treatment response in patients from 21 MDD studies (n¼735) and 7 BD studies
(n¼88). Serum and plasma subgroups were analyzed, publication bias was assessed and heterogeneity
was investigated.
Results: Serum and plasma BDNF were decreased in acute MDD and BD, and did not differ in euthymia in
comparison with control subjects. Antidepressive treatment increased serum BDNF levels in MDD in
responders (Cohen's d (d)¼1.27, p¼4.4E-07) and remitters (d¼0.89, p¼0.01), significantly more than in
non-responders (d¼0.11, p¼0.69). For plasma BDNF in MDD and for BD, the evidence was insufficient for
a meta-analysis. Although no significant difference was found between serum and plasma ES, variance of
plasma ES was higher.
Limitations: Between-study heterogeneity was explained only partially; signs of publication bias in
serum studies.
Conclusion: Serum BDNF might be regarded as a biomarker for the successful treatment of MDD. Serum
measurements seem more reliable than plasma ones. Further research should focus on defining optimal
time points for BDNF measurements and increase evidence for the usage of BDNF as a predictive
biomarker in BD.
& 2014 Elsevier B.V. All rights reserved.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433
2. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433
2.1. Literature search and inclusion criteria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 433
2.2. Data extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
2.3. Risk of bias assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
2.4. Quantitative data synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
3. Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/jad
Journal of Affective Disorders
http://dx.doi.org/10.1016/j.jad.2014.11.044
0165-0327/& 2014 Elsevier B.V. All rights reserved.
Abbreviations: BDNF, brain-derived neurotrophic factor; MDD, major depressive disorder; BD, bipolar disorder; ES, effect size; SMD, standardized mean difference,
Cohen's d; CI, confidence intervals
n Corresponding author at: Department of Neurology, Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstrasse 1a, 04103 Leipzig, Germany.
E-mail address: polyakova@cbs.mpg.de (M. Polyakova).
Journal of Affective Disorders 174 (2015) 432–440
23
3.1. Results of the systematic literature search . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
3.2. Group difference analysis based on cross-sectional studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 434
3.2.1. MDD meta-analysis: BDNF is decreased in acute mood episodes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
3.2.2. BD meta-analysis: BDNF is decreased in acute mood episodes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
3.2.3. BD vs. MDD meta-analysis: no significant differences among disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 435
3.3. Treatment effect analysis based on longitudinal studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436
3.3.1. MDD meta-analysis: BDNF is increased in responders and remitters in contrast to non-responders . . . . . . . . . . . . . . . . . . . . . 436
3.3.2. BD review: a trend for increased BDNF in responders in contrast to non-responders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436
3.4. Investigation of between-study heterogeneity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 436
3.4.1. Subgroup analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
3.4.2. Mixed effect meta-regression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
3.5. Publication bias . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
4. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 437
Conflict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
Role of funding source . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
Appendix A. Supporting information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 438
1. Introduction
Brain-derived neurotrophic factor (BDNF) is a member of the
neurotrophin family. For over 30 years, research on BDNF has been
fruitful in many fields, from basic to clinical. Through dendritic
arborization and synaptic consolidation, BDNF mediates neuronal
plasticity, migration, and survival in both the central and periph-
eral nervous system (Bramham and Messaoudi, 2005; Greenberg
et al., 2009). It is secreted by neurons and peripheral cells such as
leukocytes (Edling et al., 2004), endothelial cells (Nakahashi et al.,
2000), and platelets (Yamamoto and Gurney, 1990), and passes the
blood–brain barrier (Pan et al., 1998).
BDNF is involved in a wide range of neuropsychiatric and
neurodegenerative diseases (Autry and Monteggia, 2012). A num-
ber of individual studies and later meta-analyses have demon-
strated decreased BDNF levels in mood disorders (Bocchio-
Chiavetto et al., 2010; Brunoni et al., 2008; Fernandes et al.,
2014; Fernandes et al., 2011; Lin, 2009; Molendijk et al., 2012;
Sen et al., 2008). The neurotrophin theory of mood disorders arose
in 2006 (Duman and Monteggia, 2006); but the initial excitement
has recently changed into a more balanced discussion (Groves,
2007; Molendijk et al., 2014). Major depressive disorder (MDD)
and bipolar disorder (BD) are prevalent and disabling mood
disorders (retrieved from 30.01.2014 from http://www.nimh.nih.
gov/; Organization., 2008). Despite progress in pharmacotherapy,
roughly half of MDD patients do not respond to the first anti-
depressant treatment (Dierckx et al., 2012; Undurraga and
Baldessarini, 2012). Response rates for the second and third
antidepressant remain even lower in patients who do not respond
to the first prescription (Murrough and Charney, 2012). In non-
responders, a clinical decision to switch medication is usually
made during the second to fourth week of treatment (Bauer et al.,
2007; Suehs B et al., 2008). Waiting several weeks until the
treatment response or medication switch is burdensome for
patients and leads to therapy dropout (Nakajima et al., 2010). In
order to reduce this time window, BDNF was suggested as an early
marker for treatment response (Tadic et al., 2011).
Today, it is well established that BDNF is decreased in mood
disorders. Discussions remain only about the degree of reduction
(Bocchio-Chiavetto et al., 2010; Brunoni et al., 2008; Molendijk
et al., 2014). On a meta-analytical level it was also shown that
BDNF increases with clinical improvement (Brunoni et al., 2008);
but the treatment response was not taken into account. However,
individual studies have shown differential BDNF restoration in
responders and non-responders (Deuschle et al., 2013; Yoshimura
et al., 2010a).
Although the relevance of BDNF for mood disorders is obvious,
the source of measured BDNF is diverse. BDNF levels can be
measured in whole blood, plasma, serum, or blood cells. Plasma
and serum BDNF levels show at least a 100-fold difference (Radka
et al., 1996; Rosenfeld et al., 1995) and may result from different
processes. Plasma levels might be responsible for the immediate
delivery of BDNF to the nervous system, while serum levels
reflect the platelet pool of this protein, which can be released
upon activation (Tamura et al., 2012). Changes in serum BDNF
levels were addressed in a recent meta-analysis by Molendijk
et al. (2014), while combined serum and plasma levels in their
meta-analysis. Both reported decreased BDNF in acute mood
episodes.
In the current meta-analysis, we aimed to elucidate three
questions: i) Is there any difference between changes in plasma
BDNF and in serum BDNF levels in mood disorders? (ii) Are there
state-dependent differences in plasma and serum BDNF levels as
suggested by other serum plasticity markers (Schroeter et al.,
2008; Schroeter and Steiner, 2009)? iii) Does BDNF restore
differentially depending on the treatment response? If so, this
would help to establish BDNF as a predictive biomarker for
successful antidepressive treatment.
We hypothesized that both plasma and serum BDNF levels are
decreased compared with healthy control subjects in acute mood
episodes and are not different from control subjects during the
euthymic state of MDD and BD. In longitudinal studies we
hypothesized that both serum and plasma levels increase only in
responders to treatment of MDD and BD.
2. Methods
2.1. Literature search and inclusion criteria
Two independent reviewers (MP, KST) conducted a literature
search through the electronic databases PubMed, ISI Web of
Science, and PsycINFO. Keywords ‘BDNF’ or ‘brain-derived neuro-
trophic factor’ were combined with either ‘depression’, ‘major
depression’, or ‘bipolar’, ‘mania’, ‘euthymia’, and ‘remission’ (last
search-27.08.2013). We screened titles, abstracts, and full texts,
when appropriate, according to predefined inclusion criteria:
(i) original peer-reviewed article, (ii) adult patients with MDD or
BD type I, (iii) absence of somatic comorbidity, (iv) BDNF serum or
plasma levels assessed, (v) case-control design of the study
comparing patients and control group or longitudinal therapy
study of the same group of patients before and after treatment,
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(vi) standardized treatment medications used (antidepressants for
MDD, mood stabilizers for BD, with addition of antipsychotics
when appropriate). We inspected reference lists of articles to
identify further relevant articles. Studies including patients with
somatic illnesses (cancer, diabetes), pregnant women, and studies
using transcranial magnetic stimulation, electroconvulsive therapy
or psychotherapy were excluded, as well as studies based on
substantially overlapping samples.
2.2. Data extraction
Based on the inclusion criteria, 68 original articles were
selected for subsequent analyses (Fig. 1). Information was
extracted and structured. In the case of insufficiently reported
data, we contacted the corresponding author via e-mail for
additional information, and most of them provided it. When the
author did not reply, we reviewed the study qualitatively only
(Yoshimura et al., 2010b).
2.3. Risk of bias assessment
Based on the recommendations of the Cochrane collaboration
handbook (Chang, 2011; Higgins JPT, 2009) and the Methods
Guide for Comparative Effectiveness Reviews (Chang, 2011;
Higgins JPT, 2009), we developed a risk of bias assessment
tool for cross-sectional and longitudinal studies. All included
questions were rated by the first author with “0”, “1”, or “2”
according to the presence of specific criteria (Supplementary
Tables 1, 2). The smaller the score, the higher the risk of bias.
The total score of each study was tested as a covariate in the meta-
regression.
2.4. Quantitative data synthesis
The software program comprehensive Meta-Analysis, version
2.2.064, (Borenstein et al., 2009) was used for statistical analysis.
Since BDNF was measured with different kits, in different popula-
tions, and, accordingly, with different absolute values, data were
normalized by calculating the standardized mean difference (SMD,
Cohen's d), with 95% confidence intervals (CI) as an effect size (ES)
estimate. According to Cohen, the magnitude of ES should be
interpreted as small with an ES40.2, medium with an ES40.5, or
large with an ES40.8. A random-effects model was chosen for the
meta-analysis because it accounts for both within- and between-
study variance. In cases where no heterogeneity is present, the
random-effects model acts as a fixed-effects model.
Sensitivity analysis was performed, excluding each individual
study from the meta-analysis. In cases where the meta-analysis
results were driven by a single study, data were reported in the
results section. Between-study heterogeneity was assessed using
Q-statistics and I2 estimate. An exploration of between-study
heterogeneity was performed by a subgroup analysis for catego-
rical predictors, and mixed-effect regression (unrestricted max-
imum likelihood) for continuous predictors.
We checked for a potential publication bias in the included
analyses by visual assessment of funnel plots, Egger's test, and
Begg and Mazumdar test. Duval and Tweedie's trim and fill
method was used to correct for the funnel plot asymmetry arising
from publication bias (Duval and Tweedie, 2000; Taylor and
Tweedie, 1998).
Meta-analyses were performed separately for the cross-
sectional and the longitudinal studies. Conventionally, clinical
treatment response was defined as a 50% reduction in the scores
of Young mania rating scale (YMRS), Hamilton depression rating
scale (HDRS) and Montgomery–Asberg depression rating scale
(MADRS) (Zajecka, 2003), remission as scores o7 on HDRS,
scores o8 on MADRS or scores o8 on YMRS (Aydemir et al.,
2005; Deuschle et al., 2013; Gervasoni et al., 2005; Sousa et al.,
2011).
For the subgroup analysis, we subdivided the cross-sectional
studies according to the polarity of mood episode (depression,
mania, and euthymia). The longitudinal MDD studies were sub-
divided according to the treatment response (remitters, respon-
ders, non-responders). Due to insufficient data, we review
longitudinal studies in BD qualitatively only. Serum and plasma
studies were analyzed separately. For both MDD and BD, we ran
mixed-effects meta-regression analyses with the predictors that
were previously described in the literature: number of patients
(Molendijk et al., 2014), patients' mean age (Bus et al., 2011;
Fernandes et al., 2011), gender (measured as percentage of males)
(Bus et al., 2011), duration of illness (Fernandes et al., 2011), and
risk of bias score.
3. Results
3.1. Results of the systematic literature search
The PRISMA flow diagram summarizes the identification of the
relevant studies (Fig. 1). Our inclusion criteria were satisfied by 48
studies with MDD patients and 19 studies involving BD patients
(Supplementary Tables 3–6). In sum, the studies taken into
account by the meta-analyses included a large group of 3365
and 758 patients with MDD and BD, respectively.
Thirty-eight studies were included in our cross-sectional MDD
meta-analysis and 19 in our cross-sectional BD meta-analysis
(Supplementary Figs. 13–19). BDNF values before and after treat-
ment were assessed in 21 MDD studies and seven BD studies. The
total score in the risk of bias assessment tool of cross-sectional
studies varied from 15 to 20, and for longitudinal studies it varied
from 11 to 18.
3.2. Group difference analysis based on cross-sectional studies
The first analysis investigated group differences for BDNF levels
between the subtypes of mood disorders, MDD and BD, and their
Records identified through 
database search (n =10061)
Additional records identified 
through other sources 
Records screened after 
duplicates removed (n = 3744)
Records excluded 
(n = 3608)
Full- text articles assessed for 
eligibility MDD (n = 83)
BD (n = 38)
Full-text articles excluded due 
to:
- No control subjects, no 
treatment used (n =15);
- Other source of BDNF (n=5)
- Other treatment (n=9)
- Overlap of the patient 
cohorts (n=7)
- Review or conference 
abstract (n=21)
Studies included in quantitative 
synthesis (meta-analysis)
MDD (n = 48) 
BD (n=19)
Fig. 1. PRISMA flow-diagram of the strategy for searching and selecting studies; BD
bipolar I disorder, BDNF brain-derived neurotrophic factor, MDD major depressive
disorder, n number of studies.
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different states (depressive, manic, and euthymic episode) and the
influence of the analysis approaches (serum vs. plasma levels).
Results are illustrated in Fig. 2.
3.2.1. MDD meta-analysis: BDNF is decreased in acute mood
episodes
Thirty-eight studies compared patients with MDD in depressive
state with control subjects, including 2447 patients and 2147
controls. High overall between-study heterogeneity (I2¼91.2)
remained despite grouping by source of BDNF and sensitivity
analysis. When compared with healthy controls, BDNF was sig-
nificantly decreased in acute MDD (d¼0.80, 95% CI 1.05 to
0.54, p¼1.1E-09, 38 effect sizes, n¼2447), but not in euthymia
(d¼0.14, 95% CI 0.38 to 0.07, p¼0.235, 11 effect sizes, n¼872;
Fig. 2).
To answer the question whether there is a difference in ES
between serum and plasma studies, we compared ES in six plasma
studies and 32 serum studies in acute MDD. One study was
included in both analyses since it measured BDNF in both plasma
and serum (Piccinni et al., 2008). Serum BDNF was significantly
decreased in patients in a depressive state compared with controls
(d¼0.81, 95% CI 1.05 to 0.56, p¼6.3E-11, 32 effect sizes,
n¼2298). A similar trend was observed in plasma studies
(d¼0.71, 95% CI¼1.55 to 0.13, p¼0.097, 6 effect sizes,
n¼149; Fig. 2). BDNF levels of patients in euthymia did not differ
significantly from healthy subjects in serum (d¼0.20, 95%
CI¼0.38 to 0.07, p¼0.116, 9 effect sizes, n¼841) and were
slightly increased in plasma studies (d¼0.40, 95% CI 0.05 to
0.85, p¼0.083, 2 effect sizes, n¼31; Fig. 2).
While in acute state there was no significant difference
between plasma and serum studies (p¼0.91), in euthymia we
observed a tendency for plasma BDNF to be higher than serum
(p¼0.076). Note that confidence intervals of plasma studies were
always wider, thus less precise. Subgroup analysis according to the
severity of depression also resulted in no significant differences
(data not shown).
3.2.2. BD meta-analysis: BDNF is decreased in acute mood episodes
This random-effects meta-analysis comprised six depressive,
eight manic, and nine euthymic state studies. BDNF levels were
significantly decreased in patients with an acute depressive
episode (d¼1.16, 95% CI 1.79 to 0.54, p¼2.5E-04, 6 effect
sizes, n¼117) and an acute manic episode (d¼0.77, 95% CI 1.10
to 0.44, p¼1.9E-05, 8 effect sizes, n¼156; Fig. 2). No significant
differences were found in BDNF levels of euthymic patients when
compared with control subjects (d¼0.05, 95% CI 0.42 to 0.43,
p¼0.098, 9 effect sizes, n¼426; Fig. 2).
According to the sensitivity analysis, ES in the manic state
might be driven by the study by Barbosa et al. (2010). In this study,
mean illness duration was 19.5 years, in others it varied from 0.2 to
12.8 years (mean 8.4 years). The large positive ES in this study
(Supplementary Fig. 18) increased the between-study heterogene-
ity by 41%. Based on these data, we excluded Barbosa et al.'s study
from the respective subgroup (Fig. 2). No significant differences
were observed between serum and plasma ES in any of the BD
subgroups. ES in acute depression and mania subgroups were
significantly lower than in the euthymic subgroup (p¼0.001 and
p¼0.009, respectively); and this difference was driven by plasma
studies (Fig. 2). Note that confidence intervals of plasma studies
were again larger than in serum studies.
3.2.3. BD vs. MDD meta-analysis: no significant differences among
disorders
Summarizing cross-sectional studies, we found decreased
serum and plasma BDNF levels in all acute episodes of both
MDD and BD when compared to control subjects. No significant
differences were found between the acute mood episodes of both
Fig. 2. Meta-analysis comparing plasma and serum levels of BDNF between major depressive disorder (MDD) and bipolar disorder (BD) in respective mood states. Cross-
sectional studies. SMD standardized mean difference. *Study by Barbosa et al. (2010) was excluded from the meta-analysis as it investigated patients with long-term BD. SMD—
Standardized mean difference. The dashed lines illustrate mean values for MDD and BD when compared with the control cohort. (For interpretation of the references to color
in this figure legend, the reader is referred to the web version of this article).
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disorders. In the euthymic state of BD and MDD, serum and plasma
BDNF levels were similar to control subjects.
3.3. Treatment effect analysis based on longitudinal studies
The second analysis investigated the effect of treatment on
BDNF levels in MDD and BD (depressive and manic states). Post-
treatment levels of BDNF were compared between remitters,
responders, and non-responders to treatment. Results are illu-
strated in Fig. 3.
3.3.1. MDD meta-analysis: BDNF is increased in responders and
remitters in contrast to non-responders
Twenty-one studies satisfied inclusion criteria for the long-
itudinal MDD meta-analysis investigating treatment effects on
serum BDNF. Four studies included only the responders group;
six studies included both the responders and the non-responders
groups. Six studies reported only the remitters group, and one
study included the remitters and non-responders groups. One
study reported pooled data. This meta-analysis included 553
patients. Median treatment duration was 6 weeks (range 2–8
weeks).
To investigate whether the treatment-related change in BDNF
(post- vs. pre-treatment) is related to treatment response, we
subdivided the whole MDD sample into remitters, responders, and
non-responders to antidepressant treatment, according to the
criteria mentioned in the Methods section. Indeed, the meta-
analysis indicated that BDNF levels increased upon treatment in
remitters (d¼0.85, 95% CI 0.39–1.29, p¼0.003, 7 effect sizes,
n¼116) and responders (d¼1.33, 95% CI 0.69–1.97, p¼5.1E-05, 11
effect sizes, n¼252), whereas in the non-responders they
remained stable (d¼0.15, 95% CI 0.33 to 0.63, p¼5.1E-05, 7 effect
sizes, n¼118) (Fig. 3). Serum BDNF changes in remitters and
responders were significantly larger than in the non-responders
(p¼0.036 and p¼0.012 respectively; Fig. 3). The data on the
plasma BDNF changes are limited and the differences between
different subgroups were not significant (Fig. 3). The overall meta-
analysis (very likely driven by the responders and the remitters)
indicated increasing BDNF values due to antidepressive treatment
in serum (ES¼0.77, p¼1.5E-06) and in plasma (ES¼0.30, p¼0.08).
3.3.2. BD review: a trend for increased BDNF in responders in
contrast to non-responders
We review the results of individual studies in this section,
because subdivision of the seven identified studies by polarity and
source of BDNF is not sufficient for meta-analysis.
In the mania group, we identified studies reporting remitters
and responders to the treatment. Two of them observed increased
BDNF levels in plasma: Palomino et al. (2006) (d¼0.56, 95%
CI¼0.19 to 1.3, p¼0.14) and de Sousa et al. (2011) (d¼1.02,
95% CI¼0.09–1.95, p¼0.03). Serum BDNF levels were assessed in
four studies, reporting controversial findings. Yoshimura et al.
(2006) (d¼0.27, 95% CI¼0.53 to 1.07, p¼0.51) and Huang et al.
(2012) (d¼0.16, 95% CI¼0.45 to 0.76, p¼0.61) found no sig-
nificant BDNF changes. Studies were conducted on 12 and 21
patients, respectively. Tramontina et al. (2009) found a statistically
significant increment in BDNF upon treatment in the sample of 10
patients (d¼0.99, 95% CI¼0.06–1.92, p¼0.04) and decreased
BDNF levels were observed in the group of three patients by
Grande et al. (2012) (d¼2.4, 95% CI¼4.5 to 0.30, p¼0.025).
Serum BDNF in the depressive episode of BD was studied by
Grande et al. (2012). They reported a trend for increased BDNF in
responders to treatment (d¼0.85, 95% CI¼0.17–1.89, p¼0.1) and
no change in the non-responders (d¼0.001, 95% CI¼1.39–1.39,
p¼0.99). Yoshimura et al. (2006) observed no significant difference
in the serum BDNF in non-responders (d¼0.13, 95% CI¼1.00 to
1.26, p¼0.81). In a later study of BD and MDD patients, the same
research group found significantly increased plasma BDNF levels in
the responders (d¼1.0, 95% CI¼0.18–1.81, p¼0.037) but not in the
non-responders (d¼0.15, 95% CI¼0.51 to 0.80, p¼0.66)
(Yoshimura et al., 2010b).
Overall, there seems to be a trend similar to MDD studies
(peripheral BDNF is increased in responders and unchanged in non-
responders to treatment) at least in the depressive state of BD, but at
the moment evidence for meta-analytic conclusions is lacking.
3.4. Investigation of between-study heterogeneity
To ensure the validity of our meta-analyses, we analyzed between-
study heterogeneity. Variation between studies revealed by a hetero-
geneity test was high in MDD meta-analyses, both cross-sectional
(I2¼91.2) and longitudinal (I2¼84.3). For cross-sectional BD meta-
analysis, heterogeneity was moderate to high (I2¼50.0–88.1). In order
Fig. 3. Meta-analysis investigating treatment effects on serum and plasma levels of BDNF with regard to treatment efficacy in major depressive disorder (MDD). Longitudinal
studies. SMD—Standardized mean difference. The dashed lines illustrate mean treatment effects for serum and plasma BDNF in MDD. (For interpretation of the references to
color in this figure legend, the reader is referred to the web version of this article).
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to distinguish the source of between-study variation, we performed
subgroup analysis and meta-regression.
3.4.1. Subgroup analysis
The subdivision of MDD studies according to BDNF source did
not reduce the between-study heterogeneity (Figs. 2 and 3), which
was in agreement with the assumption that signal-to-noise ratio
analyses by calculating SMD eliminates, or at least reduces, this
possible bias. In BD, such subgroup analysis decreased hetero-
geneity in mania, but did not affect the depressive and euthymic
state analysis. In longitudinal MDD studies of serum BDNF, the
heterogeneity was reduced in the remitters and the non-responders
subgroups when compared to the overall heterogeneity.
3.4.2. Mixed effect meta-regression
Predefined moderator variables were patients' age, sex (mea-
sured as % of males), disease duration, and risk of bias score. We
did not find any significant correlations across any of the meta-
analyses.
3.5. Publication bias
The publication bias was detected and corrected by a trim and
fill procedure in three out of 10 meta-analyses: i) meta-analysis of
cross-sectional studies of serum BDNF levels in depressive state of
MDD, ii) meta-analysis of longitudinal studies of serum BDNF
levels in responders, and iii) non-responders subgroups in MDD
(Supplementary Figs 2, 10, 11). In the meta-analysis of cross-
sectional studies in the depressive state MDD, correction of pooled
ES from serum studies led to its reduction from d¼0.81 (95%
CI¼1.05 to 0.54) to d¼0.48 (95% CI¼0.72 to 0.22). In
the responders subgroup from longitudinal meta-analysis of
serum BDNF studies, correction increased pooled ES from
d¼1.33 (95% CI¼0.69–1.97) to d¼1.52 (95% CI¼0.86–2.19). In
the non-responders subgroup from longitudinal meta-analysis of
serum BDNF studies, corrected ES decreased from d¼0.15 (95%
CI¼0.33 to 0.63) to d¼0.12 (95% CI¼0.44 to 0.20). Since
correction for publication bias led to comparable results, we
conclude that publication bias did not substantially affect the
results of our meta-analysis.
4. Discussion
In the current meta-analysis we confirmed the previous find-
ings of reduced BDNF levels in acute, but not in euthymic, mood
episodes (Bocchio-Chiavetto et al., 2010; Brunoni et al., 2008;
Fernandes et al., 2014; Fernandes et al., 2011; Lin, 2009; Molendijk
et al., 2012; Sen et al., 2008). This was true for both MDD and BD,
with no significant differences among their ES. Serum and plasma
ES were not different in the cross-sectional studies, but the CI for
plasma studies was always wider, and thus less precise.
Moreover, our meta-analyses revealed findings that, to our
knowledge, have not been reported before. Analysis of longitudi-
nal studies indicated that BDNF is differentially restored upon
treatment, namely BDNF levels increase in remitters and respon-
ders, but remain unchanged in non-responders. This difference
was significant for MDD and a trend was observed in BD, although
more evidence is needed to draw meta-analytic conclusions in BD.
Therefore, BDNF may become a useful treatment biomarker for
MDD, whereas any inferences for BD are premature.
BDNF is involved in a wide range of psychiatric and neurolo-
gical disorders (Autry and Monteggia, 2012). Fernandes et al.
(2009) observed decreased serum BDNF levels in bipolar depres-
sion compared to MDD patients. Monteleone et al. (2008) found
no significant differences between the groups of euthymic BD or
MDD patients or the acute MDD group. On the meta-analytic level,
there is no credible evidence that differences between the acute
mood episodes of BD and MDD exist. However, a clear difference
between BDNF levels in euthymic and acute mood states in both
BD and MDD (Fernandes et al., 2013b) supports our finding that
BDNF is restored as a result of successful treatment.
To establish BDNF as a biomarker for the successful treatment
of mood disorders, three aspects should be discussed: Which
BDNF source is preferable, at which time point is the BDNF change
reliably detectable and clinically meaningful, and how strong is
the association between BDNF and treatment efficiency?
By different estimations, BDNF levels in serum are 100–200-
fold higher than in plasma (Radka et al., 1996; Rosenfeld et al.,
1995). Plasma BDNF represents the circulating protein, and serum
BDNF constitutes the sum of plasma levels and, mainly, BDNF
released from platelets during clotting (Fujimura et al., 2002;
Radka et al., 1996; Rosenfeld et al., 1995). Similar to other
neurotrophins, BDNF is rapidly eliminated from plasma with a
half-life time of 2.771 min. The main clearance mechanisms are
uptake and subsequent degradation in the liver; and to a lesser
extent in the kidneys and lungs (Pardridge et al., 1994). To our
knowledge, the lifespan of platelet BDNF has not yet been
determined, but it is known that platelets remain in peripheral
blood for about 10 days and are able to store and release BDNF
upon activation (Fujimura et al., 2002; Harker et al., 2000).
Therefore, plasma levels reflect a short-term BDNF content, and
serum levels reflect a relatively long-lasting BDNF. The increased
serum BDNF in the responders group should, in turn, reflect
the BDNF accumulated by platelets during the treatment period.
The underlying physiological mechanisms remain to be eluci-
dated: the origin of platelet BDNF, the ration of BDNF isoforms,
and the relation to antidepressants or to the pure disease
physiology etc.
Relationships between serum and plasma BDNF levels are not
well described. A high positive correlation (r¼0.73) in healthy
volunteers was reported by Yoshimura et al. (2010c). In this study
the difference between plasma and serum levels was 14-fold,
which is much smaller than previously reported by Radka et al.
(1996) and Rosenfeld et al. (1995), but the authors did not control
for potential platelet contamination of plasma samples (Yoshimura
et al., 2010c). Bocchio-Chiavetto et al. (2010) did not find any
correlation between plasma and serum BDNF in patients with
MDD (p¼0.259). Studies specifically focusing on the relations
between serum and plasma BDNF levels are needed to understand
if these levels are independent or not.
The interpretation of similar ES between the plasma and the
serum cross-sectional studies should be done cautiously, and
should account for a small number of included plasma studies,
their large confidence intervals, and high heterogeneity. Moreover,
determination of BDNF in serum is rather stable and reproducible
(Elfving et al., 2010; Trajkovska et al., 2007; Tsuchimine et al.,
2014), while plasma levels are more strongly affected by the
handling of material (Elfving et al., 2010; Tsuchimine et al.,
2014). The longer plasma samples are kept at room temperature
(in hours), the higher their absorbance scores in the ELISA
detection system (Elfving et al., 2010; Tsuchimine et al., 2014).
For serum BDNF, storage in the freezer for more than 3 years was
shown to decrease BDNF levels (Bus et al., 2011). In addition,
anticoagulants used for plasma preparation may further alter
BDNF plasma measurements (Tsuchimine et al., 2014); another
potential reason for large variance in plasma levels of BDNF. Based
on previous methodological findings and more narrow confidence
intervals in serum studies, one might conclude that serum levels
are generally more reliable.
Most interestingly, we found significantly higher BDNF levels in the
serum of responders when compared with non-responders in MDD on
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the meta-analytic level. This result clarifies partly controversial find-
ings in the literature with differential BDNF changes in responders and
non-responders in most original studies (Huang et al., 2008; Lee and
Kim, 2008; Umene-Nakano et al., 2009; Yoshimura et al., 2010a), but
opposite results in others (Basterzi et al., 2009; Yoshimura et al., 2007).
In our longitudinal meta-analysis, BDNF levels were measured at
different time points. Treatment time ranged from 2–8 weeks, with
a median of 6 weeks. One may reasonably argue that in MDD, a
marker which is significant during the sixth week of treatment cannot
support clinical decisions, since clinically antidepressant response is
obvious around week 3 or 4. This issue was addressed by one pilot
study (Dreimuller et al., 2012; Tadic et al., 2011). Tadic et al. (2011)
revealed that absence of clinical improvement combined with
unchanged serum BDNF could predict non-response reliably at the
end of the second week of treatment (between day 7 and 14,
specificity increased from 67 to 100%). The combination of increased
plasma BDNF levels and HDRS scores of the same patients could
predict the treatment response already on day 7 with a sensitivity of
67% and a specificity of 93%. The best relative BDNF cut-off score for
prediction of response on day 7 was 126% (Dreimuller et al., 2012).
However, one has to be aware that these data are limited to 39
patients. Supporting this data, Rojas et al. (2011) observed an early
parallel increase of serum BDNF and clinical improvement. An
association between treatment response and serum BDNF levels on
day 7 was also reported by Delini-Stula et al. (2012).
In order to develop a biomarker for the treatment response,
additional studies addressing the strength of association between
BDNF and treatment efficiency are required. Instead of comparing
overall pre- and post-treatment BNDF, attention should be focused
on the sensitivity and specificity of BNDF as a biomarker of
treatment response, optimal time point, and source of BDNF
measurement. Additional control for depression course may add
valuable information, as patients with recurrent depression tend
to show decreased BDNF over time even when reaching clinical
remission (Bus et al., 2014). Since different ELISA kits use different
measurement scales, the percent change of BDNF should be used
for the sensitivity and specificity analyses. Using the kits sensitive
to different BDNF isoforms would pave the way for a better
understanding of the role of BDNF in treatment response.
Last but not least, we used the meta-regression to discriminate
factors leading to high between-study heterogeneity. Based on the
patients' average age, gender, illness, or treatment duration, meta-
regression has its limitations. Most of the included cross-sectional
studies were already controlled for age; excluding the effect of
aging across the studies (Schroeter et al., 2011). Some of the
studies were also controlled for gender. Therefore, we could
observe gender effects between studies only partially. Mean illness
duration for the study may be different from the true within-study
distribution. The only precise factors were risk of bias scores and
treatment duration for longitudinal studies, but we did not detect
any relationship with BDNF change in our analysis. Since between-
study relationships are observational by nature, inferences based
on such meta-regression may be misleading and only individual
patient level can resolve such discrepancies (Thompson and
Higgins, 2002).
A major limitation of our study is the high heterogeneity
between the included studies. We could not control for potential
moderators: physical activities, body-mass index, handling, and
storage of material; usually they were not reported in the clinical
studies. However, a priori, we excluded a potential confound,
physical comorbidity, and allowed only standard medications. In
longitudinal MDD studies we were able to partially explain
heterogeneity by the treatment response, and in mania cross-
sectional studies the sensitivity analysis revealed a study that
drove the whole result and increased heterogeneity by 41%. The
second limitation, publication bias, was corrected by the trim and
fill procedure, which even increased the difference between serum
BDNF changes in the responders and non-responders.
In conclusion, meta-analytic evidence suggests that BDNF is a
biomarker for the successful treatment of mood disorders, in
particular MDD. Serum measurements seem to be more reliable
than plasma measurements. Further research should focus on
defining optimal time points for BDNF measurements to support
early clinical decisions and increase evidence for the usage of
BDNF in BD.
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SUPPLEMENTARY MATERIAL 
Table 1 Risk of bias assessment tool for cross-sectional studies. 
Risk of bias 
domain 




Selection bias Are two groups matched by age and gender? 0 1 2 
Are two groups similar by psychiatric and somatic 
comorbidity? 
0  1  2  
Were patients and controls selected randomly 
from the target population? 
0 1 2 
Detection bias Was the same diagnostic method applied to both 
groups? 
0 1 2 
Did the same person assess two groups? 0  1  2  
Was diagnosis made in accordance with 
international classifications using standardized 
tools? 
0 1 2 
Was normality of distribution checked and 
appropriate statistical test applied? 
0 1 2 
Were the confounding variables assessed and 
treated appropriately (diurnal fluctuations, 
handling and storage of samples, joint ELISA 
measurements, body mass index)?* 
0 1 2 
Performance 
bias 
Were the outcome assessors blinded to 
participants? 
0 1 2 
Attrition bias Was attrition (dropout, exclusion of participants) a 
concern in the study?  
2 1 0 
Reporting bias Are all prespecified outcomes reported? 0 1 2 
 Total 0 to 22points 
 None of the confounding variables – 0 points; 1 – 2 variables – 1 point, 2 and more –2 points. 
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Table 2 Risk of bias assessment tool for longitudinal studies. 
Risk of bias 
domain 




Selection bias Were patients selected randomly from the target 
population? 
0 1 2 
Was medication assigned randomly? 0  1  2  
Was the group homogeneous by means of 
psychiatric and somatic comorbidity? 
0 1 2 
Detection bias Did the same person assess all patients? 0 1 2 
Was diagnosis made in accordance with 
international classifications using standardized 
tools? 
0  1  2  
Were the confounding variables assessed and 
treated appropriately (diurnal fluctuations, 
handling and storage of samples, joint ELISA 
measurements, body mass index)?*?* 
0 1 2 
Performance 
bias 
Were the outcome assessors blinded to 
participants? 
0 1 2 
Attrition bias Was attrition (dropout, exclusion of participants) a 
concern in the study?  
2 1 0 
Reporting bias Are all prespecified outcomes reported? 0 1 2 
 Total 0 to 18 points 




Table3. Studies included in the MDD cross-sectional meta-analysis 
Reference Source 
 of  
BDNF 
Patients  Controls units 





Age BDNF N Age BDNF 
mean SD mean SD mean SD mean SD 
Acute state               
Karege, 2002 (1) serum 30 34.0 ±5.0 a 50.0 36.0 8 22.6 3 30 38.0 9 26.5 7 ng/ml 
Shimizu,2003 (2) serum 17 27.8±10.2 75.0 40.8 13.6 17.6 9.6 50 41.9 15.9 27.7 11.4 ng/ml 
Aydemir, 2005 (3) serum 10 23.02±4.6 20.0 31.8 14.3 17.9 9.1 10 39.8 7.1 31.6 8.6 ng/ml 
Gervasoni, 2005 (4) serum 26 32.8±4.9 a 42.3 40.5 10.7 22.6 3.6 26 39.6 12.2 26.4 3.6 ng/ml 
Gonul, 2005 (5) serum 28 27.3±3.5 25.0 35.5 8.1 20.8 6.7 18 35.7 5.8 26.8 9.3 ng/ml 
Karege, 2005 (6) plasma 43 32.0±4.0 a 37.2 36.0 10 1685 243 35 31.0 11.8 2165 349 pg/ml 
Laske, 2005 (7) serum 16 26.2 31.3 61.3 NA 19.7 3.3 30 58.1 NA 21.3 5.4 ng/ml 
Aydemir, 2006 (8) serum 20 39.75±7.4 0.0 35.6 7.5 27.68 13.74 20 34.6 7.86 41.16 15.14 ng/ml 
Yoshimura, 2007 (9) serum 42 23.5±6.7 35.7 47.0 19 9.51 6.49 40 45.0 15.0 23.4 10.1 ng/ml 
Huang, 2008 (10) serum 111 35.1±4.9 22.8 36.0 10.1 10.9 7.1 107 28.9 5.1 14.1 7 ng/ml  
Lee, 2008 (11) plasma 32 29.488.6 34.4 44.2 17.3 698.2 537.7 50 38.5 9.7 830.7 624.8 pg/ml 
Monteleone, 2008 (12) serum 11 19.9±3.5 18.2 45.7 13.6 29 15.9 22 40.1 16.4 42.5 12.5 ng/ml 
Piccinni, 2008 (13) plasma 15 22.8±5.3 13.3 44.2 10.8 2900 1900 15 38.5 9.2 5400 2300 pg/ml 
 serum 15 22.8±5.3 13.3 47.0 10.8 19300 8800 15 36.9 16.4 33600 8600 pg/ml 
Basterzi, 2009 (14) serum 45 25.7±5.5 33.3 32.0 11.0 42005 12630 15 36.0 10.0 47727 7698 pg/ml 
Fernandes, 2009 (15) serum 10 26.3 40.0 44.8 17.0 0.35 0.08 30 41.0 11.9 0.38 0.12 pg/µg 
Gorgulu, 2009 (16) serum 42 24.3±4.7 26.8 36.4 11.3 20.49 4.31 31 35.0 12.2 33.83 7.14 ng/ml 
Matrisciano, 2009 (17) serum 21 19.0±5.3 52.4 42.4 8.0 35.4 15.2 20 31.8 5.9 64.1 13.1 ng/ml 
Ozan, 2010 (18) serum 66 24.1±1.06 28.8 33.0 2.3 22.13 6.47 56 34.0 ? 27.27 6.5 ng/ml 
Umene-Nakano, 2009 
(19) 
plasma 20 >15 75.0 45.0 9.0 9.8 5.2 20 43.0 7.0 21.1 7 ng/ml 
Diniz, 2010 (20) serum 29 18.0(14-22) 20.7 71 NA 603.43 276.87 42 69.5 NA 1016.14 902.61 pg/l 
Eker, 2010 (21) serum 25 24.4±4.8 28.0 32.1 9.3 21.7 6.6 22 29.7 6.4 27 5.7 ng/ml 
Hung, 2010 (22) serum 25 32.7±0.82 34.5 38.4 2.15 21.7 6.6 22 33.0 1.17 27 5.7 ng/ml 
Bocchio-Chiavetto,2010 
(23) 
serum 55 22.7±4.6a 20.0 43.4 10.0 5.24 3.7 53 42.6 10.1 5.5 3.58 pg/ml 
Shi, 2010 (24) plasma 25 28.6±6.8 37.5 69.2 6.4 29.6 12.4 59 70.0 6.2 40.7 11.3 pg/ml 
Molendijk, 2011 (25) serum 962 33±12.9 b  66.8 42.6 11.0 9.14 3.51 382 45.7 12.3 9.4308 3.1755 ng/ml 
Satomura, 2011 (26) serum 109 19.4±8.7 41.3 39.8 14.5 20321.2 8180 163 45.7 16.9 27105.5 8310.2 pg/ml 
Serra-Millas, 2011 (27) plasma 14 24.0±4.35 16.7 54.4 16.1 496.8 132.3 14 52.5 14.1 311.5 90.6 pg/ml 
Su, 2011 (28) serum 18 NA 100.0 21.9 2.0 5.7 6.5 21 25.0 3.0 12.5 3 ng/ml 
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Sozeri-Varma, 2011 (29) serum 30 17.1±4.92 80.0 39.8 16.3 1453.4 144.51 40 34.6 7.6 1632.23 252.93 pg/ml 
Wolkowitz, 2011 (30) serum 29 26.1±8.3 34.5 39.1 10.0 14.88 5.41 28 39.0 10.0 20.91 7.07 ng/ml 
Karlovic, 2013 (31) serum 122 27.3±5.6 45.9 46.5 12.4 37.5 13.3 142 44.8 14.2 56.8 6.3 ng/ml 
Chu,2012 (32) serum 12 NA 100.0 82.4 4.4 115.1 57.2 122 81.8 5.0 548.8 370.6 Pg/ml 
Deuschle, 2013 (33) serum 56 23.0±4.2 67.4 52.2 15.9 7.73 5.005 14 56.7 11.6 6.64 2.11 ng/ml 
Elfving, 2012 (34) serum 162 NA 16.7 46.5 9.6 31206 7280 289 45.7 10.4 29274 6806 pg/ml 
Oral , 2012 (35) serum 39 30.0±8.3 c  28.2 26.3 4.0 1.75 0.35 40 27.2 4.0 1.91 0.36 ng/ml 
Yoshida, 2012 (36) serum 69 11.8 ±5.5 d 35.4 40.5 9.7 21.09 5.6 78 37.2 9.8 23.11 5.9 ng/ml 
Papakostas, 2013 (37) serum 36 21.4±4.4 25.0 42.5 9.8 15174 8163 43 30.0 8.6 10096 6946 pg/ml-1 
Ristevska-Dimitrovska, 
2013 (38) 
serum  23 28.52±4.02 52.2 44.22 NA 13.15 6.75 23 44.04 NA 25.95 9.17 ng/ml 
 serum 10 NA 0 51.2 NA 26.84 8.66 10 38 NA 25.04 2.88 ng/ml 
               
Euthymia               
Aydemir, 2005 (3) serum 10 <25% on HDRS 20.0 31.8 14.3 34.6 7.1 10 39.8 7.1 31.6 8.6 ng/ml 
Gervasoni, 2005 (4) serum 26 <8 a 42.3 40.5 10.7 24.40 3.6 26 39.6 12.2 26.4 3.6 ng/ml 
Neumeister, 2005 (39) serum 25 1.1±1.2 33.3 39.8 12.7 8.206 * 1.6491* 20 33.7 12.8 7.885* 1.3000* pg/ml 
Monteleone, 2008 (12) serum 24 3.3 ±2.6 20.8 49.2 12.7 29.4 11.9 22 40.1 16.4 42.5 12.5 ng/ml 
Matrisciano, 2009 (17) serum 7 ≤ 7 57.2 42.4 7.5 52.3 12.7 20 31.8 5.9 64.1 13.1 ng/ml 
  7 ≤ 7 57.2 43.7 9.5 54.9 12.2 20 31.8 5.9 64.1 13.1 ng/ml 
  7 ≤ 7 42.8 41.3 7.9 41.6 14.1 20 31.8 5.9 64.1 13.1 ng/ml 
Molendijk, 2011 (25) serum 539 16.8±10.3b  28.9 43.1 12.9 9.2 3.2 382 45.7 12.3 9.4308 3.1755 ng/ml 
  161 20.3±10.6b 29.2 43.1 45.4 9.2 3.4 382 45.7 12.3 9.4308 3.1755 ng/ml 
Serra-Millas, 2011 (27) plasma 14 3.93±3.95 16.7 54.4 16.1 369.9 151.5 14 52.5 14.1 311.5 90.6 pg/ml 
Pillai, 2012 (40) plasma 17 according to SCID NA 67.1 5.7 248.90 117.55 43 67.0 5.3 210.12 103.55 pg/ml 
Deuschle, 2013 (33) serum 11 ≤ 7 31.8 50.5     18.0 8.5 5.54 14 56.7 11.6 6.64 2.11 ng/ml 
 serum 14 ≤ 7 42.1 54.1     13.8 8.61 6.91 14 56.7 11.6 6.64 2.11 ng/ml 
Ristevska-Dimitrovska, 
2013 (38) 
serum  23 ≤ 7 52.2 44.22 NA 24.73 11.8 10 44.04 NA 25.95 9.17 ng/ml 
serum 10 ≤ 7 0 51.2 NA 30.33 9.25 10 38 NA 25.04 2.88 ng/ml 
               
Abbreviations: HDRS – Hamilton depression rating scale; a MADRS – Montgomery- Asberg depression rating scale; b IDS - inventory of depressive symptoms ; c BDI 










Patients  Controls  






Age BDNF N Age BDNF units 
mean SD mean SD mean SD mean SD  
Mania  
Laske, 2005 (7) Medicated serum 8 NA 25 50.9 NA 15.7 03.07. 30 58.1 NA 21.3 5.4 ng/ml 
Cunha, 2006 
(41)  




Drug-free plasma 14 29.5±11.6 57.14 25.93 6.9 3.78 1.99 12 26.27 7.3 7.92 3.75 ng/ml 
Yoshimura, 
2006 (43) 




Drug-free plasma 30 36.9±0.5 23.0 26.0 4.0 224.8 76.5 30 26.5 5.2 318.5 114.2 pg/ml 
Tramontina, 
2009 (45) 












Drug-free plasma 34 28.5±6.2 38.2 49.6 14.2 3161.1 1409.3 38 42.9 9.7 1211 1043.4 pg/ml 
Huang, 2012 
(48) 
Drug-free serum 26 42.1±7.5 46.15 33.2 11.7 4.2 4 56 32.5 5.7 6.7 10.1 ng/ml 










Medicated serum 20 18.1±9.0 95 48.6 10.8 13755.2 7932.2 14 43.7 12.9 13400.4 9107 pg/ml 
Yoshimura, 
2006 (43) 














Medicated plasma 40 23.4±7.5 24.5 41.32 8.5 0.15 0.08 30 41.0 11.9 0.38 0.12 pg/µg 
protein 
Su, 2011 (28) Drug-free serum 10 
 




Medicated serum 32 3.16±5.44; 
4.28 ±4.16 




Drug-free serum 28 3.92±3.29; 
9.27±3.74 
39.3 42.54 11.5 27.9 14.8 22 44.08 13.8 42.5 12.5 ng/ml 
Tramontina, 
2007 (50) 






Medicated serum 30 1.53 ±2.8; 
3.80±7.10 





Medicated serum 30 3.6 ±4.1; 
9.20±6.00 
30 41.4 8.4 0.33 0.16 30 43.2 6.4 0.57 0.24 pg/ml 
 
Dias, 2009 (52) Medicated serum 65 1.0±1.72; 
2.6±2.36 
 
36.9 37.8 10.5 0.28 0.21 50 33.6 9.7 0.24 0.21 pg/ml 
Barbosa, 2010 
(47) 
Medicated plasma 19 1.3±2.5; 
1.9±1.8 
42.1 44.5 10.9 2695.8 1570.1 38 42.9 9.7 1211 1043.4 pg/ml 
Rybakowski, 
2010 (53, 54) 
Medicated plasma 60 0.6 ±0.9/ 
2.6±1.8 
41.6 52.6 10.2 23.6 13.3 60 52.1 13.6 28.9 10.9 ng/ml 
Barbosa, 2012 
(53) 
Medicated plasma 25 1.08 ±1.53 / 
1.52 ±1.64 
32 50.88 9.1 3991.542 2358.264 25 48.04 7.1 1752.191 1358.96 pg/ml 
Chou, 2012 
(55) 
Medicated plasma 23 3.1±0.9/ 
6.1±1.8a  
26.1 36.5 8.9 328 242.4 33 37.6 7.8 334.5 343.6 pg/ml 
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Abbreviations: HDRS – Hamilton depression rating scale; YMRS – Young mania rating scale; aMADRS - Montgomery-Asberg depression rating scale; 
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Table 5. Studies included in MDD longitudinal meta-analysis. 





















 units  
mean SD mean SD mean SD  
Aydemir, 2005 (3)  remitters serum 10 23.2±4.6  8w  VNL  20.0 31.8 14.3 17.90 9.10 34.60 7.10  ng/ml 
Gonul , 2005 (5) responders serum 28 27.28±3.53  8w  VNL, SER, FLX, 
PRX 
25.0 35.5 8.1 20.80 6.70 33.30 9.89  ng/ml 
Gervasoni, 2005 
(4) 




42.3 40.5 10.7 22.60 3.60 24.40 3.6  ng/ml 
Aydemir, 2006 (8) responders serum 20 39.75±7.4 6w ES 0 35.55 7.6  27.68  13.74 38.57 15.3  ng/ml 
Yoshimura, 2007  
(56) 
responders serum 14 24 ± 7 8w  PRX  37.7 47 19  9.10  7.70 22.00 8.5  ng/ml 
non-
responders 
12  9.60  8.00 13.80 6.70  ng/ml 
responders  7 23 ± 6 MLN  9.90  9.00 18.20 9.10  ng/ml 
non-
responders 
9  9.60  4.60 13.40 7.10  ng/ml 
Huang, 2008 (57) responders serum 58 34.8 ± 4.7 4w FLX, PRX, 
VNL, MIR 
18.0 37.4 10.3  11.70  7.70 13.10 9.10  ng/ml 
non-
responders 
21 28.4 ± 4.8 37.0 10.2  7.80  5.50 8.80 7.30  ng/ml 
Lee, 2008 (58) responders plasma 24 29.5±8.6 6w CTP, PRX, VNL 34.4 46.6 16.7  733.00  512.20 1153.6 766.00  pg/ml 
non-
responders 
8 29.9±7.9 36.7 17.6  593.50  634.00 654.70 559.80  pg/ml 
Piccinni, 2008 (59) responders serum 9 22.8 ± 5.3 4w  CTP, SER, PRX, 
AMT, IMI, 
TrIMI, DesIP 
13.3 47.0 10.8 19300.0 8800.00 22089.00 8 373.00  pg/ml 
plasma 9 2900.00 1900.00 4448.00 2 095.00  pg/ml 
Yoshimura, 2008 
(60)  
responders serum 5 22±6 4w SER+ RIS 28.5 54.0 10.0 8.10 2.70 11.50 0.90  ng/ml 
non-
responders 
5 7.80 2.20 7.90  2.40  ng/ml 
Hellweg, 2008 
(61) 
pooled serum 20 23.8±5.1 5w AMT 22.5 49.7 14.4 13.00 3.70 15.10 5.90  pg/ml 
pooled 20 22.6±3. PRX 51.4 14.4 13.20 5.10 12.00 4.80  pg/ml 
Basterzi, 2009 
(14) 
responders serum 17  26.5 ± 4.9  6w VNL, FLX 26.8 31.0 14.0 43280.0 13932.0 50011.00 12060.00  pg/ml 
non-
responders 
12  25.7 ± 3.5  32.0 11.0 39214.0 11439.0 44362.00 14369.00  pg/ml 
Matrisciano, 2009 
(17) 
remitters  serum 7 19 ±5.3 6 month SER 52.4 42.4 7.5 29.40 12.60 52.30 12.7  ng/ml 
7 19.4±4.5 VNL 43.7 9.5 32.20 14.00 54.90 12.2  ng/ml 
7 14.3± 5.9 ES 41.3 7.9 44.40 16.40 41.60 14.1  ng/ml 




22 14.42 12.53 14.76 13.59  ng/ml 
Gorgulu, 2009 
(16) 
responders serum 22 24.3±5.0 6w SER 26.8 33.3 11.2 19.54 4.26 52.29 6.76  ng/ml 
responders 19 25.5±4.5 SER+ Total 
sleep 
deprivation  
40.0 11.7 21.59 4.34 45.20 8.85  ng/ml 
Shi, 2010 (24) responders plasma 15 28.6±6.8  
 
6w FLX, SER 37.5 69.2 6.5 859.83 211.36 906.94 145.44  pg/ml 
Rojas, 2011 (62) responders serum 26 23.5 ±5.2 6w VNL 29.4 42.5 11.5 8.1 7.8    pg/ml 
non-
responders 
8 22.1 ±2. 39.6 10.8 16.3 12.1 5.6 1.23  pg/ml 
Serra-Millas, 2011 
(27) 
responders plasma 16 24±4.35 8w ES 16.7 38.5 16.0 496.8 132.3 454.39 167.75  pg/ml 
Wolkowitz, 2011 
(30) 
responders serum 9 26.1 ±8.3 8w ES 64.0 39.0 10.1 16.88 5.81 18.14 4.71  ng/ml 
non-
responders 
 6 12.7 4.5 16.42 2.49  ng/ml 
                
Kurita, 2012 (63) remitters plasma 38 33.7±8.9a 8w AMT, CLM; 
IMI, FLX, 
MPT, MLN, 
PRX, SER, TRZ, 
SLP 





30.0 50.4 15.2 2932.0 2373.0 2117.0 2042.0  pg/ml 
Dreimuller, 2012 
(64) 
pooled plasma 39 20.8±4.5 2w ES, SER, FLX, 
VNL, DLX, 
MIR, AMT 
48.7 44.8 13.2 298.00 196.00 334.00 157.00  pg/ml 
Deuschle,2013 
(33) 




remitters serum 23 28.52±4.02 3w SER, PRX, VEN 52.2 44.22 NA 13.15 6.75 24.73 11.80  ng/ml 
 remitters serum 10 NA 3w NA 0 51.2 NA 26.84 8.66 30.33 9.25  ng/ml 
                
Abbreviations: HDRS – Hamilton depression rating scale; aMADRS  - Montgomery-Asberg depression rating scale; ES -escitalopram; SER - sertraline; FLX- 
fluoxetine; VNL - venlafaxine; DLX - duloxetine; MIR - mirtazapine; AMT - amitriptyline; CLM – clomipramine; MPT - maprotiline; MLN - milnacipran; PRX - 




Table 6. Longitudinal studies on BDNF in bipolar disorder. 




























responders plasma 14 NA 4 Li + aa/p na 23.7 1.0 3.78 1.9 5.12 2.78 ng/ml 
Yoshimura, 
2006 (43) 
responders serum 12 22±5.0 4 RSP; RSP 
+ VA 
44.4 34 15.0 23.4 11 26.5 12 pg/ml 
Tramontina, 
2009 (45) 




responders plasma 10 37.3±9.5 4 Li 
 
60 25.4 7.5 406.3 69.5 510.9 127.1 pg/ml 
Grande, 2012 
(66) 









responders serum 21 42.1±7.5 4 VA or Li 
+ A/P 






serum 6 24.0±6.0 4 RSP; 
RSP+ VA 
44.4 34 15.0 16.1 8 17.1 7 pg/ml 
Grande, 2012 
(66) 















48.0348 12.96763 48.0481 12.66
159 
pg/ml 
Abbreviations: YMRS – Young mania rating scale; HDRS – Hamilton depression rating scale;   Li – lithium; VA – valproic acid; a/p – antipsychotics; aa/p – atypical 
antipsychotics; a/d – antidepressants; m/s  - mood stabilizer; QTP – quetiapine; RSP – risperidone.   
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Funnel plots for cross-sectional meta-analyses 
Figure 1. Funnel plot for cross-sectional studies of BDNF plasma levels in patients with MDD in acute state versus control subjects. 
 
Figure 2. Funnel plot for cross-sectional studies of BDNF serum levels in patients with MDD in acute state versus control subjects. Reflects signs of publication bias. 
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Figure 3. Funnel plot for cross-sectional studies of BDNF serum levels in patients with MDD in euthymic state versus control subjects. 
 
Figure 4. Funnel plot for cross-sectional studies of BDNF serum levels in patients with BD depressive state versus control subjects. 
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Figure 5. Funnel plot for cross-sectional studies of BDNF plasma levels in patients with BD manic state versus control subjects. 
 
Figure 6. Funnel plot for cross-sectional studies of BDNF serum levels in patients with BD manic state versus control subjects. 
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Figure 7. Funnel plot for cross-sectional studies of BDNF plasma levels in patients with BD euthymic state versus control subjects. 
 
Figure 8. Funnel plot for cross-sectional studies of BDNF serum levels in patients with BD euthymic state versus control subjects. 
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Funnel plots for longitudinal studies 
Figure 9. Funnel plot for longitudinal studies of BDNF levels change in serum of patients with MDD who reached remission. 
 
Figure 10. Funnel plot for longitudinal studies of BDNF levels change in serum of patients with MDD who responded to treatment. Reflects signs of publication 
bias. 
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Figure 11. Funnel plot for longitudinal studies of BDNF levels change in serum of patients with MDD who did not respond to treatment. Reflects signs of 
publication bias. 
 
Figure 12. Funnel plot for longitudinal studies of BDNF levels change in plasma of patients with MDD who responded to treatment 
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Figure 13. Forest plot for meta-analysis of cross-sectional studies of serum BDNF levels in depressive state of MDD. 
 
 
Study name Subgroup within study Diagnosis Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Aydemir, 2005 depression MDD -1.547 0.510 0.260 -2.547 -0.548 -3.036 0.002
Aydemir, 2006 depression MDD -0.932 0.333 0.111 -1.585 -0.280 -2.800 0.005
Basterzi, 2009 depression MDD -0.492 0.302 0.091 -1.083 0.099 -1.631 0.103
Bocchio-Chiavetto, 2010 depression MDD -0.071 0.193 0.037 -0.449 0.306 -0.371 0.711
Chu,2012 depression MDD -1.221 0.312 0.097 -1.832 -0.610 -3.918 0.000
Deuschle, 2012 depression MDD 0.237 0.299 0.090 -0.350 0.824 0.792 0.428
Diniz, 2009 depression MDD -0.575 0.246 0.061 -1.058 -0.092 -2.335 0.020
Eker, 2010 depression MDD -0.855 0.305 0.093 -1.454 -0.257 -2.801 0.005
Elfving, 2012 depression MDD 0.277 0.099 0.010 0.084 0.470 2.808 0.005
Fernandes, 2009 depression MDD -0.268 0.366 0.134 -0.986 0.450 -0.732 0.464
Gervasoni, 2005 depression MDD -1.056 0.296 0.088 -1.636 -0.475 -3.566 0.000
Gonul, 2005 depression MDD -0.768 0.313 0.098 -1.381 -0.156 -2.459 0.014
Gorgulu, 2009 depression MDD -2.348 0.306 0.094 -2.948 -1.747 -7.665 0.000
Huang, 2008 depression MDD -0.454 0.137 0.019 -0.723 -0.185 -3.308 0.001
Hung, 2010 depression MDD -0.855 0.305 0.093 -1.454 -0.257 -2.801 0.005
Karege, 2002 depression MDD -0.724 0.267 0.071 -1.247 -0.202 -2.717 0.007
Karlovic, 2012 depression MDD -1.901 0.149 0.022 -2.192 -1.610 -12.793 0.000
Laske, 2005 depression MDD -0.334 0.312 0.097 -0.945 0.276 -1.073 0.283
Matrisciano, 2009 depression MDD -2.019 0.384 0.147 -2.771 -1.267 -5.260 0.000
Molendijk, 2011 depression MDD -0.085 0.060 0.004 -0.204 0.034 -1.406 0.160
Monteleone, 2008 depression MDD -0.986 0.389 0.151 -1.748 -0.224 -2.537 0.011
Oral , 2012 depression MDD -0.451 0.228 0.052 -0.897 -0.004 -1.977 0.048
Ozan, 2009 depression MDD -0.793 0.189 0.036 -1.162 -0.423 -4.202 0.000
Papakostas, 2013 depression MDD 0.675 0.232 0.054 0.220 1.130 2.907 0.004
Piccini, 2008(1) depression MDD -1.644 0.545 0.297 -2.712 -0.575 -3.015 0.003
Satomura, 2011 depression MDD -0.822 0.129 0.017 -1.074 -0.569 -6.386 0.000
Shimizu,2003 depression MDD -0.919 0.292 0.085 -1.491 -0.348 -3.151 0.002
Sozeri-Varma, 2011 depression MDD -0.837 0.252 0.063 -1.331 -0.344 -3.327 0.001
Su, 2011 depression MDD -1.380 0.357 0.128 -2.080 -0.680 -3.864 0.000
Wolkowitz, 2011 depression MDD -0.960 0.280 0.078 -1.509 -0.412 -3.432 0.001
Yoshida, 2012 depression MDD -0.351 0.167 0.028 -0.677 -0.024 -2.105 0.035
Yoshimura, 2007 depression MDD -1.645 0.256 0.065 -2.146 -1.144 -6.436 0.000
Ristevska-Dimitrovska, 2013 depression MDD -1.590 0.338 0.114 -2.253 -0.927 -4.700 0.000
-0.806 0.123 0.015 -1.047 -0.564 -6.536 0.000
-4.00 -2.00 0.00 2.00 4.00
Decreased in depression Increased in depression
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Figure 14. Forest plot for meta-analysis of cross-sectional studies of plasma BDNF levels in depressive state of MDD. 
 
 
Figure 15. Forest plot for meta-analysis of cross-sectional studies of serum BDNF levels in euthymic state of MDD. 
 
Study name Subgroup within study Diagnosis Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Karege, 2005 depression MDD -1.626 0.262 0.069 -2.140 -1.112 -6.201 0.000
Lee, 2008 depression MDD -0.224 0.227 0.052 -0.669 0.221 -0.985 0.325
Piccini, 2008 depression MDD -1.185 0.511 0.261 -2.187 -0.183 -2.319 0.020
Serra-Millas, 2011 depression MDD 1.634 0.437 0.191 0.779 2.490 3.744 0.000
Shi. 2010 depression MDD -0.954 0.250 0.062 -1.444 -0.465 -3.821 0.000
Umene-Nakano, 2008 depression MDD -1.833 0.377 0.142 -2.571 -1.094 -4.864 0.000
-0.713 0.429 0.184 -1.554 0.128 -1.662 0.097
-4.00 -2.00 0.00 2.00 4.00
Decreased in depression Increased in depression
Study name Subgroup within study Diagnosis Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Aydemir, 2005 remission MDD 0.380 0.451 0.204 -0.504 1.265 0.843 0.399
Gervasoni, 2005 remission MDD -0.556 0.283 0.080 -1.110 -0.002 -1.966 0.049
Matrisciano, 2009 remission MDD -0.907 0.456 0.208 -1.801 -0.013 -1.989 0.047
Monteleone, 2008 remission MDD -1.075 0.316 0.100 -1.693 -0.456 -3.404 0.001
Neumeister, 2005 remission MDD 0.210 0.301 0.090 -0.380 0.799 0.697 0.486
Matrisciano, 2009 (1) remission MDD -0.714 0.450 0.202 -1.595 0.168 -1.587 0.113
Matrisciano, 2009 (2) remission MDD -1.686 0.495 0.245 -2.657 -0.715 -3.402 0.001
Molendijk, 2011 (1) remission MDD -0.072 0.067 0.004 -0.203 0.059 -1.081 0.279
Molendijk, 2011 (2) remission MDD -0.071 0.094 0.009 -0.255 0.113 -0.757 0.449
Deuschle, 2013 remission MDD 0.467 0.408 0.167 -0.333 1.267 1.144 0.253
Deuschle, 2013 (1)) remission MDD 0.386 0.381 0.146 -0.362 1.133 1.011 0.312
Ristevska-Dimitrovska, 2013 remission MDD -0.110 0.379 0.144 -0.853 0.633 -0.290 0.772
Ristevska-Dimitrovska, 2013 (1) remission MDD 0.772 0.464 0.215 -0.136 1.681 1.666 0.096
-0.197 0.125 0.016 -0.442 0.048 -1.573 0.116
-4.00 -2.00 0.00 2.00 4.00
Decreased in remission Increased in remission
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Figure 16. Forest plot for meta-analysis of cross-sectional studies of plasma BDNF levels in euthymia state of major depression. 
 
Figure 17. Forest plot for meta-analysis of cross-sectional studies of plasma and serum BDNF levels in depressive state of BD.
 
Study name Subgroup within study Diagnosis Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Serra-Millas, 2011 remission MDD 0.468 0.383 0.147 -0.283 1.219 1.221 0.222
Pillai, 2012 remission MDD 0.360 0.288 0.083 -0.205 0.926 1.250 0.211
0.399 0.230 0.053 -0.052 0.851 1.733 0.083
-4.00 -2.00 0.00 2.00 4.00
Decreased in remission Increased in remission
Group by
Source
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
plasma Fernandes, 2009 depression -2.322 0.311 0.097 -2.932 -1.712 -7.461 0.000
plasma Yoshimura, 2006(1) depression -0.837 0.480 0.230 -1.777 0.103 -1.745 0.081
plasma -1.648 0.597 0.356 -2.818 -0.479 -2.763 0.006
serum Su, 2011(1) depression -1.964 0.458 0.210 -2.862 -1.067 -4.288 0.000
serum Cunha, 2006 depression -0.510 0.285 0.081 -1.069 0.049 -1.789 0.074
serum de Oliveira, 2009 depression -1.661 0.434 0.189 -2.512 -0.810 -3.826 0.000
serum de Oliveira, 2009(1) depression -0.967 0.400 0.160 -1.751 -0.183 -2.418 0.016
serum Mackin, 2006 depression 0.042 0.349 0.121 -0.641 0.725 0.121 0.904
serum -0.971 0.375 0.141 -1.706 -0.236 -2.588 0.010
Overall -1.163 0.318 0.101 -1.785 -0.541 -3.662 0.000
-4.00 -2.00 0.00 2.00 4.00
Decreased in acute state Increased in acute state
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Figure 18. Forest plot for meta-analysis of cross-sectional studies of plasma and serum BDNF levels in manic state of BD (including a study of Barbosa, 2010). 
 




Study name Subgroup within studyDiagnosis Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
plasma Barbosa, 2010 mania BD 1.586 0.271 0.073 1.056 2.116 5.862 0.000
plasma Machado-Vieira, 2007 mania BD -0.964 0.273 0.074 -1.499 -0.429 -3.534 0.000
plasma Palomino, 2006 mania BD -1.413 0.439 0.193 -2.274 -0.551 -3.214 0.001
plasma Tramontina, 2009 mania BD -0.632 0.458 0.210 -1.531 0.266 -1.380 0.168
plasma -0.317 0.518 0.268 -1.333 0.698 -0.612 0.540
serum Cuncha, 2006(1) mania BD -1.052 0.267 0.071 -1.575 -0.530 -3.946 0.000
serum De Oliveira, 2009 mania BD -1.390 0.396 0.157 -2.167 -0.613 -3.505 0.000
serum De Oliveira, 2009(1) mania BD -0.550 0.365 0.133 -1.266 0.165 -1.507 0.132
serum Huang, 2012 mania BD -0.288 0.238 0.057 -0.756 0.179 -1.210 0.226
serum Yoshimura, 2006 mania BD -0.105 0.365 0.134 -0.821 0.611 -0.288 0.774
serum -0.673 0.458 0.210 -1.571 0.225 -1.469 0.142
Overall -0.517 0.343 0.118 -1.189 0.156 -1.506 0.132
-4.00 -2.00 0.00 2.00 4.00
Decreased in mania Increased in mania
Group by
Source
Study name Subgroup within studyDiagnosis Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
plasma Machado-Vieira, 2007 mania BD -0.964 0.273 0.074 -1.499 -0.429 -3.534 0.000
plasma Palomino, 2006 mania BD -1.413 0.439 0.193 -2.274 -0.551 -3.214 0.001
plasma Tramontina, 2009 mania BD -0.632 0.458 0.210 -1.531 0.266 -1.380 0.168
plasma -1.001 0.290 0.084 -1.569 -0.433 -3.456 0.001
serum Cuncha, 2006(1) mania BD -1.052 0.267 0.071 -1.575 -0.530 -3.946 0.000
serum De Oliveira, 2009 mania BD -1.390 0.396 0.157 -2.167 -0.613 -3.505 0.000
serum De Oliveira, 2009(1) mania BD -0.550 0.365 0.133 -1.266 0.165 -1.507 0.132
serum Huang, 2012 mania BD -0.288 0.238 0.057 -0.756 0.179 -1.210 0.226
serum Yoshimura, 2006 mania BD -0.105 0.365 0.134 -0.821 0.611 -0.288 0.774
serum -0.657 0.206 0.042 -1.061 -0.254 -3.194 0.001
Overall -0.773 0.168 0.028 -1.102 -0.444 -4.605 0.000
-4.00 -2.00 0.00 2.00 4.00




Figure 19. Forest plot for meta-analysis of cross-sectional studies of plasma and serum BDNF levels in euthymic state of bipolar disorder.
 




Study name Subgroup within study Medication Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
plasma Barbosa, 2010(1) euthymia Medicated 1.197 0.303 0.092 0.604 1.790 3.956 0.000
plasma Rybakowski, 2010 euthymia Medicated -0.436 0.185 0.034 -0.798 -0.074 -2.360 0.018
plasma Barbosa, 2012 euthymia Medicated 1.164 0.306 0.094 0.564 1.763 3.804 0.000
plasma Chou, 2012 euthymia Medicated -0.021 0.272 0.074 -0.554 0.511 -0.078 0.938
plasma 0.442 0.344 0.118 -0.232 1.116 1.285 0.199
serum Cunha, 2006(2) euthymia Medicated -0.133 0.250 0.063 -0.624 0.357 -0.532 0.595
serum Monteleone, 2006 euthymia Drug-free -1.055 0.304 0.092 -1.650 -0.459 -3.472 0.001
serum Tramontina, 2007 euthymia NA -0.250 0.127 0.016 -0.499 -0.001 -1.964 0.049
serum Kauer-Sant’Anna, 2009 euthymia Medicated 0.666 0.265 0.070 0.146 1.186 2.510 0.012
serum Kauer-Sant’Anna, 2009(1) euthymia Medicated -1.177 0.280 0.078 -1.725 -0.629 -4.208 0.000
serum Dias, 2009 euthymia Medicated 0.190 0.189 0.036 -0.179 0.560 1.010 0.312
serum -0.278 0.276 0.076 -0.819 0.264 -1.004 0.315
Overall 0.005 0.215 0.046 -0.417 0.427 0.023 0.982
-4.00 -2.00 0.00 2.00 4.00
De c re a s e d  in  e u th y ic  s ta te  o f  BD In c re a s e d   in  e u th y ic  s ta te  o f  BD
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
 Aydemir, 2006 Responders 0.749 0.327 0.107 0.108 1.390 2.289 0.022
 Basterzi, 2009 Responders 0.517 0.349 0.122 -0.167 1.200 1.482 0.138
 Gonul , 2005 Responders 1.480 0.302 0.091 0.889 2.071 4.906 0.000
 Gorgulu, 2009 Responders 5.796 0.688 0.473 4.449 7.144 8.431 0.000
 Piccinni, 2008 Responders 0.325 0.475 0.225 -0.605 1.255 0.684 0.494
 Umene Nakano, 2009 Responders 0.346 0.234 0.055 -0.113 0.805 1.477 0.140
 Wolkowitz, 2011 Responders 0.238 0.473 0.224 -0.689 1.165 0.504 0.615
 Yoshimura, 2008 Responders 1.689 0.737 0.543 0.246 3.133 2.293 0.022
Gorgulu, 2009 (1) Responders 3.387 0.506 0.256 2.395 4.380 6.692 0.000
Huang, 2008 (1) Responders 0.166 0.186 0.035 -0.198 0.531 0.893 0.372
Yoshimura, 2007 (3) Responders 1.591 0.434 0.188 0.741 2.441 3.668 0.000
Yoshimura, 2007 (4) Responders 0.917 0.429 0.184 0.076 1.758 2.137 0.033
1.327 0.327 0.107 0.685 1.969 4.051 0.000
-4.00 -2.00 0.00 2.00 4.00
Decreased in Responders Increased in Responders
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Figure 21. Forest plot for meta-analysis of longitudinal studies of serum BDNF levels in patients with major depression who reached remission. 
 
Figure 22. Forest plot for meta-analysis of longitudinal studies of serum BDNF levels in patients with major depression who did not respond to treatment. 
 
 
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Matrisciano, 2009 (2) Remission 0.183 0.536 0.287 -0.867 1.233 0.342 0.732
Matrisciano, 2009 (1) Remission 1.729 0.626 0.392 0.501 2.957 2.760 0.006
Deuschle,2012 (2) Remission 0.020 0.378 0.143 -0.721 0.760 0.052 0.959
 Matrisciano, 2009 Remission 1.810 0.635 0.403 0.566 3.054 2.852 0.004
 Gervasoni, 2005 Remission 0.500 0.282 0.079 -0.052 1.052 1.775 0.076
 Deuschle,2012 Remission 0.473 0.432 0.187 -0.375 1.320 1.093 0.274
 Aydemir, 2005 Remission 2.046 0.552 0.305 0.964 3.128 3.707 0.000
Ristevska-Dimitrovska, 2013 Remission 1.205 0.321 0.103 0.576 1.833 3.759 0.000
Ristevska-Dimitrovska, 2013 (1)Remission 0.390 0.451 0.204 -0.495 1.274 0.863 0.388
0.837 0.228 0.052 0.389 1.285 3.663 0.000
-4.00 -2.00 0.00 2.00 4.00
Decreased in remission Increased in remission
Study name Subgroup within study Statistics for each study Std diff in means and 95% CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Basterzi, 2009 (1) Non-responders 0.396 0.412 0.170 -0.412 1.204 0.962 0.336
Huang, 2008 Non-responders 0.155 0.309 0.096 -0.451 0.760 0.501 0.617
Kurita,2012 (1) Non-responders 0.368 0.451 0.203 -0.516 1.252 0.816 0.414
Rojas, 2011 Non-responders -1.244 0.303 0.092 -1.838 -0.650 -4.106 0.000
Umene Nakano, 2009(1) Non-responders 0.026 0.302 0.091 -0.565 0.617 0.086 0.931
Wolkowitz, 2011 (1) Non-responders 1.023 0.614 0.377 -0.180 2.226 1.666 0.096
Yoshimura, 2007 (1) Non-responders 0.569 0.545 0.297 -0.499 1.638 1.044 0.297
Yoshimura, 2007 (2) Non-responders 0.635 0.483 0.233 -0.312 1.582 1.315 0.189
Yoshimura, 2008 (1) Non-responders 0.043 0.633 0.400 -1.196 1.283 0.069 0.945
0.147 0.244 0.060 -0.331 0.626 0.604 0.546
-2.00 -1.00 0.00 1.00 2.00
Decreased in Responders Increased in Responders
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Figure 20. Forest plot for meta-analysis of longitudinal studies of plasma BDNF levels in patients with major depression who reached remission. 
 
Figure 23. Forest plot for meta-analysis of longitudinal studies of plasma BDNF levels in patients with major depression who responded to treatment. 
 
Figure 24. Forest plot for meta-analysis of longitudinal studies of plasma BDNF levels in patients with major depression who did not respond to treatment. 
  
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
 Kurita,2012 Remission 0.388 0.232 0.054 -0.066 0.842 1.676 0.094
0.388 0.232 0.054 -0.066 0.842 1.676 0.094
-4.00 -2.00 0.00 2.00 4.00
Decreased in remission Increased in remission
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Serra-Millas, 2011Responders -0.281 0.355 0.126 -0.977 0.416 -0.790 0.429
Piccinni, 2008 Responders 0.774 0.489 0.239 -0.184 1.732 1.584 0.113
Lee, 2008 (1) Responders 0.646 0.296 0.088 0.065 1.226 2.180 0.029
 Shi, 2010 Responders 0.260 0.367 0.134 -0.459 0.978 0.708 0.479
0.329 0.236 0.056 -0.133 0.792 1.396 0.163
-4.00 -2.00 0.00 2.00 4.00
Decreased in responders Increased in responders
Study name Subgroup within study Statistics for each study Std diff in means and 95%  CI
Std diff Standard Lower Upper 
in means error Variance limit limit Z-Value p-Value
Lee, 2008 Non-responders 0.102 0.500 0.250 -0.878 1.083 0.205 0.838
0.102 0.500 0.250 -0.878 1.083 0.205 0.838
-4.00 -2.00 0.00 2.00 4.00
Decreased in non-responders Increased in non-responders
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Abstract
Emerging data suggest that Electro-Convulsive Treatment (ECT) may reduce depressive
symptoms by increasing the expression of Brain-Derived Neurotrophic Factor (BDNF). Yet,
conflicting findings have been reported. For this reason we performed a systematic review
and meta-analysis of the preclinical and clinical literature on the association between ECT
treatment (ECS in animals) and changes in BDNF concentrations and their effect on behavior.
In addition, regional brain expression of BDNF in mouse and human brains were compared
using Allen Brain Atlas. ECS, over sham, increased BDNFmRNA and protein in animal brain
(effect size [Hedge’s g]: 0.38−0.54; 258 effect-size estimates,N = 4,284) but not in serum (g =
0.06, 95%CI = -0.05−0.17). In humans, plasma but not serum BDNF increased following
ECT (g = 0.72 vs. g = 0.14; 23 effect sizes, n = 281). The gradient of the BDNF increment in
animal brains corresponded to the gradient of the BDNF gene expression according to the
Allen brain atlas. Effect-size estimates were larger following more ECT sessions in animals
(r = 0.37, P < .0001) and in humans (r = 0.55; P = 0.05). There were some indications that the
increase in BDNF expression was associated with behavioral changes in rodents, but not in
humans. We conclude that ECS in rodents and ECT in humans increase BDNF concentra-
tions but this is not consistently associated with changes in behavior.
Introduction
Electro Convulsive Treatment (ECT) has been used as a treatment for mood disorders for
years. There is little doubt on the clinical efficacy of ECT [1, 2], yet, how it improves mood
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remains unclear [3, 4]. Emerging data have led to the idea that ECT may reduce depressive
symptoms by increasing the expression of Brain-Derived Neurotrophic Factor (BDNF), a key
regulator of neuronal functioning [5]. This idea rests on the neurotrophin hypothesis, which
posits that depressive disorders are secondary to a stress-induced lowered expression of BDNF
[6]. Complementary, it predicts that antidepressants are efficacious, because they increase
BDNF expression and herewith boost neuronal plasticity [7–9].
Preclinical and clinical studies both have provided support for the neurotrophin hypothesis.
Nibuya et al. [10], for instance, showed in rats that Electro-Convulsive Shocks (ECS, the equiv-
alent of ECT in animals) increases the expression of hippocampal BDNF mRNA. This has
been replicated and extended to other brain regions (e.g., the amygdala [11]) and was shown
for BDNF protein levels [12]. Interestingly, and in line with the neurotrophin hypothesis, some
studies show that the increase in BDNF following ECS is associated with a decrease in depres-
sion-like behaviors.
Measurements in brain tissue, as they are applied in preclinical studies, obviously cannot be
pursued in humans. Clinical studies usually measure the change in peripheral (e.g., blood
serum) BDNF protein concentrations over treatment with ECT. The validity of this approach
is based on the observation that the brain is in part the source of BDNF in peripheral tissues
[12, 13]. Clinical studies show that peripheral BDNF concentrations increase following treat-
ment with ECT, as evidenced by a recent a meta-analysis (Hedge’s g = 0.38, 11 studies, 221 sub-
jects) [14]. In contrast to some individual preclinical (e.g., Li et al. [15]) and clinical studies
(e.g., Hu et al. [16]), this meta-analysis did not find evidence for the notion that changes in
BDNF concentrations over treatment are related to the clinical efficacy of ECT. This omission
may be due to a limited number of trials and patients and the use of group-level statistics [17].
An additional factor explaining the lack of association may be that serum and plasma BDNF
measurement were merged in the analyses. Plasma levels are likely to reflect momentary BDNF
protein expression, while serum levels reflect accumulated (over a period of about 10 days)
BDNF [18–20]. The combination of plasma and serum measurement in a single meta-analysis,
as was done by Brunoni et al. [14], therefore may not be biologically plausible.
Notwithstanding some contradictory findings, the data above suggest a relation between
ECT treatment and BDNF expression. The goal of this study, then, was to evaluate, through
systematic review and meta-analyses, the preclinical (i.e., rodent) and clinical (i.e., human) lit-
erature on changes in BDNF concentrations and behavior over the course of ECS and ECT
respectively. To fulfill this translational aim, we first will pool the preclinical literature on the
relationships between ECS, BDNF and depression-like behavior. Next, we will aggregate effect-
sizes of ECT treatment on BDNF concentrations and clinical improvement as they are reported
in the human literature. This will be done partially using meta-analysis on individual data
because this better suits the questions at hand given a limited number of trials and patients that
are available [17].
Materials and Methods
We adhered to the guidelines that are recommended by the preferred reporting items for sys-
tematic reviews and meta-analyses statement [21].
Search Strategy
We searched PUBMED, Embase, and PsychInfo through December 1st 2014 to identify eligible
studies on changes in peripheral and central BDNF concentrations as a function of treatment
with ECT. The following keywords were used: ‘electroconvulsive’ or ‘ECT’ or ‘ECS’ in combi-
nation with ‘BDNF’ or ‘brain derived neurotrophic factor’. This was supplemented by
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backward searches in which the references to the seminal papers of interest were screened for
preclinical and clinical studies and by examining the reference sections of the retrieved papers.
The literature search, decisions on inclusion, data extraction, and quality control were per-
formed independently by two of the authors (MP and MM).
Inclusion and Exclusion Criteria
We included peer-reviewed preclinical and clinical studies that reported data on BDNF con-
centrations as a function of ECS/ECT (i.e., ECS/ECT versus sham and pre versus post treat-
ment). Inclusion was independent of ECS/ECT characteristics (e.g., number of sessions) and
methodological characteristics of the study (e.g., tissue in which BDNF was sampled). For the
clinical studies diagnosis of major- or bipolar depression had to be based on international
classifications.
Non-empirical studies such as reviews were excluded according to review protocol, as were
case studies, studies that were not peer reviewed, and studies that were not written in Dutch,
English, French, German or Spanish. Where study samples overlapped we excluded the study
that reported on the fewest number of subjects.
Data Extraction
From each paper we extracted, as primary outcomes, mean BDNF concentrations (and Stan-
dard Deviation [SD]) in treatment conditions versus sham and/or before and after ECS/ECT or
indices on this change (e.g., the standardized mean difference). We also extracted data on
mean age, gender distribution, specifics of the ECS/ECT treatment, and the method that was
applied to quantify the amount of BDNF (e.g., RT-PCR).
From the preclinical studies we further extracted data on the strain of animal that was used,
the weight and age of the animals, the brain-region in which BDNF was measured, and the
amount of time between ECS treatment and decapitation. Data on behavioral changes due to
ECS were extracted where provided.
From the clinical studies we in addition extracted data on depression severity pre- and post
ECT, whether participants exhibited a clinical response to ECT, the antidepressant that were
used, and the amount of time between the last ECT session and blood draw for BDNF determi-
nation. In order to perform subgroup comparisons according to treatment response we con-
tacted the authors of the clinical studies and asked them to provide anonymised Individual
Patients Data (IPD) [17]. In those cases where non-significant results were reported (e.g.,
P>.05) and authors did not reply to our request for exact outcome data, we set the association
at P = .50, indicating no association.
We assessed the methodological quality of the preclinical and clinical studies using the
ARRIVE guidelines[22] and the Newcastle-Ottawa Scale (NOS) [23] respectively. In addition
we used the risk of bias assessment tool for the longitudinal studies [24]. We refer to the Sup-
plement for detailed information on quality assessment (S1 Text, S1 Table, S2 Table, S3 Table).
Statistical Analysis
Analyses were performed using Comprehensive Meta-Analyses 2.0 [25] and SPSS version 21.0
[26].Random effects models (i.e., models that include sampling- and study level error) were
applied to calculate pooled effect-sizes on changes in central and peripheral BDNF concentra-
tions as a function of ECS/ECT. As effect-size measure we chose to use Hedges’ g, a standard-
ized metric that corrects for bias related to small sample sizes [27]. All outcomes were weighted
using inverse variance methods [25]. Statistical significance was assessed using a Z-statistic at a
Confidence Interval (CI) of 95%. The amount of between-study heterogeneity in outcomes was
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quantified using the I2 measure [28] and assessed for statistical significance using the Q-statis-
tic[25].
The stability of our results was evaluated through meta-analyses that were run in specific
subgroups: (I) by brain region in which BDNF was assessed (clustered as follows: Dentate
Gyrus [DG], hippocampus not DG, cortex, other brain regions, and in serum [S4 Table], (II)
single versusmultiple ECT sessions, and (III) the type of BDNF that was measured (i.e., BDNF
mRNA versus protein and BDNF in serum versus in plasma). The possible moderating effects
of between-study differences on outcomes were evaluated by calculating correlation coeffi-
cients between the values for the moderator and the outcome of the studies.
For the analyses on preclinical data, the animal strain that was used, duration of treatment,
the amount of time between the last ECT session and decapitation for BDNF measurements,
and the quality score were considered as potential moderators. For clinical data analysis,
obtained IPD were combined with the aggregated data using a two-step approach. In a first
step summary statistics were calculated for each subgroup from single studies. In the second
step summary statistics from the IPD were combined in meta-analysis as described above.
Treatment response was considered as reduction of depression severity scores by50%. Dura-
tion of treatment and the quality score were considered as potential moderators of the effect-
sizes retrieved from clinical studies.
Visual inspection of funnel plots and the Egger test were used to assess publication bias
[29]. In case of publication bias we used trim-and-fill procedures to estimate effect-sizes after
bias has been taken into account [30].
Results
Preclinical Studies
Our search generated 97 papers of which 23 [10–11,15,33–51] fulfilled the inclusion criteria
(see Fig 1 for a flow-chart). From these we could extract 280 effect-size estimates (k) on a total
of 4,670 animals (mean n = 17 per effect-size, range 8–30) on changes in BDNF concentrations
in animals that were subjected to ECS as compared to sham treatment or, in one case, to base-
line.[31] Mean number of ECS sessions was 5 (range: 1–14). Mean time that passed between
last ECS session and decapitation was 40 hours (range: 1–504 hours). We refer to Table 1 for
the included studies and general information on them. S5 Table and S6 Table provide addi-
tional information on the animals that were used and the methods that were applied.
Meta-analysis over preclinical findings
ECS was associated with increased BDNF concentrations in comparison to sham treatment
(g = 0.40, 95% CI = 0.35−0.44, P< .0001; 280 effect-sizes, N = 4,284). Meta-analyses by specific
brain region showed a larger effect-size (P< .05) when BDNF was assessed in the DG
(g = 0.54) as compared to assessments in the hippocampus and the cortex (g: 0.38−0.41 respec-
tively). Yet, effect-sizes were significant regardless in which brain area BDNF was sampled (see
Table 2). Interestingly, the observed gradient of ECS induced increases in BDNF protein corre-
sponds to the gradient of BDNF gene expression across the whole brain in mice and humans as
assessed in the genome wide atlas of the Allen Institute for Brain Sciences (Seattle, WA, USA,
see www.brain-map.org) [52]. Results of this analysis are illustrated in Fig 2 with highest gene
expression in DG, followed by hippocampus and other brain regions.
Evidence for increases in serum BDNF concentrations (i.e., in blood serum) following ECS
was not found in the preclinical data (g = 0.06, 95% CI = -0.05−0.17). In fact, the pooled effect-
size on serum measurement was smaller as compared to the ones calculated on central BDNF
(P-values all< .001). Studies that subjected animals to multiple ECS’s yielded larger effect-size
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as compared to studies that applied single ECS (P< .0001). Yet, also a single ECS session was
associated with an increase in BDNF (see Table 2). The pooled effect size that was derived
from studies that measured BDNF mRNA was larger as the one from studies that measured
BDNF protein (P< .0001) although the latter also was statistically significant (see Table 2).
Between-study heterogeneity in outcomes was identified (I2 = 51%, Q = 572.13, P< .00001).
The number of ECS sessions that was applied and the time that passed between the last ECS ses-
sion and measurement appeared to be sources of the observed heterogeneity. A larger number of
treatment sessions, in general was associated with larger effect size estimates (r = 0.36, R2 = 0.13,
P< .0001) and a longer gap in time between the last ECS session and decapitation with smaller
effect-size-estimates (r = -0.27, R2 = 0.07, P< .0001). The correlation between the number of
ECS and ECS induced increase in BDNF was also present within the multiple treated animals
(r = 0.35, R2 = 0.13, [202 data points], P< .0001). The methodological quality of a study was
unrelated to outcome.
Fig 1. Prisma flow diagram of the search strategy and its results.
doi:10.1371/journal.pone.0141564.g001
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The funnel plot and the Egger’s test suggested evidence for publication bias in the overall
analysis (t[278] = 10.41, P< .0001). Imputation of 15, presumed missing, effect-size estimates
resulted in a symmetric funnel-plot. The pooled effect-size estimate that was recalculated after
imputation was only slightly smaller as compared to the one derived in the original analysis
(g = 0.38, 95% CI = 0.35−0.41). Between-study heterogeneity, correlations between outcomes
and moderators, and publication bias in outcomes were rather similar in analyses that were
run separately in the subgroups (see Table 3).
ECS, BDNF and changes in behaviour. There was too little comparable data on behav-
ioral tests (e.g., the open-field test) to perform meta-analysis on. In case similar behavioral par-
adigms were applied, often the outcome measures over studies were different. This was for
Table 1. Basic information on the preclinical studies included in the meta-analysis.
Study Animal A ECT n B
Lindefors et al.[32] Sprague-Dawley rats Single: 1 p/d for 1 d 6
Nibuya et al.[10] Sprague-Dawley rats Single: 1 p/d for 1 d and Multiple: 1 p/ for 10 d 8
Zetterström et al.[33] Sprague-Dawley rats Single: 1 p/d for 1 d and Multiple: 5 over 10 d 5
Chen et al.[34] Sprague-Dawley rats Multiple: 1 p/d for 10 d 6
Altar et al. [11] Wistar rats Single: 1 p/d for1, 2 and 3 d and Multiple: 1 p/d
for 4, 6, 10 d
7–9
Angelucci et al.[35] FRL and FSL rats Multiple: 1 p/d for 10 d 7
Dias et al.[36] Sprague-Dawley rats Single: 1 p/d for1, 2 and 3 d, and Multiple: 1 p/d
for 10 d
5
Newton et al. [37] Sprague-Dawley rats Single: 1 p/d for1 d and Multiple: 1 p/d for 10 d 5
Jacobsen et al.[38] Wistar rats Multiple: 1 p/d for 10 d 8
Li et al.[39] Wistar rats Multiple: 6 or 14 for 6 or 14 d 15
Ploski et al. [40] Sprague-Dawley rats Multiple: 1 p/d for 14 d 8
Conti et al. [41] Sprague-Dawley rats Multiple: 8 for 2 d 8
Li et al. [15] Wistar rats Multiple: 14 for 14 d 7–8
Sartorius et al.[31] Sprague-Dawley rats Single: 1 p/d for1 d and Multiple: 1 p/d for 5 d 8





Multiple: 5 p/d for 5 d 10
Luo et al.[44] Wistar rats Multiple: 1 p/d for 6–14 d 10
O'Donovan et al.[45] Sprague-Dawley rats Multiple: 10 sessions over 3–4 weeks 8
Ryan et al.[46] Sprague-Dawley rats Single: 1 p/d for 1 d and Multiple: 10 sessions
over 21–28 d
8
Segawa et al. [47] Sprague-Dawley rats Single: 1 p/d for1 d and Multiple: 1 p/d for 10 d 8
Segi-Nishida et al.
[48]
C57BL/6N mice Single: 1 p/d for 1 d and Multiple: 1 p/d for 6 and
for 14 d
4





Multiple: 5 p/d for 5 d 9–
10
A all studies assessed male animals. Sartorius et al.[31] and Gersner et al.[51] did not specify the sex of the
animals they used.
B n is given per group and, in general can be doubled for the experimental vs sham comparison.
All studies applied sham ECT as the control condition, except for the study by Sartorius et al.[31] in which
baseline was considered as the control condition.
In the S5 Table we present additional information on the included preclinical studies (e.g., age and weight
of the animals).
doi:10.1371/journal.pone.0141564.t001
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instance so for swimming time in the FST for which we could extract 48 effect-size estimates
(910 animals, range: 11−30 per effect-size) on total swimming time in the FST. Together,
these showed that ECS, over sham, increased swimming time (g = 0.26, 95% CI = 0.19−0.32,
P< .0001). The increase in swimming time correlated positively with the increase in BDNF
(r = 0.37, R2 = 0.14, P< .001). Note though that these effect sizes came from only four studies
that widely differed in for instance in time of sacrifice after ECS and other variables that poten-
tially can confound the observed relation. The association, thus, should be interpreted with
caution.
Sensitivity analyses. None of the study findings was unduly driven by the effect of a par-
ticular study (data not shown). Furthermore, effect-size estimates were not related (P = .49) to
whether or a particular study used a stress paradigm (e.g., chronic unpredictable mild stress).
Method of BDNF measurement was not associated with the amount of change in detectable
BDNF (P = .17; see S6 Table for the methods of measurement by study). Animal strain was
tested as a potential effect modifier (see S6 Table for the animal strain that was used in each
individual study). Analyses showed that there were no differences in ECS induced increases in
BDNF as a function of strain of animal that was used in the experiment (P = .18).
Clinical Studies
Our search for clinical studies generated 111 publications of which 14 fulfilled the inclusion cri-
teria (see Fig 1 for a flow-chart). From these papers we obtained 23 effect-size estimates on
changes in BDNF concentrations over the course of ECT (N = 250 subjects a [mean n = 13 per
Table 2. Pooled effect-size estimates, heterogeneity and publication bias for the animal studies by sub-groupmeta-analyses indicated in the row.
k N Hedges’ g (95% CI) Heterogeneity Publication bias
I2 Q Egger’s t
BDNF sampled in: A
DG 25 384 0.54 (0.42–0.67) *** 23.6% 31.4 3.1 *
Hippocampus 124 2,032 0.38 (0.32–0.45) *** 49.3% 242.8 *** 5.2 ***
Cortex 57 982 0.41 (0.32–0.51) *** 51.5% 115.6 *** 3.3 **
Other 61 976 0.44 (0.34–0.54) *** 56.8% 138.9 *** 6.9 **
Serum 13 296 0.06 (-0.05–0.17) 0.1% 6.7 0.3
Number of sessions: B
Single treatment 78 1,282 0.22 (0.12–0.29) *** 44.3% 138.3 *** 5.5 **
Multiple treatment 202 3,388 0.46 (0.38–0.48) *** 49.6% 398.9 *** 8.8 **
BDNF type: C
BDNF protein 147 2,795 0.35 (0.29–0.41) *** 49.0% 286.5 *** 8.2 **
BDNF mRNA D 133 1,875 0.46 (0.39–0.53) *** 51.0% 224.8 *** 7.5 **
A Effect-size estimates were of a larger magnitude in studies that measured central- as compared to serum BDNF (all P-values < .001). Furthermore,
larger effect-size estimates were found in the DG as compared to those found in the hippocampus and the cortex (P-values < .05). There were no
statistically significant differences in pooled effect-size estimates derived from the hippocampus, the cortex and other brain regions (all P-values > .5).
B Chronic ECS yielded larger effect-size estimates as compared to single ECS (P < .0001).
C Studies that sampled BDNF mRNA yielded larger effect-size estimates as compared to studies that sampled BDNF protein (P < .01).
D Among the studies that are characterized as measuring BDNF mRNA were 3 effect-sizes on BDNF RNA and 9 on the precursor protein pro-BDNF.
Excluding these effect-sizes did not change the results.
* Statistical significant at P < .05
** Statistical significance at P < .01
*** Statistical significance at P < .001.
doi:10.1371/journal.pone.0141564.t002
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Fig 2. Gene expression of BDNF across the whole brain as assessed in Allen Brain Atlas (Seattle, WA, USA). In mice, gene expression was the
highest in the DG/hippocampus as investigated by In Situ Hybridization (ISH), where warm colors indicate high expression. Note that contrast and brightness
were enhanced in original images to increase visibility of the effects here. Black bars correspond to 2 mm. Gene expression in humans is shown as
individually normalized gene expression (Z-scores normalized to whole human brain expression). The heat map shows scores across the whole human brain
and for each of the six subjects contained in the database beside each other, where red indicates high and green indicates low expression. Bars represent
mean normalized gene expression and standard deviation across one female and five male subjects included. Search conducted on 17th October 2014 for
human and on 9th October 2014 for mice data. *** P < 0.001; ** P < 0.01; * P < 0.05, two-tailed Student’s t-test against 0. For details on the methods we
refer to Mueller et al.[53]
doi:10.1371/journal.pone.0141564.g002
Table 3. Pearson’s correlation coefficients on the relation between study characteristics and study effect size (by meta-analysis indicated in the
columns).
All DG Hippocampus Cortex Other
BDNF mRNA and protein k = 267, n = 4,374 k = 25, n = 384 k = 124, n = 2,032 k = 57, n = 982 k = 61, n = 976
Number of treatments A 0.36*** 0.10 0.43*** 0.46*** 0.28*
Time of measurement after last ECT -0.22*** -0.38 -0.17 -0.30* -0.35**
BDNF mRNA k = 133, n = 1,489 k = 25, n = 384 k = 65, n = 933 k = 17, n = 222 k = 26, n = 336
Number of treatments 0.29** 0.10 0.29* 0.41 0.20
Time of measurement after last ECT -0.39** -0.38 -0.24 -0.29 -0.38
BDNF protein k = 147, n = 2,795 k = 0, n = 0 k = 59, n = 1,099 k = 40, n = 744 k = 35, n = 640
Number of treatments 0.48*** NA 0.61*** 0.54*** 0.25
Time of measurement after last ECT -0.21* NA -0.10 -0.32* -0.33*
A The correlation between number of treatments and outcome was also present in studies that applied multiple treatments (r = .35 (202 data points) P <
.0001).
Abbreviation. NA; Not Applicable.
* Statistically significant at P < .05
** statistically significant at P < .01
*** statistically significant at P < .001.
NOTE. There was no evidence for between-study heterogeneity in the meta-analyses on serum BDNF levels. Correlational analyses therefore were not
performed in this sub-group.
doi:10.1371/journal.pone.0141564.t003
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effect-size, range 3–48]). Ten studies [16, 54–62] reported on serum BDNF alternations (16
effect sizes) and 4 studies [63–66] (7 effect sizes) on plasma BDNF alterations. Table 4 and S7
Table provide details of the included studies.
Meta-analysis over clinical findings. Overall peripheral BDNF was significantly increased
after ECT as compared to baseline (g = 0.35, 95% CI = 0.034–0.67, P = 0.03; 23 effect sizes,
n = 281). BDNF levels increased in plasma (g = 0.72, 95% CI = 0.22–1.23, P = 0.004; 7 effect
sizes, n = 108) but not in serum (g = 0.14, 95% CI = -0.29–0.56, P = 0.67; 16 effect sizes,
n = 173). However, the difference between serum and plasma subgroups did not rich the signif-
icance threshold (P = 0.10; Table 5). When subdivided into responders and non-responders
subgroups, BDNF increased non-significantly in both the responders- (g = 0.40 95% CI = 0.02–
0.82, P = 0.06; 13 effect sizes, n = 214) and non-responders subgroups (g = 0.22 95% CI =
-0.38–0.82, P = 0.48; 9 effect sizes, n = 47). There was no different pattern of results when com-
paring the pooled effect sizes from studies that measured BDNF in serum versus plasma
(Table 5). However, significant differences could be observed between plasma and serum
BDNF in the non-responders subgroups (P = 0.05).
Sensitivity analysis showed that the results were not substantially affected by a single study.
We observed overall high heterogeneity in outcomes between the studies (Q = 63.11[22]
P<0.001, I2 = 65.14%). This appeared to be driven by the responder subgroups in both serum
Table 4. Basic information on the clinical studies included in the meta-analysis.
Study Diagnosis Source Response N (f/m) BDNF levels
Pre-treatment Post-treatment Unit
mean SD mean SD
Bocchio-Chiavetto et al.[54] MDD serum Yes 20 (14/6) 27.10 9.31 27.95 8.03 ng/ml
No 3 (2/1) 31.2 8.42 31.2 8.3 pg/ml
Marano et al.[63] MDD, BD plasma Yes 13 (3/10) 83.1 63.0 202.5 179.1 pg/ml
No 2 (1/1) 119.5 33.3 265.5 236.6 pg/ml
Okamoto et al.[55] MDD, BD serum Yes 12 (6/6) 7.9 9.9 15.1 11.1 ng/ml
No 6 (3/3) 11.5 11.0 9.4 7.5 ng/ml
Fernandes et al.[56] MDD, BD serum Yes (73.33%) 15 (10/5) 0.3 0.1 0.3 0.1 pg/ml
Gronli et al.[57] MDD, BD serum Yes 10 (NA) 1242.5 187.0 1395.7 517.7 pg/ml
Piccinni et al. [64] MDD, BD plasma Yes 8 (5/3) 2.9 1.3 5 1.8 ng/ml
No 10 (4/6) 1.5 0.5 2.7 1.4 ng/ml
Hu et al.[16] MDD serum Yes 24 (20/4) 5.5 1.9 8.08 3.5 ng/ml
No 4 (3/1) 6.5 3.4 6.9 3.1 ng/ml
Gedge et al.[58] MDD serum Yes 5 (2/3) 13.3 6.7 12.4 4.3 ng/ml
No 6 (5/1) 7.2 5.2 12.2 3.1 ng/ml
Haghighi et al.[65] MDD plasma Yes (75%) 20 (5/15) 151.0 174.7 376.7 299.3 pg/ml
Lin et al.[66] MDD, BD plasma Yes 48 (38/10) 3652.8 2372.6 3512.6 2104.9 pg/ml
MDD, BD No 7 (6/1) 3085.3 2005.6 4190.7 1917.9 pg/ml
Stelzhammer et al.[59] MDD serum Yes 3 (3/0) 20.4 13.5 8.2 4.5 ng/ml
No 4 (2/2) 22.7 7.01 14.3 5.4 ng/ml
Bilgen et al.[60] MDD serum Yes 30 (19/11) 1990.5 510 2713.3 382.8 pg/ml
Bumb et al.[61] MDD serum 20 (10/10) 2596.7 1101.5 3001.8 1118.5 pg/ml
Kleimann et al.[62] MDD serum Yes 6 541.2 294.9 342.8 134.4 pg/ml
No 5 721.8 364.1 506.3 142.0 pg/ml
Abbreviations: MDD, major depressive disorder; BD, bipolar disorder
doi:10.1371/journal.pone.0141564.t004
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and plasma (see Table 5). In line with the rodent findings, the number of ECT treatments was
positively correlated with the effect sizes in combined serum and plasma subgroup (r = 0.55;
P = 0.05). The number of subjects and methodological quality of the study was not associated
with outcomes (data not shown).
Publication bias was detected in the serum subgroup and induced by the studies by Stelz-
hammer et al. [59] and Kleimann et al. [62], two negative studies with particularly low power.
Correction for publication bias by Trim-and-Fill procedure led to an increased effect size
(g = 0.57, 95% CI = 0.11−1.04; 11 effect sizes, n = 101). Overall, and in the plasma subgroup, no
publication bias was detected.
Discussion
Our systematic review and meta-analyses investigated changes in BDNF concentrations as a
function of ECS and ECT. Our main findings are: (A) in rodents, ECS increases BDNF mRNA
and protein concentration (or synthesis/release) in the brain, with largest effect sizes measured
in the DG, (B) the increase in BDNF is positively correlated with number of treatments and
negatively with the time between the last ECT and BDNF measurement, (C) BDNF concentra-
tions do not increase in the course of treatment in rodent and human serum, yet they increased
in human plasma, and (D) the increase in BDNF following ECT is also related to the number
of treatment sessions but not to clinical outcome in human studies.
In preclinical studies ECS increased BDNF secretion throughout the brain. Activation of
distinct promoters of the BDNF gene is responsible for a differently regulated BDNF expres-
sion over brain regions [67, 68]. Four out of nine possible BDNF transcripts are expressed in
the rat brain [69]. While in most brain regions one or two transcripts are produced, all four are
activated in the DG following ECT [36]. Interestingly, BDNF expression as elicited by ECS
appeared to be highest in the DG. This relates well to what the Allen brain atlas shows: BDNF
expression in the DG of mice and human brains is highest in this region. A constant supply of
Table 5. Pooled effect-size estimates, heterogeneity and publication bias for the clinical studies by sub-groupmeta-analyses indicated in the row.
k n Hedges’ g (95% CI) Heterogeneity Publication bias
BDNF in serum and plasma A I2 Q Egger’s t
Responders to ECT 13 214 0.40 (0.02–0.82) * 75.6% 44.8 *** 0.7
Non-responders to ECT 9 47 0.22 (-0.38–0.82) 40.5% 14.5 1.1
Overall 23 281 0.37 (0.034–0.67) * 65.1% 63.1 *** 1.1
BDNF in plasma A
Responders to ECT 4 89 0.66 (0.06–1.26) * 74.7% 11.9 ** 4.0
Non-responders to ECT 3 19 0.87 (-0.04–1.78) 0.0% 0.63 0.2
Overall 7 108 0.72 (0.22–1.23) ** 57.9% 14.3* 2.5
BDNF in serum A
Responders to ECT 9 125 0.22 (-0.36–0.80) 78.4% 37.0*** 2.7*
Non-responders to ECT 6 28 -0.13 (-0.94–0.68) 35.8% 7.8 0.7
Overall 16 173 0.14 (-0.29–0.56) 69.1% 48.6*** 3.1**
A Effect size estimates were medium and significant in studies that measured BDNF in responders subgroup and non-significant in non-responders
subgroup. However, there were no statistically significant differences in pooled effect-size estimates between the responders and non-responders
subgroups (all P-values > .5).
* Statistical significance at P < .05
** Statistical significance at P < .01
*** Statistical significance at P < .001
doi:10.1371/journal.pone.0141564.t005
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BDNF here is not restricted to effects of ECS. This may serve neurogenesis, as the DG is one of
the main sources of progenitor cells [70, 71].
The effect of single ECS on BDNF concentrations seems to be short-lived (6–8 hours [10,
49]) and does not involve a hard reset after which BDNF expression remains at a constant
higher level. The effect of multiple ECS lasted longer as compared to single treatment: up to 14
days post-ECS [15, 31, 39, 45]. On the meta-analytical level this was reflected by a positive cor-
relation between number of treatments and BDNF levels in rodents, and a trend towards such
an association (P = .06) in humans.
Interestingly, effect sizes were larger for BDNF mRNA as compared to protein concentra-
tions. Several posttranscriptional mechanisms can be responsible for this. First, protein synthe-
sis may be inhibited by a specific class of microRNA molecules, that bind target mRNA and
induce its degradation. Several microRNAs are associated with BDNF depletion [72, 73], one
of them, microRNA-212, was increased after ECS in rat’s DG [46]. Second, there is evidence of
activity-dependent mRNA trafficking of BDNF to dendrites, where it can be stored and trans-
lated on demand [74]. Third, an increased BDNF turnover after ECS was proposed[38] and
makes sense in light of findings of neurogenesis after ECT [71, 75].
Once BDNF is synthesized it can act locally, be transferred to neighboring brain areas
through axonal anterograde transport or secreted to the blood stream. The later property
allowed scientists to make inferences about central BDNF secretion from peripheral measure-
ments. However, initial findings of a high positive correlation between central and serum
BDNF [76] were not confirmed [77, 78] or at least depended on animal strain and brain region
[31]. Neither a correlation between CSF and serum BDNF in humans was demonstrated [79].
In rodents we demonstrated increments in brain but not in the serum BDNF levels.
In clinical studies, ECT increased peripheral BDNF levels with a small to moderate effect
size (g = 0.35). Compared to a previous meta-analysis on this topic [14], we included newly
published studies, obtained individual patient data and took the source of BDNF (i.e., plasma
versus serum) into account. This approach revealed significantly enhanced BDNF after ECT in
plasma and not in serum.
Although both plasma and serum BDNF levels are decreased in acute major and bipolar
depression [24, 80], they seem to restore differently following antidepressant treatment [24].
The difference between responders and non-responders that we observed in serum BDNF after
pharmacological antidepressant treatment was not demonstrated after ECT. Neither did we
observe an increase in serum BDNF after ECT. This differs for plasma measurements, where
ECT seems to lead to an increase of BDNF but antidepressant treatment did not [24]. Such dif-
ference may point to different mechanisms of action of ECT and antidepressants on BDNF
synthesis and release.
Limitations
Our study has a number of limitations. First, obviously we could not match the preclinical and
clinical studies according to depressive state, only (roughly) according to the treatment applied.
Most of the animal studies used healthy male animals and did not account for the effects of sex
and disease on BDNF. The clinical studies, in turn, included both sexes and were based on
treatment-resistant depression cases. Furthermore, none of these studies controlled for relevant
confounders in longitudinal studies assessing BDNF, such as seasonality [81]. Plasma BDNF
studies could be further confounded by measurement errors [24]. Secondly, due to limited data
we had to combine treatment effects on major- and bipolar depression even though imaging
studies show differential response to ECT for these two groups [82]. Thirdly, most of the clini-
cal studies included antidepressants and ECT premedication which may have affected BDNF
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concentrations. Fourthly, while meta-analysis of preclinical data had enough power and
showed small to medium heterogeneity, the meta-analysis of clinical data was underpowered
and showed signs of publication bias. Due to the limited power we could not control for the
impact of ELISA kit manufacturer on effect sizes. Finally, effect-size estimates for the preclini-
cal data may have been suboptimal in terms of precision because they were often estimated
based on P-value and N.
Conclusions
Despite the limitations, animal and human studies seem to complement each other with regard
to effects of ECT on BDNF: ECT increases brain BDNF in animals and plasma BDNF in
humans. In animals regional BDNF increments after ECT (i.e., the DG) corresponded to areas
with distinct expression shown in the Allen brain atlas. Besides, multiple treatments as com-
pared to single ECT were associated with a larger increase in BDNF in both animals and
humans, which is suggestive for a dose-response effect of ECS on BDNF.
Future Directions
The questions that remain unsolved are: (1) why plasma but not serum BDNF increased in
human studies, (2) what is the relationship between BDNF and behavior, and (3) are incre-
ments in BDNF after ECT/ECS related to neurogenesis?
The potential differences between serum and plasma may arise from several aspects. Firstly,
plasma BDNF levels reflect momentary BDNF content whereas serum levels reflect BDNF that
has been accumulated over several days or even weeks [18 – 20]. Secondly, plasma measure-
ments are very sensitive to the laboratory conditions and, thus, error prone [24]. Future studies
(following strict methodological recommendations) should clarify whether plasma increment
is not an artifact and further investigate the nature of plasma and serum BDNF.
A larger number of studies is needed to understand the relation of behavioral outcomes to
BDNF levels. For clinical studies such outcome measurement is well established: response to
treatment or clinical remission. Preclinical studies, however, reported rather different, in terms
of timeframe and behavioral assessment, data. Therefore, for the later at least partial overlap in
outcome variables with previous studies is needed.
Though the behavioral data is still mixed, neurogenesis is required to achieve antidepressive
effect of ECS [83]. Survival of newborn neurons is supported by BDNF [84]. The causality and
the dose-response relationships between ECS, BDNF, neurogenesis and behavior are the next
questions to adress. Moderators of BDNF functioning, most notably the common genetic vari-
ant val66met that has been associated with activity dependent BDNF expression [85], might be
considered. Relating variation at this locus to hippocampal morphology [86] and functioning
[87] however has thus far led to mixed results.
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S1 Table. Quality of the included preclinical studies 
Between-Group Studies Introduction [3 max] Methods [21 max] Results [6 max] Discussion [5 max] Total [35 max] 
Lindefors et al. (1995) 1.5 8.0 5.0 3.0 17.5 
Nibuya et al. (1995) 2.0 10.5 4.5 2.0 19.0 
Zetterström et al. (1998) 2.0   6.0 5.0 1.0 14.0 
Chen et al. (2001) 3.0 10.0 5.0 3.0 21.0 
Altar et al. (2003) 2.0 15.0 5.0 2.0 24.0 
Angelucci et al. (2003) 2.0 14.0 4.0 3.0 23.0 
Dias et al. (2003) 3.0 11.0 5.0 3.0 22.0 
Newton et al. (2003) 2.0 11.0 5.0 2.0 20.0 
Jacobsen et al. (2004) 2.0 12.0 5.0 3.0 22.0 
Li et al. (2006) 3.0   9.0 5.0 2.0 19.0 
Ploski et al. (2006) 2.0   8.0 5.0 3.0 18.0 
Conti et al. (2007) 2.0   8.0 4.0 3.5 17.5 
Li et al. (2007) 3.0 11.0 5.0 3.0 22.0 
Sartorius et al. (2009) 3.0 10.0 4.0 3.0 20.0 
Gersner et al. (2010) 2.0 11.0 4.0 2.0 19.0 
Kyeremanteng et al. (2012) 2.0 15.0 4.0 3.0 24.0 
Luo et al. (2012) 2.5 13.0 5.0 2.5 23.0 
O’Donovan et al. (2012) 3.0 14.0 5.0 3.0 25.0 
Ryan et al. (2013) 1.0   8.0 5.0 3.0 17.0 
Segawa et al. (2013) 3.0 12.0 5.0 3.0 23.0 
Segi-Nishida et al. (2013) 2.5 11.0 5.0 2.0 22.5 
Dryvig et al. (2014) 2.0   9.0 5.0 1.0 17.0 
Kyeremanteng et al. (2014) 3.0 13.0 4.0 3.0 23.0 




Quality of the preclinical studies 
Based on the ARRIVE guidelines for reporting animal research (Kilkenny et al., 2010), two of us (MP and MLM) evaluated the methodological- and reporting 
quality of the included studies. Overall quality of a study was defined as the number of items that was met by the particular study. Agreement among the 
raters was excellent (Cohen’s Kappa = 0.95, Standard Error [SE] = 0.1). Overall, the included studies met on average 20 of the 35 quality items (range 14.0 – 
25.0). See Table S4 for the quality of each study (overall, and subdivided by introduction, method, results, and discussion).  The quality-score of an individual 
study was unrelated to the effect-size of the study (r = -0.005, P = .93). The quality score was related to sample size (r = 0.22, P = .002) and year of 
publication (r = 0.57, P < .0001), indicating that studies that used a larger number of animals and/or that were more recently published were in general of a 
higher quality.  
Quality of the clinical studies 
Based on the Newcasltle-Ottowa Scale (NOS; Wells et al, 2014; The Cochrane Collaboration, 2014), the quality assessment tool that is recommended by the 
Cochrane collaboration (2014) and the Risk of Bias tool for Longitudinal Studies (RBLS) (Polyakova et al, 2014), two of us (MP and MLM) evaluated the 
quality of the included clinical studies. Overall quality of a study was defined as the number of items that was met by the particular study on each of these 
scales individually. Agreement among the raters was high (Cohen’s Kappa = 0.90, SE = 0.05 for the NOS and Cohen’s Kappa = 0.76, SE = 0.06 for the RBLS). 
The included studies met on average 2 of the 8 NOS quality items (range 1 – 4) and 14 of the 35 RBLS items (range 11 – 16). See Table S5 and S6 for the NOS 
and RBLS quality score of the included studies respectively. Both, the NOS and the RBLS quality-score were unrelated to the effect-size of the study (r = 0.15, 
P = .61 and r = 0.09, P = .76 respectively. The NOS quality score was unrelated to sample size (r = -0.17, P = .56) and year of publication (r = 0.10, P = .74). The 
RBLS quality score also was unrelated to year of publication (r = -0.16, P = P = .60) but it was related to sample size (r = 0.64, P = .02), so that studies that 
used a larger number of subjects were in general of a higher quality.  
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S3 Table Quality of the included clinical studies as measured with the RBLS 
 Selection [4 max] Detection [8 max] Performance [2 max] Attrition [2 max] Reporting [2 max] Total [18 max] 
Bocchio-Chiavetto et al. (2006) 3 7 1 2 1 15 
Marano et al. (2006) 3 5 2 2 2 14 
Okamoto et al. (2008) 3 7 1 2 2 15 
Fernandes et al. (2009) 2 6 1 2 2 13 
Gronli et al.2009 3 5 1 0 2 11 
Piccinni et al. (2009) 3 6 1 2 2 14 
Hu et al. (2010) 3 6 1 2 2 14 
Gedge et al. (2012) 3 4 1 2 2 12 
Haghighi et al. (2013) 3 4 1 2 2 12 
Lin et al. (2013) 3 8 1 2 2 16 
Stelzhammer et al. (2013) 3 6 1 2 2 14 
Bilgen et al. (2014) 3 7 1 2 2 15 
Bumb et al. (2014) 2 6 1 2 2 13 
Kleinmann et al. (2014) 2 6 1 2 2 13 
Mean 2.8 5.9 1.1 1.9 1.9 13.6 
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S4 Table.  Brain regions in which BDNF was sampled in the preclinical studies that we included. Brain regions are presented alphabetically. The third column: ‘Unit of analyses’ indicates in which 
‘analysis’ unit the region was clustered.  
Tissue sampled Frequency 
 
Unit of analyses References 
Anterior olfactory nucleus   1 Other Conti et al. (2007) 
Basolateral amygdaloid nuclei   1 Other Conti et al. (2007) 
Brainstem   4 Other Kyeremanteng et al. (2014) 
CA1 14 Hippocampus Nibuya et al. (1995), Zetterström et al. (1998), Chen et al. (2001), Conti et al. (2007) 
CA2   1 Hippocampus Conti et al. (2007) 
CA3 15 Hippocampus Nibuya et al. (1995), Zetterström et al. (1998), Chen et al. (2001), Jacobsen et al. (2004), Conti et al. (2007) 
Cerebellum   8 Other Kyeremanteng et al. (2012, 2014) 
Claustrum   1 Other Conti et al. (2007) 
Dentate gyrus 17 Hippocampus Nibuya et al. (1995), Zetterström et al. (1998), Chen et al. (2001), Jacobsen et al. (2004), Ryan et al. (2013) 
Dorsal endopiriform nucleus   1 Other Conti et al. (2007) 
Dorsal hippocampus   1 Hippocampus Li et al. (2007), Gersner et al. (2010) 
Dorsal raphe nucleus   1 Other Conti et al. (2007) 
Enthorinal cortex    2 Other Altar et al. (2001), Conti et al. (2007),  
Frontal cortex 29 Cortex Nibuya et al. (1995), Altar et al. (2001), Angelucci et al. (2003), Altar et al. (2004), Jacobsen et al. (2004), Kyeremanteng et al. (2012, 2014) 
Frontal parietal cortex   6 Cortex Zetterström et al. (1998) 
Granual layer the dentate gyrus   1 Hippocampus Conti et al. (2007) 
Granule layer cerebellum   1 Other Conti et al. (2007) 
Hippocampus 
75 Hippocampus 
Altar et al. (2001), Newton et al. (2003), Altar et al. (2004), Angelucci et al. (2003), Li et al. (2006), Ploski et al. (2006), Sartorius et al. (2009), 
Kyeremanteng et al. (2012, 2014), Luo et al. (2012), O’Donovan et al. (2012), Segawa et al. (2013), Segi-Nishida et al. (2013), Dryvig et al. (2014) 
Hypothalamus   8 Other Kyeremanteng et al. (2014) 
Medial amygdaloid nucleus   1 Other Conti et al. (2007) 
Medial prefrontal cortex   3 Cortex Chen et al. (2001) 
Neocortex   8 Cortex Kyeremanteng et al. (2012, 2014) 
Nucleus accumbens   1 Other Gersner et al. (2010) 
Occipital cortex   1 Cortex Angelucci et al. (2003) 
Paraventricular thalamic nucleus    1 Other Conti et al. (2007) 
Table SI continues on the next page 
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Table SI continued 
Parietal cortex   1 Cortex Nibuya et al. (1995), Altar et al. (2001) 
Pirfiform cortex   4 Other Zetterström et al. (1998) 
Pirfiform gyrus   7 Other Conti et al. (2007) 
Polymorph layer of the dentate gyrus   1 Hippocampus Conti et al. (2007) 
Posterior cortical amygdaloid nucleus   1 Other Conti et al. (2007) 
  Prefrontal cortex 10 Cortex Conti et al. (2007), Sartorius et al. (2009) 
Prefrontal cortex layer III   1 Cortex Conti et al. (2007) 
Peripheral serum 13 Periphery Sartorius et al. (2009), Kyeremanteng et al. (2012) 
Septum   1 Other Altar et al. (2001) 
Striatum 13 Other Altar et al. (2001), Angelucci et al. (2003); Gersner et al. (2010), Kyeremanteng et al. (2014) 
Thalamus   4 Other Kyeremanteng et al. (2014) 
Ventral hippocampus   1 Hippocampus Gersner et al. (2010) 
Ventral tegmental area   1 Other Gersner et al. (2010) 





S5 Table.  Basic information on the animals that were used in the preclinical studies that were included in our meta-analysis. 
Study Animal  Age in weeks weight 
Lindefors et al. (1995) Male Sprague-Dawley rats  N.K. 150 - 200 gr 
Nibuya et al. (1995) Male Sprague-Dawley rats  N.K. 150 - 200 gr 
Zetterström et al. (1998) Male Sprague-Dawley rats N.K. N.K. 
Chen et al. (2001) Male Sprague-Dawley rats N.K. 160 - 180 gr 
Altar et al. (2003) Male Wistar rats N.K. 230 - 250 gr 
Angelucci et al. (2003) Flinders Sensitive Line rats 
Flinders Resistant Line rats 
10 N.K. 
Dias et al. (2003) Male Sprague-Dawley rats N.K. 200 - 250 gr 
Newton et al. (2003) Male Sprague-Dawley rats N.K. 160 - 180 gr 
Jacobsen et al. (2004) Male Wistar rats N.K. 200 - 300 gr 
Li et al. (2006) Male Wistar rats 8 - 10 N.K. 
Ploski et al. (2006) Male Sprague-Dawley rats N.K. 180 - 220 gr 
Conti et al. (2007) Male Sprague-Dawley rats 8 - 10  N.K. 
Li et al. (2007) Male Wistar rats 8 - 10 300 - 330 gr 
Sartorius et al. (2009) Sprague-Dawley rats (no sex specified) 8  N.K. 
Gersner et al. (2010) Sprague-Dawley rats (no sex specified) 8  N.K. 
Kyeremanteng et al. (2012) Male Wistar-Kyoto rats 
Male Wistar rats 
7 - 8  
7 - 8  
250 - 350 gr 
150 - 250 gr 
Luo et al. (2012) Male Wistar rats N.K. 200 - 240 gr 
O’Donovan et al. (2012) Male Sprague-Dawley rats N.K. 150 - 200 gr 
Ryan et al. (2013) Male Sprague-Dawley rats N.K. 150 - 200 gr 
Segawa et al. (2013) Male Sprague-Dawley rats N.K. 250 - 300 gr 
Segi-Nishida et al. (2013) Male C57BL/6N mice 9 - 12 N.K. 
Dryvig et al. (2014) Male Sprague-Dawley rats N.K. 270 - 350 gr 
Kyeremanteng et al. (2014) Male Wistar-Kyoto rats 
Male Wistar rats 
7 - 8  
7 - 8 
150 - 200 gr 
200 - 300 gr 
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S6 Table. Basic methodological information on the preclinical studies that were included in our meta-analysis 
Study Method BDNF type Other condition Behavioral tests Sacrificed after 
Lindefors et al. (1995) In situ hybridization BDNF mRNA None None immediately 
Nibuya et al. (1995) in situ hybridization, 
Northern blot 
BDNF mRNA None None 2 and 18 hours 
Zetterström et al. (1998) In situ hybridization BDNF mRNA None None 6, 24, 48 and 504 
hours 
Chen et al. (2001) In situ hybridization BDNF mRNA Ketamine add-on conditions None 2 hours 
Altar et al. (2003) ELISA BDNF mRNA, BDNF protein None None 6, 15, 36, 72, 134, 
and 240 hours  
Angelucci et al. (2003) ELISA BDNF protein None None 24 hours 
Newton et al. (2003) RT PCR BDNF RNA None None 2 and 6 hours 
Jacobsen et al. (2004) ELISA, in situ hybridization BDNF mRNA None None 18 hours 
Li et al. (2006) ELISA BDNF protein ACTH add-on conditions Forced swim, locomotor activity, rearing 
behavior, wet-dog response 
6 hours 
Ploski et al. (2006) In situ hybridization BDNF RNA None None 6 hours 
Conti et al. (2007) In situ hybridization BDNF mRNA None None 6 hours 
Li et al. (2007) ELISA BDNF protein None Forced swim test, open-field test: 
locomotor activity 
24, 48, and 168 
hours 
Sartorius et al. (2009) ELISA BDNF protein None None 3, 8, 24, 72, 168, 
and 336 hours 
Gersner et al. (2010) ELISA BDNF mRNA None Home-cage locomotion, 
exploration/novelty induced behavior, 
forced swim test, Morris water maze, 
sucrose preference test,  
1 hour 
Kyeremanteng et al. (2012) ELISA BDNF protein None None 24 and 168 hours 
Luo et al. (2012) ELISA BDNF protein Saline-proponol conditions Sucrose preference, open-field test 24 hours 
O’Donovan et al. (2012) ELISA BDNF protein None Forced swim test, water plus maze 336 hours 
Ryan et al. (2013) qRT PCR BDNF mRNA None None 96 hours 
Segawa et al. (2013) Western blot,  
qRT PCR 
BDNF mRNA, protein, Pro-BDNF None None 1, 2, 4, 8, and 24 
hours 
Segi-Nishida et al. (2013) In situ hybridization, qRT 
PCR 
BDNF mRNA None Food intake 2, 4, and 24 hours 
Dryvig et al. (2014) qRT PCR BDNF mRNA None  1, 4, 8, 16, 24, and 
48 hours 
Kyeremanteng et al. (2014) ELISA BDNF protein None Conditioned emotional response, forced 
swim test, open field test 




S7  Table  Basic information on the patients that were included in the clinical studies that were included in our meta-analysis. 
Study Characteristics of subjects Sub-group  N (f/m) ECT Depression ratings 
Number of sessions Time point of measurement 
Diagnosis  Treatment resistance 
 
Age  Pre-ECT Post-ECT 
Bocchio-Chiavetto et al., (2006) MDD 
yes 54.0±16.2 responders 20 (14/6) 
7 day after the last ECT  
34.90±7.31# 8.10 ± 3.24 
yes 45.0±27.0 Non- responders 3 (2/1) 29.67±2.01# 14.00±13.11 
Marano et al., (2006) MDD, BD 
NA 55.9±21.7 Responders 13 (3/10) 
7 day after the 4th ECT 
27.5±6.3 7.9±3.5 
NA 62.0±24.0 Non-responders 2 (1/1) 29.0±1.4 16.0±0 
Okamoto et al., (2008) MDD, BD 
yes 58.6±13.9 Responders 12 (6/6) 
12 1 week after last ECT 
25.0 ± 8.2* 10.3± 3.4 
yes 62.4±15.1 Non-responders 6 (3/3) 20.6 ± 4.4* na 
Fernandes et al., (2009) MDD, BD yes 52.7±15.9 
Responders 
(73.33%) 
15 (10/5) 11.23 day after the last ECT  24.15 ± 6.32* 24.15±6.32* 
Gronli et al., (2009) MDD, BD yes 70 (40-85) Responders 10 (NA) 12 immediately prior to discharge 23.1* 6.0* 
Piccinni et al., (2009) MDD, BD 
yes 47.4±16.7 Responders 8 (5/3) 8.6 
1 week after last ECT 
24.1 ± 5.3** 6.8 ± 3.1 
yes 42.9± 17.9 Non-responders 10 (4/6) 8 24.1 ± 5.3** 6.8 ± 3.1 
Hu et al., (2010) MDD 
Not known 43.9±13.8 Responders 24 (20/4) 
6 day after the last ECT 
31.6±4.79 * 6.5±3.7 
Not known 23.3±4.2 Non-responders 4 (3/1) 30.0±3.9* 18.0 ± 4.1 
Gedge et al., (2012) MDD 
yes 45.7±12.2 Responders 5 (2/3) 
12 1 week after ECT 
25.6 ±4.93* 7.8±1.3 
yes 47.7±7.9 Non-responders 6 (5/1) 22.17 ±4.40* 17.83 ± 4.79  
 





Haghighi et al., (2013) MDD no 30.7±5.8 Responders (75%) 20 (5/15) 12 na 39.35±10.46** 35.10 ±7.18 
Lin et al., (2013) 
MDD, BD yes 47.4±12.0 Responders 48 (38/10) 
9.2 after the last ECT 
31.5±8.6* 5.8±3.6 
MDD, BD yes 40.1±8.7 Non-responders 7 (6/1) 26.1±6.5* 17.3±8.1 
Stelzhammer et al., (2013) 
 
MDD 
yes 49.7±7.2 Responders 3 (3/0) 
12 6h after last ECT 
32.3±5.7 17.7±10.7 
yes 58.0±7.7 Non-responders 4 (2/2) 22.8±4.6 21.3 ±6.6 
Bilgen et al., (2014) MDD Not known 33.0±5.9 responders 30 (19/11) 5.06 At the day of response 30.66±4.11** 
15.73±3.36*
* 
Bump et al., 2014 MDD Not known 51.7±13.7 NA 20 (10/10) 11.25 Varies 31.2±8.1** NA 
Kleinmann et al., 2014 MDD yes 47±16.5 NA 11(6/5) 10 24 h after 1st, 4th, 7th and 10th ECT 34±8.3# NA 
Abbreviations: MDD – major depressive disorder; BD – bipolar disorder;  “ – HDRS-6; * - HDRS-17; **- HDRS-21; ***- HDRS-24; # - MADRS 
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Minor depression is diagnosed when a patient suffers from 2 to 4 depressive symptoms
for at least 2 weeks. Though minor depression is a widespread phenomenon, its
pathophysiology has hardly been studied. To get a first insight into the pathophysiological
mechanisms underlying this disorder we assessed serum levels of biomarkers for
plasticity, glial and neuronal function: brain-derived neurotrophic factor (BDNF), S100B
and neuron specific enolase (NSE). 27 subjects with minor depressive episode and 82
healthy subjects over 60 years of age were selected from the database of the Leipzig
population-based study of civilization diseases (LIFE). Serum levels of BDNF, S100B
and NSE were compared between groups, and correlated with age, body-mass index
(BMI), and degree of white matter hyperintensities (score on Fazekas scale). S100B was
significantly increased in males with minor depression in comparison to healthy males,
whereas other biomarkers did not differ between groups (p = 0.10–0.66). NSE correlated
with Fazekas score in patients with minor depression (rs = 0.436, p = 0.048) and in the
whole sample (rs = 0.252, p = 0.019). S100B correlated with BMI (rs = 0.246, p = 0.031)
and with age in healthy subjects (rs = 0.345, p = 0.002). Increased S100B in males with
minor depression, without alterations in BDNF and NSE, supports the glial hypothesis of
depression. Correlation between white matter hyperintensities and NSE underscores the
vascular hypothesis of late life depression.
Keywords: minor depression, late life depression, S100B, BDNF, NSE, glia, white matter hyperintensities,
biomarker
INTRODUCTION
Minor depression is a widespread phenomenon in late life (Hegerl and Schoenknecht, 2009;
Polyakova et al., 2015). According to the fourth edition of the diagnostic statistical manual of mental
disorders (DSM-IV) a person suffering from two to four depressive symptoms for at least 2 weeks
has a minor depressive episode. For diagnosis of minor depressive disorder one additionally has
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to exclude a history of major depression (American Psychiatric
Association, 2000). In clinical practice patients with minor
depressive symptoms may represent an independent minor
depressive episode or a subsyndromal stage of major depression
(Park et al., 2010). Every fourth patient with minor depression
develops major depression within 2 years after diagnosis (Lyness
et al., 1999) and 13% of subjects with minor depression have
attempted suicide at least once (Eaton et al., 1995). With regard
to these data proper diagnosis and management of minor
depression might become an approach to prevent a more severe
depressive disorder.
Although plenty of studies have been conducted to elucidate
the etiology of major depression, the pathophysiology of minor
depression is still unknown. Possible research directions include
the glial, neurotrophic and vascular hypotheses of depression.
Alterations of peripheral biomarkers of brain structure and
function might shed light on the pathological changes in central
mechanisms. Brain derived neurotrophic factor (BDNF), S100B
and neuron specific enolase (NSE) are among the most studied
biomarkers in affective disorders, in particular major depressive
disorder (Schroeter et al., 2002; Hetzel et al., 2005; Andreazza
et al., 2007; Schroeter and Steiner, 2009; Kalia and Silva,
2015).
BDNF, associated with plasticity in the central and peripheral
nervous system, is decreased in serum in acute major depressive
episodes and restored in remission (Molendijk et al., 2014). The
glial marker protein S100B is elevated during major depressive
episodes and decreased following successful treatment (Schroeter
et al., 2013). Thus, fluctuations in serum levels of BDNF and
S100B seem to be state markers for major depression. This
is supported by powerful meta-analyses including a very high
number of subjects (Schroeter et al., 2008; Polyakova et al.,
2015). NSE is a marker for neuronal injury. In contrast to BDNF
and S100B, serum NSE levels seem to be stable in depression
suggesting mainly glial dysfunction (Schroeter et al., 2013).
However, a recent publication reported increased NSE levels in
cerebrospinal fluid (Schmidt et al., 2015), leaving more space for
discussion.
Due to clinical similarities with major depression, we expect
similar biomarker changes in minor depression. Since BDNF
levels do not correlate with depression severity (Molendijk
et al., 2011), decreased serum BDNF might also be observed
in minor depression. In this disorder it might reflect impaired
constitutive or activity-dependent BDNF expression, resulting in
impaired brain plasticity. Increased S100B in minor depression
may indicate early glial pathology that precedes specific neuronal
changes such as in major depression (Rajkowska, 2000).
Unaltered (comparing to healthy controls) NSE should confirm
that there is no neuronal damage in minor depression.
To further explore the etiology of minor depression we
analyzed serum levels of BDNF, S100B and NSE in subjects with
minor depression and healthy control subjects from the Leipzig
population-based study of civilization diseases (LIFE). Serum
levels of BDNF, S100B and NSE were considered as primary
outcomes. In analogy to major depression we hypothesized a
decrease of BDNF and an increase of S100B, without changes of
NSE in minor depression.
An association between late life minor depression and the
vascular hypothesis of depression (Taylor et al., 2013) was
investigated in explorative analyses by correlating white matter
hyperintensities to serum markers. In order to control for
confounding variables we correlated age and body mass index
(BMI) with serum markers. Correlation of serum markers with
clinical and imaging parameters, such as age, BMI and extent




Twenty seven subjects 60 years and older satisfying the DSM-IV
criteria for minor depressive episode and eighty two healthy
control subjects were selected from the LIFE study. LIFE study
includes a representative sample from the Leipzig population
(Loeffler et al., 2015). All of the participants provided their
written informed consent in accordance with the Declaration
of Helsinki before participation in the study. The study was
approved by the ethics board of the Medical Faculty of the
University of Leipzig. At the moment of subjects’ selection the
LIFE study database included 1617 subjects over 60 years of
age. Every subject underwent structured psychiatric interview,
neuropsychological testing, clinical examination, blood sampling
and scanning with multimodal magnetic resonance imaging
(MRI).
Diagnostic Criteria and Laboratory
Procedures
Minor depressive episode according to DSM-IV criteria was
diagnosed based on the structured clinical interview for DSM-
IV axis I disorders (SCID). White matter hyperintensities were
rated by experienced neuroradiologists using the Fazekas scale
(Fazekas et al., 1987) in fast fluid-attenuated inversion recovery
(FLAIR) images.
Blood samples were collected from the subject’s cubital vein at
the first day of the study. The mean time between blood sampling
and psychiatric interview was 10.0 (4.3) days for subjects with
minor depression and 13.0 (9.0) for healthy subjects. All samples
were collected uniformly in the morning, following overnight
fasting. Serum was prepared using the standard operating
procedures. In brief, samples were left for 45 min for clotting,
followed by a centrifugation step (10 min, 2750 g, 15◦C). Samples
were then filled in straws (CryoBioSytems IMV, France) by
an automatic aliquoting system (DIVA, CryoBioSytems IMV,
France). After that serum samples were stored at −80◦C. To
minimize freeze-thaw cycles, samples were sorted in a cryogenic
work bench (temperatures below −100◦C) and automatically
stored in tanks with a coolable top frame in the gas phase of liquid
nitrogen (Askion, Germany; Loeffler et al., 2015).
S100B and NSE were measured with monoclonal 2-site
immunoluminometric assays performed on the fully mechanized
system LIAISON (Diasorin, Dietzenbach, Germany). The
detection limit for the assays was 0.02 µg/l and 0.04 µg/l
(described in detail elsewhere (Streitbuerger et al., 2012). BDNF
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was measured in serum with an ELISA manufactured by R&D
systems (Wiesbaden, Germany). The sensitivity of the assay was
20 ng/L leading to a measuring range of 62.5 until 4000 ng/L.
Interassay coefficients of variation were between 9.4 and 11.1%
formean BDNF concentrations between 362 and 2079 ng/L. Note
that serum samples were diluted 1:20 before measuring them
with the assay.
Statistical Analyses
Statistical analyses were performed using SPSS version 22
(IBM, Chicago, IL, USA). Complex assessment of the data
distributions were performed including visual assessment of the
histograms, skewness and kurtosis of the data, as well as by
Kolmogorov–Smirnoff and Shapiro-Wilk test. Since the protein
levels were non-normally distributed and different numbers of
subjects were included in patients’ and controls’ groups we
applied non-parametric Mann-Whitney U test for evaluation
of group differences. The differences in demographic factors
were assessed by independent t-test or by chi-square test. The
impact of sex differences and a history of depression were
assessed by subgroup analyses. The correlation analyses between
serum markers, clinical/imaging and demographic data were
performed by calculating Spearmen correlation coefficients. We
expected directed changes for BDNF and S100B in minor
depression in comparison with control subjects, therefore
one-tailed α-level for statistical significance was set at 0.05
for these biomarkers. For NSE and the correlation analyses
two-tailed α-level at 0.05 was chosen. The statistical power was
calculated using G-power 3.1.9.2. (Faul et al., 2009). Generally,
data are presented as means and standard deviations (SD). Dot
plots represent the distributions of the protein levels and their
medians.
RESULTS
The demographics, clinical and imaging data, and serum marker
levels of the patients and healthy control subjects are presented
in Table 1. Both cohorts were matched for age, education, BMI
and the extent of white matter hyperintensities as measured with
the Fazekas scale.
BDNF, S100B and NSE did not differ between patients in
minor depressive episode and healthy control subjects (Table 1).
Since the two groups differed with regard to sex, we conducted
additionally sex-specific analyses. Figure 1 illustrates results
with dot plots for the three serum marker proteins across the
whole groups, and specifically for each sex. When the analysis
was stratified by sex we observed significantly increased S100B
(p = 0.034) in males with minor depressive episode (0.092 µg/l
[0.012]) in comparison with healthy male controls (0.067 µg/l
[0.004]).
As depicted in the Figure 2, serum S100B levels were
significantly lower in healthy males (0.067 µg/l [0.004]) in
comparison with healthy females (0.115 µg/l [0.029]; p = 0.01),
whereas there was no sex difference in the minor depression
group (male: 0.091 µg/l [0.12]; female: 0.088 µg/l [0.011];
p = 0.53). Removal the abovementioned female outlier did not
affect the differences between healthy males and females for
S100B. BDNF and NSE did not differ neither between the groups
stratified by sex (males p = 0.13–0.95; females p = 0.40–0.42), nor
when male and female subjects were compared within the minor
depression subgroup (p = 0.10–0.98).
Similarly, presence of the history of major depression did
not affect the levels of BDNF, S100B or NSE in the minor
depression group (p = 0.10–0.50); neither in comparison with
healthy controls (p = 0.13–0.38; Figure 3).
As presented on Figure 1 one female control subject presented
with extremely high S100B value, above three SD of the group.
To control for the impact of this subject on the analysis of
S100B we performed an additional analysis of S100B excluding
this subject’s data. In this analysis we observed a trend,
p = 0.078, for increased S100B in the whole minor depression
group (0.088 µg/l [0.043]) in comparison with healthy controls
(0.074 µg/l [0.032]).
We observed a positive correlation between S100B and BMI
in the whole sample (rs = 0.204, p = 0.04), and in healthy subjects
(rs = 0.246, p = 0.03), and a positive correlation between S100B
TABLE 1 | Demographical, clinical/imaging data and serum markers in patients and healthy control subjects.
Whole group Males Females
MinD HC MinD HC MinD HC
Number (with a history of depression) 27 (14) 82 7 (3) 58 21 (11) 24
Age 71.2 (4.5) 70.0 (4.1) 71.4 (4.8) 70.3 (4.1) 71.1 (4.5) 69.6 (4.3)
Sex (male/female) 7/21∗∗∗ 51/31∗∗∗
Education (<12years/>12 years) 24/4 58/24 5/2 37/15 19/2 22/9
Fazekas score (0/1/2/3) 6/16/5/0 25/45/12/0 2/4/0/0 17/27/7/0∗ 4/12/5/0 8/18/5/0
BMI (kg/m2) 27.1 (4.9) 28.1 (4.6) 26.7 (2.1) 27.8 (3.7) 27.2 (5.7) 28.7 (5.9)
BDNF (µg/L) 25.8 (5.4) 25.2 (5.9) 29.6 (14.2) 24.7 (4.3) 26.1 (4.9) 26.1 (7.8)
NSE (µg/L) 11.8 (2.6) 11.9 (2.1) 11.9 (2.9) 11.7 (2.3) 11.7 (2.6) 12.2 (1.7)
S100B (µg/L) 0.088 (0.043) 0.086 (0.11) 0.088 (0.03)∗ 0.067 (0.03)∗† 0.088 (0.05) 0.12 (0.16)†
MinD, minor depression; HC, healthy controls; BMI, body-mass index; BDNF, brain derived neurotrophic factor; NSE, neuron specific enolase; †Significant difference
between males and females at p < 0.05; ∗Significant difference between minor depression and healthy controls group at p < 0.05; ∗∗∗Significant difference between
minor depression and healthy controls group at p < 0.001; Student’s t-test for age and body mass index, chi-square test for categorical data, Mann-Whitney U test for
BDNF, NSE, S100B.
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FIGURE 1 | Dot plot for the distribution of serum markers’ levels in subjects and healthy controls (first row), separately for males (second row), and
females (third row). Median levels of the serum markers are depicted with black horizontal lines. Note that the distribution of S100B in males is depicted on a
zoomed scale. MinD, minor depression; HC, healthy controls; BDNF, brain derived neurotrophic factor; NSE, neuron specific enolase.
and age in the whole sample (rs = 0.229, p = 0.02) and in healthy
control subjects (rs = 0.345, p = 0.002).
A significant positive correlation was found between age and
the degree of white matter hyperintensities as measured with the
Fazekas score both, in the whole sample (rs = 0.425, p < 0.001),
and in subgroups (minor depression: rs = 0.462, p = 0.04; healthy
controls: rs = 0.421, p < 0.001). With regard to serum markers,
Fazekas score correlated positively with NSE in the whole sample
(rs = 0.252, p = 0.02) and in patients with minor depression
(rs = 0.436, p = 0.048). In the healthy control sample the Fazekas
score correlated positively only with S100B (rs = 0.261, p = 0.04).
Finally, we examined whether our groups were large
enough to detect the predicted impact of minor depression
on serum BDNF and S100B. The statistical power calculations
using G-Power for Mann-Whitney tests were based on the
previous meta-analyses of BDNF and S100B alterations in major
depression (Schroeter et al., 2013; Polyakova et al., 2015). These
calculations lead to required sample sizes of n = 36 per group for
BDNF and n = 5 per group for S100B.
DISCUSSION
In this study, for the first time to our knowledge, we evaluated
serum levels of BDNF, S100B and NSE in subjects with minor
depressive episode. We found evidence for increased S100B
in males with minor depression without any alterations of
NSE, which was in agreement with our hypotheses. BDNF was
unchanged, although we expected a decrease in analogy to
major depression. In assessment of the secondary outcomes we
observed a positive correlation between NSE and Fazekas score
in minor depression and in the whole sample. S100B correlated
positively with age and BMI in the whole sample and in healthy
controls.
Our hypotheses were initially built on data derived from
major depression studies. In minor depression we didn’t detect
the hypothesized difference for BDNF. One explanation of such
a negative finding might be that neurotrophic functions are
not impaired at the subthreshold level of depression. Then the
substantial differences in the pathophysiology of these disorders
arise. Nevertheless, one might also argue that the sample size
was too low. The calculation of the required sample size using
G-Power for BDNF indeed showed that our minor depressive
group might have been underpowered (27 subjects instead of the
36 required). In this study we reached only 75% of statistical
power. To solve the power issue future studies should involve
larger sample size.
For S100B the sample size was obviously large enough to
detect the expected group effects (27 subjects instead of five
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FIGURE 2 | Dot plot for the distribution of serum markers’ levels in healthy males and females (first row), and males and females with minor
depression (third row). Median levels of the serum markers are depicted with black horizontal lines. Note that the outlier from the healthy females group is not
depicted on the S100B plot. MinD, minor depression; HC, healthy controls; BDNF, brain derived neurotrophic factor; NSE, neuron specific enolase.
required). Indeed, we observed a trend for increased S100B in
the whole minor depression group and significantly increased
S100B in males with minor depression in comparison with
control subjects. Though we did not rule out potential non-
brain sources of S100B in our study, this finding points to the
similarities between major and minor depression. Moreover, the
fact that differences in S100B are less prominent than in major
depression suggests that clinical presentation mirrors to some
extend molecular changes.
The findings we describe are based on the concept that
serum S100B changes are related to alterations in the brain.
However, S100B, as well as BDNF, and NSE might originate
from non-brain sources. For instance, various subtypes of
leukocytes can secrete S100B (Miki et al., 2013; Fujiya et al.,
2014; Moutsatsou et al., 2014). Thrombocytes are the largest
source for serum BDNF (Fujimura et al., 2002), adipocytes
produce both S100B and BDNF (Fujiya et al., 2014; Huang
et al., 2014), finally NSE may originate from damaged peripheral
nerves (Li et al., 2013). Because we did not assume relevant
biases related to these potentially confounding sources in minor
depression, we did not control for potential non-brain sources of
the serum markers in our study. Note that we compared subjects
with minor depression to matched healthy control subjects and
considered, therefore, differences and not absolute values of
FIGURE 3 | Dot plot for the distribution of serum markers’ levels in subjects with minor depression with or without a history of depression. Median
levels of the serum markers are depicted with black horizontal lines. MinD, minor depression, HC, healthy controls; BDNF, brain derived neurotrophic factor; NSE,
neuron specific enolase.
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S100B. Moreover, changes of S100B in leukocytes have been
shown only in bipolar disorder (Moutsatsou et al., 2014), whereas
for unipolar depression, which is more relevant for our data, no
studies are available in the literature so far. Future studies might
transcend these limitations by including larger and more strictly
selected cohorts and controlling for non-brain sources of these
markers.
The concept of leakage from the brain obviously has its
limitations. S100B, as well as BDNF, and NSE might originate
from non-brain sources. Various subtypes of leucocytes can
secrete S100B (Miki et al., 2013; Fujiya et al., 2014; Moutsatsou
et al., 2014), thrombocytes are the largest source for serum
BDNF (Fujimura et al., 2002), adipocytes produce both S100B
and BDNF (Fujiya et al., 2014; Huang et al., 2014), finally NSE
originate from damaged peripheral nerves (Li et al., 2013).
Interestingly, S100B was not different between males and
females with minor depression, rather it differed between healthy
males and females. This finding is in line with previous studies
showing no sex differences in major depression (Arolt et al.,
2002; Hetzel et al., 2005), but contradicts another one showing
increased S100B in females with major depression (Yang et al.,
2008). The differences between our and the former study might
be attributed to the differences in the studied samples with regard
to disease severity and age. Further studies are in agreement
with our finding for healthy subjects by showing higher S100B
in healthy female than male adults (Streitbuerger et al., 2012) and
children (Gazzolo et al., 2003). Overall, the literature on effects of
gender on S100B did not reach consensus so far. Whether gender
differences in S100B reflect the differences in susceptibility to
disease and whether S100B is a gender-specific marker of minor
depression needs more systematic assessment.
S100B, as an index for glial alterations, is modified by age in
major depression (Schroeter et al., 2011). In minor depression
we did not find a correlation between S100B and age. Instead,
S100B correlated positively with age in healthy controls. This
finding is in line with cerebrospinal fluid studies (van Engelen
et al., 1992; Nygaard et al., 1997), but contradicts later serum
studies (Wiesmann et al., 1998; Portela et al., 2002). One
potential reason for these differences is again the different disease
severity. According to Rajkowska’s observations development of
depressive disorder starts with glial alterations and progresses
with age (Rajkowska, 2000). If late life minor depression is a
subtle manifestation of major disorder, absence of correlation
between S100B and age in minor depression might add to
Raikowska’s hypothesis.
A weak positive correlation between S100B and BMI was
not surprising. S100B is secreted by adipocytes and is involved
in the pathogenesis of obesity as shown in vitro (Fujiya et al.,
2014) and in vivo (Buckman et al., 2014). Positive correlation of
serum S100B with BMI was previously reported in a combined
sample of cognitively intact lean and obese subjects (Steiner et al.,
2010a) and in subjects with schizophrenia (Steiner et al., 2010b).
In our study the positive correlation in the whole sample was
likely driven by the healthy subgroup, with no such association
in minor depressive episode. As correlations between S100B
and age/BMI were detected only in healthy subjects but not in
the minor depression group, and both cohorts were matched
regarding mean age and BMI, we assume that age and BMI did
not drive the S100B effects in minor depression.
The finding of positive correlation between S100B and white
matter hyperintensities in healthy subjects is in agreement
with a study by Streitbuerger et al. (2012). These authors
reported an association between serum S100B and the diffusion
tensor imaging parameters fractional anisotropy and radial
diffusivity in white matter tracts in healthy females. From the
biological point of view increased secretion of S100B might
reflect neuroinflammation that accompanies neuronal damage
(Kabadi et al., 2015).
We detected also a positive correlation between serum NSE
and Fazekas score in the whole sample and in the minor
depression subgroup. NSE, a peripheral marker of neuronal
damage, might be either of central (Cheng et al., 2014)
or peripheral origin (Li et al., 2013). In major depression
a central origin is suggested by the correlation with white
matter hyperintensities. Finally, the extent of white matter
hyperintensities correlated with age in both cohorts, healthy and
minor depressive subjects, which is in line with the literature
(Nyquist et al., 2015). In combination with the correlation
between white matter hyperintensities and the neuronal injury
marker NSE in minor depression, our data might support the
vascular hypothesis of late life depression (Taylor et al., 2013;
Taylor, 2014).
Limitations
As already discussed our study was limited by a relatively small
sample size, which might have hampered, in particular, the
detection of BDNF effects. Another limitation might be the
inclusion of patients having a history of depression. Thus, not all
patients could be qualified as having minor depressive disorder.
We addressed this issue in the subgroup analysis and found
that inclusion of the subjects with a history of depression did
not affect our results. In fact, such a sample mirrors a real life
situation when psychiatrists need to make a clinical judgement
and select a treatment strategy. Note, moreover, that our subjects
were chosen from a representative population study.
The findings we describe are based on the concept that
serum S100B changes are related to alterations in the brain.
However, S100B, as well as BDNF, and NSE might originate
from non-brain sources. For instance, various subtypes of
leukocytes can secrete S100B (Miki et al., 2013; Fujiya
et al., 2014; Moutsatsou et al., 2014). Thrombocytes are
the largest source for serum BDNF (Fujimura et al., 2002),
adipocytes produce both S100B and BDNF (Fujiya et al.,
2014; Huang et al., 2014), finally NSE may originate from
damaged peripheral nerves (Li et al., 2013). Because we
did not assume relevant biases related to these potentially
confounding sources in minor depression, we did not control
for potential non-brain sources of the serum markers in our
study. Note that we compared subjects with minor depression
to matched healthy control subjects and considered, therefore,
differences and not absolute values of S100B. Moreover,
changes of S100B in leukocytes have been shown only in
bipolar disorder (Moutsatsou et al., 2014), whereas for unipolar
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depression, which is more relevant for our data, no studies
are available in the literature so far. Future studies might
transcend these limitations by including larger and more strictly
selected cohorts and controlling for non-brain sources of these
markers.
CONCLUSION
In this study we made a first attempt to assess serum levels
of BDNF, S100B, and NSE in minor depression. We found
evidence for increased glial marker S100B in males with minor
depression and a similar trend in the whole minor depressive
group, but no significant evidence of BDNF and NSE alterations.
The positive correlation of NSE with Fazekas score as a measure
for white matter hyperintensities in minor depression supports
the vascular hypothesis of late life depression.
AUTHOR CONTRIBUTIONS
MP, PS, MLS have designed the study, analyzed and interpreted
the data, drafted and revised the manuscript content; MP
and CS selected the subjects from LIFE study database, JK
was responsible for the laboratory detection of the serum
markers; LL and KTH were responsible for ratings of white
matter hyperintensities, CS, KA, ML, TL, SRH, AV contributed
to data acquisition. All authors have critically reviewed the
manuscript and approved its final version. All authors agree to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.
FUNDING
This study has been supported by the International Max
Planck Research School on Neuroscience of Communication
(IMPRS NeuroCom; MP), by LIFE—Leipzig Research Center for
Civilization Diseases at the University of Leipzig—funded by the
European Union, European Regional Development Fund and by
the Free State of Saxony within the framework of the excellence
initiative (CZ, KA, TL, SRH, AV, PS and MLS), by the German
Consortium for Frontotemporal Lobar Degeneration, funded by
the German Federal Ministry of Education and Research (MLS),
and by the Parkinson’s Disease Foundation (MLS; Grant No.
PDF-IRG-1307).
REFERENCES
American Psychiatric Association. (2000). Diagnostic and Statistical Manual of
Mental Disorders, 4th Edn, Text Revision. Washington, DC.
Andreazza, A. C., Cassini, C., Rosa, A. R., Leite, M. C., de Almeida, L. M., Nardin,
P., et al. (2007). Serum S100B and antioxidant enzymes in bipolar patients.
J. Psychiatr. Res. 41, 523–529. doi: 10.1016/j.jpsychires.2006.07.013
Arolt, V., Peters, M., and Rothermundt, M. (2002). Neuroplasticity in major
depression may be indicated by S100B. Eur. Psychiatry 17, 159S–159S. doi: 10.
1016/s0924-9338(02)80691-5
Buckman, L. B., Anderson-Baucum, E. K., Hasty, A. H., and Ellacott, K. L. (2014).
Regulation of S100B in white adipose tissue by obesity in mice. Adipocyte 3,
215–220. doi: 10.4161/adip.28730
Cheng, F., Yuan, Q., Yang, J., Wang, W., and Liu, H. (2014). The prognostic
value of serum neuron-specific enolase in traumatic brain injury: systematic
review and meta-analysis. PLoS One 9:e106680. doi: 10.1371/journal.pone.01
06680
Eaton, W. W., Badawi, M., and Melton, B. (1995). Prodromes and
precursors–epidemiologic data for primary prevention of disorders with
slow onset. Am. J. Psychiatry 152, 967–972. doi: 10.1176/ajp.152.7.967
Faul, F., Erdfelder, E., Buchner, A., and Lang, A.-G. (2009). Statistical power
analyses using G∗Power 3.1: tests for correlation and regression analyses.
Behav. Res. Methods 41, 1149–1160. doi: 10.3758/brm.41.4.1149
Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I., and Zimmerman, R. A. (1987).
MR signal abnormalities at 1.5-T in Alzheimer dementia and normal aging.AJR
Am. J. Roentgenol. 149, 351–356. doi: 10.2214/ajr.149.2.351
Fujimura, H., Altar, C. A., Chen, R., Nakamura, T., Nakahashi, T., Kambayashi,
J., et al. (2002). Brain-derived neurotrophic factor is stored in human platelets
and released by agonist stimulation. Thromb. Haemost. 87, 728–734.
Fujiya, A., Nagasaki, H., Seino, Y., Okawa, T., Kato, J., Fukami, A., et al. (2014). The
Role of S100B in the interaction between adipocytes and macrophages. Obesity
(Silver Spring) 22, 371–379. doi: 10.1002/oby.20532
Gazzolo, D., Michetti, F., Bruschettini, M., Marchese, N., Lituania, M., Mangraviti,
S., et al. (2003). Pediatric concentrations of S100B protein in blood: age- and
sex-related changes. Clin. Chem. 49, 967–970. doi: 10.1373/49.6.967
Hegerl, U., and Schoenknecht, P. (2009). Subdiagnostic depression. Are there
treatments with clinically relevant effects? Nervenarzt 80, 532–539. doi: 10.
1007/s00115-008-2622-z
Hetzel, G., Moeller, O., Evers, S., Erfurth, A., Ponath, G., Arolt, V., et al. (2005).
The astroglial protein S100B and visually evoked event-related potentials before
and after antidepressant treatment. Psychopharmacology (Berl) 178, 161–166.
doi: 10.1007/s00213-004-1999-z
Huang, T., Larsen, K. T., Ried-Larsen, M., Moller, N. C., and Andersen,
L. B. (2014). The effects of physical activity and exercise on brain-derived
neurotrophic factor in healthy humans: a review. Scand. J. Med. Sci. Sports 24,
1–10. doi: 10.1111/sms.12069
Kabadi, S. V., Stoica, B. A., Zimmer, D. B., Afanador, L., Duffy, K. B., Loane,
D. J., et al. (2015). S100B inhibition reduces behavioral and pathologic changes
in experimental traumatic brain injury. J. Cereb. Blood Flow Metab. doi: 10.
1038/jcbfm.2015.165 [Epub ahead of print].
Kalia, M., and Silva, J. C. E. (2015). Biomarkers of psychiatric diseases: current
status and future prospects. Metabolism 64, S11–S15. doi: 10.1016/j.metabol.
2014.10.026
Li, J., Zhang, H., Xie, M., Yan, L., Chen, J., and Wang, H. (2013). NSE, a potential
biomarker, is closely connected to diabetic peripheral neuropathy. Diabetes
Care 36, 3405–3410. doi: 10.2337/dc13-0590
Loeffler, M., Engel, C., Ahnert, P., Alfermann, D., Arelin, K., Baber, R., et al.
(2015). The LIFE-Adult-Study: objectives and design of a population-based
cohort study with 10,000 deeply phenotyped adults in Germany. BMC Public
Health 15: 691. doi: 10.1186/s12889-015-1983-z
Lyness, J. M., King, D. A., Cox, C., Yoediono, Z., and Caine, E. D. (1999).
The importance of subsyndromal depression in older primary care patients:
prevalence and associated functional disability. J. Am. Geriatr. Soc. 47, 647–652.
doi: 10.1111/j.1532-5415.1999.tb01584.x
Miki, Y., Gion, Y., Mukae, Y., Hayashi, A., Sato, H., Yoshino, T., et al. (2013).
Morphologic, flow cytometric, functional and molecular analyses of S100B
positive lymphocytes, unique cytotoxic lymphocytes containing S100B protein.
Eur. J. Haematol. 90, 99–110. doi: 10.1111/ejh.12036
Molendijk, M. L., Bus, B. A., Spinhoven, P., Penninx, B. W., Kenis, G., Prickaerts,
J., et al. (2011). Serum levels of brain-derived neurotrophic factor in major
depressive disorder: state-trait issues, clinical features and pharmacological
treatment.Mol. Psychiatry 16, 1088–1095. doi: 10.1038/mp.2010.98
Molendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A., Penninx, B.W., and Elzinga,
B. M. (2014). Serum BDNF concentrations as peripheral manifestations of
depression: evidence from a systematic review and meta-analyses on 179
associations (N=9484).Mol. Psychiatry 19, 791–800. doi: 10.1038/mp.2013.105
Frontiers in Cellular Neuroscience | www.frontiersin.org 7 October 2015 | Volume 9 | Article 406
95
Polyakova et al. S100B, BDNF, NSE in minor depression
Moutsatsou, P., Tsoporis, J. N., Salpeas, V., Bei, E., Alevizos, B., Anagnostara, C.,
et al. (2014). Peripheral blood lymphocytes from patients with bipolar disorder
demonstrate apoptosis and differential regulation of advanced glycation end
products and S100B. Clin. Chem. Lab. Med. 52, 999–1007. doi: 10.1515/cclm-
2013-0978
Nygaard, O., Langbakk, B., and Romner, B. (1997). Age- and sex-related changes of
S-100 protein concentrations in cerebrospinal fluid and serum in patients with
no previous history of neurological disorder. Clin. Chem. 43, 541–543. doi: 10.
1016/s0303-8467(97)81581-8
Nyquist, P. A., Bilgel, M., Gottesman, R., Yanek, L. R., Moy, T. F., Becker, L. C.,
et al. (2015). Age differences in periventricular and deep white matter lesions.
Neurobiol. Aging 36, 1653–1658. doi: 10.1016/j.neurobiolaging.2015.01.005
Park, J. H., Lee, J. J., Lee, S. B., Huh, Y., Choi, E. A., Youn, J. C., et al. (2010).
Prevalence of major depressive disorder and minor depressive disorder in an
elderly Korean population: Results from the Korean Longitudinal Study on
Health and Aging (KLoSHA). J. Affect. Disord. 125, 234–240. doi: 10.1016/j.
jad.2010.02.109
Polyakova, M., Stuke, K., Schuemberg, K., Mueller, K., Schoenknecht, P., and
Schroeter, M. L. (2015). BDNF as a biomarker for successful treatment of
mood disorders: a systematic & quantitative meta-analysis. J. Affect. Disord.
174, 432–440. doi: 10.1016/j.jad.2014.11.044
Portela, L. V., Tort, A. B., Schaf, D. V., Ribeiro, L., Nora, D. B., Walz, R., et al.
(2002). The serum S100B concentration is age dependent. Clin. Chem. 48,
950–952.
Rajkowska, G. (2000). Postmortem studies in mood disorders indicate altered
numbers of neurons and glial cells. Biol. Psychiatry 48, 766–777. doi: 10.
1016/s0006-3223(00)00950-1
Schmidt, F. M., Mergl, R., Stach, B., Jahn, I., and Schoenknecht, P. (2015). Elevated
levels of cerebrospinal fluid neuron-specific enolase (NSE), but not S100B
in major depressive disorder. World J. Biol. Psychiatry 16, 106–113. doi: 10.
3109/15622975.2014.952776
Schroeter, M. L., Abdul-Khaliq, H., Diefenbacher, A., and Blasig, I. E. (2002).
S100B is increased in mood disorders and may be reduced by antidepressive
treatment. Neuroreport 13, 1675–1678. doi: 10.1097/00001756-200209160-
00021
Schroeter, M. L., Abdul-Khaliq, H., Krebs, M., Diefenbacher, A., and Blasig,
I. E. (2008). Serum markers support disease-specific glial pathology in major
depression. J. Affect. Disord. 111, 271–280. doi: 10.1016/j.jad.2008.03.005
Schroeter, M. L., Sacher, J., Steiner, J., Schoenknecht, P., and Mueller, K. (2013).
Serum S100B represents a new biomarker for mood disorders. Curr. Drug
Targets 14, 1237–1248. doi: 10.2174/13894501113149990014
Schroeter, M. L., and Steiner, J. (2009). Elevated serum levels of the glial marker
protein S100B are not specific for schizophrenia or mood disorders. Mol.
Psychiatry 14, 235–237. doi: 10.1038/mp.2008.85
Schroeter, M. L., Steiner, J., and Mueller, K. (2011). Glial pathology is modified
by age in mood disorders - a systematic meta-analysis of serum S100B in vivo
studies. J. Affect. Disord. 134, 32–38. doi: 10.1016/j.jad.2010.11.008
Steiner, J., Schiltz, K., Walter, M., Wunderlich, M. T., Keilhoff, G., Brisch, R., et al.
(2010a). S100B serum levels are closely correlated with body mass index: an
important caveat in neuropsychiatric research. Psychoneuroendocrinology 35,
321–324. doi: 10.1016/j.psyneuen.2009.07.012
Steiner, J., Walter, M., Guest, P., Myint, A. M., Schiltz, K., Panteli, B., et al. (2010b).
Elevated S100B levels in schizophrenia are associated with insulin resistance.
Mol. Psychiatry 15, 3–4. doi: 10.1038/mp.2009.87
Streitbuerger, D.-P., Arelin, K., Kratzsch, J., Thiery, J., Steiner, J., Villringer,
A., et al. (2012). Validating serum S100B and neuron-specific enolase as
biomarkers for the human brain - a combined serum, gene expression
and MRI study. PLoS One 7:e43284. doi: 10.1371/journal.pone.00
43284
Taylor, W. D. (2014). Clinical practice. Depression in the elderly. N. Engl. J. Med.
371, 1228–1236. doi: 10.1056/NEJMcp1402180
Taylor, W. D., Aizenstein, H. J., and Alexopoulos, G. S. (2013). The vascular
depression hypothesis: mechanisms linking vascular disease with depression.
Mol. Psychiatry 18, 963–974. doi: 10.1038/mp.2013.20
van Engelen, B. G., Lamers, K. J., Gabreels, F. J., Wevers, R. A., Van Geel, W. J.,
and Borm, G. F. (1992). Age-related changes of neuron-specific enolase, S-100
protein and myelin basic protein concentrations in cerebrospinal fluid. Clin.
Chem. 38, 813–816.
Wiesmann, M., Missler, U., Gottmann, D., and Gehring, S. (1998). Plasma S-100b
protein concentration in healthy adults is age- and sex-independent. Clin.
Chem. 44, 1056–1058.
Yang, K., Xie, G.-R., Hu, Y.-Q., Mao, F.-Q., and Su, L.-Y. (2008). The effects of
gender and numbers of depressive episodes on serum S100B levels in patients
with major depression. J. Neural Transm. 115, 1687–1694. doi: 10.1007/s00702-
008-0130-8
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Polyakova, Sander, Arelin, Lampe, Luck, Luppa, Kratzsch,
Hoffmann, Riedel-Heller, Villringer, Schoenknecht and Schroeter. This is an open-
access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution and reproduction in other forums is
permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 October 2015 | Volume 9 | Article 406
96
The letter to editor No Changes in Gray Matter Density or Cortical Thickness in Late-
Life Minor Depression is published open access on the website of Journal of clinical 
psychiatry. 
 
The Journal of Clinical Psychiatry does not allow publication of this letter in the online 

















97 - 108 
 
3. GENERAL DISCUSSION 
In the framework of the current thesis significance and biological correlates of minor 
depression, a subthreshold depressive disorder, as categorized by the DSM-IV were 
investigated. The experimental results are discussed in detail in respective sections. The 
discussion section will summarize important findings of our studies.  Thereafter, the 
discussion will focus on limitations of this work, implications for research, clinical practice 
and general conclusions. 
 
3.1 Summary of results  
Prevalence of minor depression 
Results of the systematic review showed that minor depression is highly prevalent in 
late life. It often accompanies somatic and cognitive disorders. The highest prevalence of 
minor depression is observed in institutionalized patients (14.4%) and patients with mild 
cognitive impairment (20-26%). At the same time, only about half of the minor depression 
cases are recognized by medical staff (nurses and general practitioners)52-54. Patients with 
minor depression have a higher risk for developing a major depressive disorder55 or even 
progression of the comorbid cognitive impairment to dementia56-58. 
 
Biomarker of neurotrophic and glial function in major and minor depression 
BDNF, a biomarker of neurotrophic function, is one of the most consistent biomarkers of 
mood disorders.  In our meta-analytical study, significantly decreased peripheral BDNF 
levels were observed in acute major depression and acute states of bipolar disorder as 
compared to healthy controls. This difference was not anymore significant when patients 
reached euthymic state. Furthermore, for the first time on the meta-analytical level, the 
exclusive increment of serum BDNF in responders to antidepressive medication was 
shown, while in non-responders BDNF levels did not change as compared to baseline. 
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Therefore, serum BDNF may be considered a state marker and a marker of treatment 
response in major depression. 
In clinical practice, one of the most efficient treatment methods for non-responders to 
antidepressive drugs is electro-convulsive therapy (ECT). We performed a translational 
meta-analysis investigating effects of ECT on BDNF. We demonstrated a similar pattern of 
BDNF expression in mouse and human brains, based on the data from the Allen Brain 
Atlas (www.brain-map.org/). Further, we showed that ECT leads to increased BDNF 
expression in the rodent brain without impact on peripheral BDNF concentrations. We 
could not observe changes of peripheral BDNF concentrations in patients that underwent 
electro-convulsive treatment. Based on the animal studies we conclude, that absence of 
peripheral BDNF changes does not imply that there are no changes in the brain and even 
if we do not see changes of peripheral BDNF in humans, some changes can still occur in 
the brain.  
 
Serum biomarkers in minor depression 
The analysis of serum biomarkers of depression did not reveal any major alterations in 
subjects with minor depression. Contrary to the main hypothesis we did not see any 
significant decrease of BNDF in minor depression. The increment of S100B was observed 
only in a small group of men with minor depression. Serum NSE levels were comparable 
between the groups as expected. These results confirm absence of neuronal damage and 
major alterations of neurotrophic function in the brain. Along with our hypothesis signs of 
early glial dysfunction were observed in men. However, this finding still needs further 
replication in larger samples. 
 
Structural brain correlates of minor depression 
In the fifth chapter structural brain scans of patients with minor depression and healthy 
controls were compared. Several parameters such as whole brain gray matter density, 
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region of interest analysis of gray matter density and cortical thickness. Despite thorough 
analyses no significant differences were detected between the groups. Therefore, the 
conclusion is - there is not enough evidence for structural brain alterations in late life minor 
depression. 
 
     Implications for research  
The limitations of the experimental work were described in detail in each individual 
study. Accordingly, this chapter focuses more on general issues that were faced during 
this work, and on future directions.  
 
Subjects’ selection 
Firstly, data from the population-based LIFE study were used. The study involved two 
days of extensive clinical assessments, cognitive tests and multi-modal MRI. After 
completion of the first round of assessments a selection bias became evident, with the 
predominant selection of high functioning elderly individuals in LIFE cohort. This led to 
lower than expected prevalence of minor depression (about 5% of the population). 
Furthermore, two thirds of subjects with minor depression did not complete the MRI 
scanning. In the end the expected number of 200 participants shrank to 38 subjects with 
minor depression. In future studies on minor or subthreshold depression other sources and 
ways of recruitment would be recommended. These could be patients recruited at 
ambulatory psychiatric clinics, hospitalized patients or patients from nursing homes. 
 
Biomarkers 
Due to time constraints we measured serum biomarkers only in half of the subjects with 
minor depression. As the LIFE study recruitment was finished, and new subjects arrived, it 
was difficult to quantify serum biomarkers in remaining subjects reliably exactly fitting first 
measurements. In the biomarker studies it is very important to use exactly the same 
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measurement procedures, including laboratory kits, standard proteins etc. Minor changes 
due to laboratory conditions might influence statistical analysis. Therefore, we recommend 
to measure serum biomarkers in one batch as soon as all probes are collected.  
 
Statistics  
In our small population all biomarkers were non-normally distributed. Blood biomarker 
levels often have non-normal distribution even in large populations. In case of any 
additional variable (such as sex in our case), that is needed to be controlled in the model, 
statistical test selection becomes very difficult. Therefore, accounting for a non-normal 
distribution and controlling for all confounding variables is necessary already at the study 
design level. 
In our experimental work we faced the multiple comparisons problem and learned 
multiple opinions on this issue. For future studies interested in multiple parameters we 
recommend to state clearly whether the study is exploratory or not and use the False 
Discovery Rate (FDR) correction. This correction is appropriate from the statistical point of 
view and clearly informs the reader about evidence level of the study. 
 
Neuroimaging  
Current neuroimaging has a wide range of modalities. For example, gray matter density, 
volume, surface or the cortical thickness can be measured in the same scan. The selection 
of the imaging modality remains to be at a certain point intuitive. However, the evidence 
shows that not every modality is suitable for every study59. In case of minor depression, 
the available neuroimaging data was very limited. In such cases we recommend to use the 
exploratory approach with several modalities and clearly state it in the publication.  
Replication of these findings will be the task of further research. 
The power of neuroimaging studies is a well-known issue. Nevertheless many studies 
are planned without power estimation. During our work we understood that, while in the 
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regular statistics the tools are available to calculate the power, for the neuroimaging 
analyses such tools are still scarce and very difficult to implement. Therefore, such tools 
are an unmet need in the light of the current replication crisis in neuroimaging. 
 
3.2  Implications for clinical practice 
In our study we observed a number of non-significant findings. Still, there are some 
implications that could be proposed for clinical practice. 
First of all, it is necessary to inform medical staff of nursing homes and somatic 
departments of the frequent co-occurence of minor depression, train them to diagnose it 
and provide help. For this, special trainings should be organized and printed materials 
distributed.    
Though our results are partly negative and, from a statistical point of view, 
uninterpretable, they might also show that no major pathology is present in minor 
depression.  In the light of absent clinical studies for the biologically driven treatment of 
minor depression64 our study suggests such easy accessible and cheap intervention as 
physical exercise might be of choice. 
 
3.3  Conclusions 
The nature and course of minor depression is not yet understood. However, the clinical 
significance is substantial. The clinical closeness to major depression makes minor 
depression a good candidate model for the search of early alterations related to 
depressive disorders. Heterogeneity, disagreement on thresholds and poor diagnostics, on 
the other hand, cause difficulties in research. 
In this thesis we used a systematic approach to determine clinical features and neural 
correlates of minor depression. We used the best available diagnostic interview and 
identified subjects from the general population. Despite benefits of the screening of large 
population, the missing neuroimaging data has substantially reduced our sample size. 
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Nevertheless, our cohort was the largest to date investigating minor depression. We 
formed our hypotheses based on large scale meta-analyses of biomarker studies and 
neuroimaging data in major depressive disorder. However, in minor depression only few 
features resembled the pathology observed in major depressive disorder. While no 
structural changes were observed in minor depression, our data indicate that subtle 
changes of glial and neurotrophic function might be present.  
Current classification systems have stepped away from the term “minor depression”, 
shifting to a dimensional approach in case of ICD-11, or refining earlier categorical 
thresholds in case of DSM-5. Regardless of the future categorization of subthreshold 
depressive disorders, minor depression provides a valuable model for early clinical 
research due to the inclusion of core depressive symptoms. We recommend adhering to 
this feature in future studies, along with rigorous clinical diagnostics. Our contributions to 
the glial and neurotrophic hypotheses of depression might become a starting point for 
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Our first study shows that, the minor depression affects nearly ten percent of 
elderly population. Its median prevalence increases in hospitalized and 
institutionalized patients and, especially, in patients with co-morbid mild cognitive 
impairment. Nearly half of minor depression cases are not recognized by the medical 
staff, and its pathophysiology remains largely unexplored. To address the latter, in 
the current thesis we tested the neurotrophic and glial hypotheses of mood disorders 
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in subjects with minor depression. Further, we looked for structural brain changes 
and markers of neuronal damage in subjects with minor depression. 
In the second study, we addressed the neurotrophic hypothesis of mood 
disorders. This hypothesis attributes an onset of depressive disorder to the impaired 
secretion of Brain Derived Neurotrophic Factor (BDNF), leading to reduced neuronal 
plasticity. Our meta-analyses confirmed that serum and plasma BDNF levels 
decreased in acute depressive episodes, and were similar between healthy subjects 
and patients in euthymic state. The unique finding of our meta-analysis is that serum 
BDNF increased only in responders to antidepressant treatment and remained stable 
in non-responders. Therefore, serum BDNF is of interest as a potential marker of 
clinical response to the antidepressant treatment.  
In the third study, we investigated whether BDNF may also mark the response 
to the Electro-Convulsive Therapy (ECT), which is widely used for the treatment 
resistant depression. Since, BDNF has a similar topographic pattern of gene 
expression in rodent and human brains; we investigated BDNF changes following 
ECT in human and rodens.  In series of translational meta-analyses peripheral BDNF 
did change significantly following ECT, neither in rodents and nor humans.  However, 
despite the unchanged BDNF in the blood, its brain synthesis (both mRNA and 
protein) had significantly increased. Hence, the absence of BDNF changes in the 
blood does not mean the absence of BDNF changes in the brain.  
In the fourth study, we assessed the serum levels of markers of neurotrophic 
(BDNF) and glial (S100B) function, and neuronal damage (Neuron Specific  Enolase, 
NSE) in subjects with minor depression and healthy controls. Serum levels of BDNF 
and NSE were not altered in subject with minor depression. In this study, we 
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observed increased serum levels of glial marker S100B in a subgroup of males with 
minor depression. This finding is in line with the described early glial changes in 
depressive disorders, and should be investigated further. 
In the fifth study, we applied three different methods to assess structural gray 
matter changes in minor depression. Neither in the Voxel-Based Morphometry (VBM) 
analysis, nor in the Region-of-Interest (ROI) approach within the meta-analytically 
derived mask, nor in the analysis of cortical thickness had we observed gray matter 
alterations. In the statistical sense, our finding cannot be interpreted, as “the absence 
of evidence is not the evidence of absence”. However, taking the broader perspective 
and very small effect sizes of cortical atrophy in major depression (the largest 
g=0,138 as reported by a recent powerful meta-analysis), one may speculate that 
clinical symptoms precede visible on the Magnetic Resonance Imaging (MRI) gray 
matter alterations in depressive disorders.  
Taken together, the minor depression is highly prevalent in the late life and, thus, 
should not be ignored. The construct of minor depression provides an in vivo model 
for detection of early changes in depressive disorders. In the current thesis, we did 
not find any significant evidence for decreased serum BDNF, NSE or gray matter 
parameters. However, we found an increment of serum S100B, supporting the glial 
hypothesis of depression.  
Future studies on minor and subthreshold depression should aim for larger 
sample sizes. Classification systems should seek agreement on definitions. 
Together, these improvements will build a reliable base for the search of 







1. Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJL et al. Burden of 
Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of 
Disease Study 2010. Plos Medicine 2013; 10(11): 12. 
 
2. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE et al. Global 
burden of disease attributable to mental and substance use disorders: findings from the 
Global Burden of Disease Study 2010. Lancet 2013; 382(9904): 1575-1586. 
 
3. APA. Diagnostic and statistical manual of mental disorders (4th ed., text revision). 
Washington, DC: Author, 2000. 
 
4. APA. Diagnostic and statistical manual of mental disorders. - Washington, DC [u.a.] : 
American Psychiatric Association. 2013. 
 
5. Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B et al. Age- and gender-
specific prevalence of depression in latest-life - Systematic review and meta-analysis. 
Journal of Affective Disorders 2012; 136(3): 212-221. 
 
6. Buechtemann D, Luppa M, Bramesfeld A, Riedel-Heller S. Incidence of late-life depression: 
A systematic review. Journal of Affective Disorders 2012; 142(1-3): 172-179. 
 
7. Organization WH. The ICD-10 classification of mental and behavioural disorders: clinical 
descriptions and diagnostic guidelines. WHON, Geneva, 1992. 
 
8. Heun R, Papassotiropoulos A, Ptok U. Subthreshold depressive and anxiety disorders in 
the elderly. European Psychiatry 2000; 15(3): 173-182. 
 
9. Gabryelewicz T, Styczynska M, Pfeffer A, Wasiak B, Barczak A, Luczywek E et al. 
Prevalence of major and minor depression in elderly persons with mild cognitive impairment 
- MADRS factor analysis. International Journal of Geriatric Psychiatry 2004; 19(12): 1168-
1172. 
 
10. Park JH, Lee JJ, Lee SB, Huh Y, Choi EA, Youn JC et al. Prevalence of major depressive 
disorder and minor depressive disorder in an elderly Korean population: Results from the 
Korean Longitudinal Study on Health and Aging (KLoSHA). Journal of Affective Disorders 
2010; 125(1-3): 234-240. 
 
11. Meeks TW, Vahia IV, Lavretsky H, Kulkarni G, Jeste DV. A tune in "a minor" can "b major": 
a review of epidemiology, illness course, and public health implications of subthreshold 
depression in older adults. J Affect Disord 2011; 129(1-3): 126-142. 
 
12. Eaton WW, Badawi M, Melton B. Prodromes and precursors - epidemiologic data for 





13. Lyness JM, Caine ED, King DA, Conwell Y, Cox C, Duberstein PR. Cerebrovascular risk 
factors and depression in older primary care patients: testing a vascular brain disease 
model of depression. Am J Geriatr Psychiatry 1999; 7(3): 252-258. 
 
14. Kumar A, Ajilore O, Zhang AF, Pham D, Elderkin-Thompson V. Cortical Thinning in 
Patients with Late-Life Minor Depression. American Journal of Geriatric Psychiatry 2014; 
22(5): 459-464. 
 
15. Kumar A, Jin ZS, Bilker W, Udupa J, Gottlieb G. Late-onset minor and major depression: 
early evidence for common neuroanatomical substrates detected by using MRI. 
Proceedings of the National Academy of Sciences of the United States of America 1998; 
95(13): 7654-7658. 
 
16. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: Review 
and meta-analysis. American Journal of Psychiatry 2000; 157(10): 1552-1562. 
 
17. Sullivan PF, Daly MJ, Ripke S, Lewis CM, Lin DY, Wray NR et al. A mega-analysis of 
genome-wide association studies for major depressive disorder. Molecular Psychiatry 2013; 
18(4): 497-511. 
 
18. O'Donovan MC, Owen MJ. The implications of the shared genetics of psychiatric disorders. 
Nature Medicine 2016; 22(11): 1214-1219. 
 
19. Pettersson E, Larsson H, Lichtenstein P. Common psychiatric disorders share the same 
genetic origin: a multivariate sibling study of the Swedish population. Molecular Psychiatry 
2016; 21(5): 717-721. 
 
20. Oxenkrug G. Serotonin - Kynurenine Hypothesis of Depression: Historical Overview and 
Recent Developments. Current Drug Targets 2013; 14(5): 514-521. 
 
21. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. 
Biological Psychiatry 2006; 59(12): 1116-1127. 
 
22. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support 
disease-specific glial pathology in major depression. J Affect Disord 2008; 111(2-3): 271-
280. 
 
23. Schmidt HD, Duman RS. The role of neurotrophic factors in adult hippocampal 
neurogenesis, antidepressant treatments and animal models of depressive-like behavior. 
Behavioural Pharmacology 2007; 18(5-6): 391-418. 
 
24. Neto FL, Borges G, Torres-Sanchez S, Mico JA, Berrocoso E. Neurotrophins Role in 
Depression Neurobiology: A Review of Basic and Clinical Evidence. Current 
Neuropharmacology 2011; 9(4): 530-552. 
 
25. Chopra K, Kumar B, Kuhad A. Pathobiological targets of depression. Expert Opinion on 
Therapeutic Targets 2011; 15(4): 379-400. 
 
26. Wang L, Leonards CO, Sterzer P, Ebinger M. White matter lesions and depression: A 




27. Iwabuchi SJ, Krishnadas R, Li C, Auer DP, Radua J, Palaniyappan L. Localized 
connectivity in depression: A meta-analysis of resting state functional imaging studies. 
Neuroscience and Biobehavioral Reviews 2015; 51: 77-86. 
 
28. Wen MC, Steffens DC, Chen MK, Zainal NH. Diffusion tensor imaging studies in late-life 
depression: systematic review and meta-analysis. International Journal of Geriatric 
Psychiatry 2014; 29(12): 1173-1184. 
 
29. Choi KS, Rajendra J, Dunlop B, Mayberg H. Clinical Staging of Major Depression: 
Multimodal-Imaging Approach. Biological Psychiatry 2017; 81(10): S241-S242. 
 
30. Hilbert K, Lueken U, Muehlhan M, Beesdo-Baum K. Separating generalized anxiety 
disorder from major depression using clinical, hormonal, and structural MRI data: A 
multimodal machine learning study. Brain and Behavior 2017; 7(3). 
 
31. MacQueen GM, Ramakrishnan K, Croll SD, Siuciak JA, Yu G, Young LT et al. Performance 
of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues 
of anxiety, nociception, and depression. Behav Neurosci 2001; 115(5): 1145-1153. 
 
32. Song L, Che W, Min-Wei W, Murakami Y, Matsumoto K. Impairment of the spatial learning 
and memory induced by learned helplessness and chronic mild stress. Pharmacol Biochem 
Behav 2006; 83(2): 186-193. 
 
33. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. 
Archives of General Psychiatry 1997; 54(7): 597-606. 
 
34. Shimizu E, Hashimoto K, Komatsu N, Nakazato M, Kobayashi K, Okamura N et al. SERUM 
LEVELS OF BRAIN - DERIVED NEUROTROPHIC FACTOR ( BDNF ) IN DEPRESSION, 
PANIC DISORDER AND SCHIZOPHRENIA. Society for Neuroscience Abstract Viewer and 
Itinerary Planner 2002; 2002: Abstract No. 803.813-Abstract No. 803.813. 
 
35. Lang UE, Hellweg R, Gallinat J. BDNF serum concentrations in healthy volunteers are 
associated with depression-related personality traits. Neuropsychopharmacology 2004; 
29(4): 795-798. 
 
36. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum 
brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog 
Neuropsychopharmacol Biol Psychiatry 2005; 29(2): 261-265. 
 
37. Manji HK, Moore GJ, Rajkowska G, Chen G. Neuroplasticity and cellular resilience in mood 
disorders. Molecular Psychiatry 2000; 5(6): 578-593. 
 
38. Schroeter ML, Sacher J, Steiner J, Schoenknecht P, Mueller K. Serum S100B Represents 
a New Biomarker for Mood Disorders. Current Drug Targets 2013; 14(11): 1237-1248. 
 
39. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons 




40. Schroeter ML, Steiner J, Mueller K. Glial pathology is modified by age in mood disorders - 
A systematic meta-analysis of serum S100B in vivo studies. Journal of Affective Disorders 
2011; 134(1-3): 32-38. 
 
41. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support 
disease-specific glial pathology in major depression. Journal of Affective Disorders 2008; 
111(2-3): 271-280. 
 
42. Taylor WD, Aizenstein HJ, Alexopoulos GS. The vascular depression hypothesis: 
mechanisms linking vascular disease with depression. Molecular Psychiatry 2013; 18(9): 
963-974. 
 
43. Wise T, Radua J, Via E, Cardoner N, Abe O, Adams TM et al. Common and distinct 
patterns of grey-matter volume alteration in major depression and bipolar disorder: 
evidence from voxel-based meta-analysis. Molecular Psychiatry 2017; 22(10): 1455-1463. 
 
44. Zhang HW, Li L, Wu M, Chen ZQ, Hu XY, Chen Y et al. Brain gray matter alterations in first 
episodes of depression: A meta-analysis of whole-brain studies. Neuroscience and 
Biobehavioral Reviews 2016; 60: 43-50. 
 
45. Wang WN, Zhao YJ, Hu XY, Huang XQ, Kuang WH, Lui S et al. Conjoint and dissociated 
structural and functional abnormalities in first-episode drug-naive patients with major 
depressive disorder: a multimodal meta-analysis. Scientific Reports 2017; 7. 
 
46. Zhao YJ, Du MY, Huang XQ, Lui S, Chen ZQ, Liu J et al. Brain grey matter abnormalities in 
medication-free patients with major depressive disorder: a meta-analysis. Psychological 
Medicine 2014; 44(14): 2927-2937. 
 
47. Sacher J, Neumann J, Funfstuck T, Soliman A, Villringer A, Schroeter ML. Mapping the 
depressed brain: A meta-analysis of structural and functional alterations in major 
depressive disorder. Journal of Affective Disorders 2012; 140(2): 142-148. 
 
48. Schmaal L, Hibar DP, Samann PG, Hall GB, Baune BT, Jahanshad N et al. Cortical 
abnormalities in adults and adolescents with major depression based on brain scans from 
20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Molecular 
Psychiatry 2017; 22(6): 900-909. 
 
49. Taki Y, Kinomura S, Awata S, Inoue K, Sato K, Ito H et al. Male elderly subthreshold 
depression patients have smaller volume of medial part of prefrontal cortex and precentral 
gyrus compared with age-matched normal subjects: A voxel-based morphometry. Journal 
of Affective Disorders 2005; 88(3): 313-320. 
 
50. Yoshikawa E, Matsuoka Y, Yamasue H, Inagaki M, Nakano T, Akechi T et al. Prefrontal 
cortex and amygdala volume in first minor or major depressive episode after cancer 
diagnosis. Biological Psychiatry 2006; 59(8): 707-712. 
 
51. Besteher B, Gaser C, Langbein K, Dietzek M, Sauer H, Nenadic I. Effects of subclinical 
depression, anxiety and somatization on brain structure in healthy subjects. Journal of 




52. Teresi J, Abrams R, Holmes D, Ramirez M, Eimicke J. Prevalence of depression and 
depression recognition in nursing homes. Social Psychiatry and Psychiatric Epidemiology 
2001; 36(12): 613-620. 
 
53. Brown EL, McAvay G, Raue PJ, Moses S, Bruce ML. Recognition of depression among 
elderly recipients of home care services. Psychiatric Services 2003; 54(2): 208-213. 
 
54. Cepoiu M, McCusker J, Cole MG, Sewitch M, Ciampi A. Recognition of depression in older 
medical inpatients. Journal of General Internal Medicine 2007; 22(5): 559-564. 
 
55. Lyness JM, King DA, Cox C, Yoediono Z, Caine ED. The importance of subsyndromal 
depression in older primary care patients: Prevalence and associated functional disability. 
Journal of the American Geriatrics Society 1999; 47(6): 647-652. 
 
56. Berger AK FL, Forsell Y, et al. The occurrence of depressive symptoms in the preclinical 
phase of AD: a populationbased study. Neurology 1999; 53: 1998–2002. 
 
57. Modrego PJ, Ferrandez J. Depression in patients with mild cognitive impairment increases 
the risk of developing dementia of Alzheimer type - A prospective cohort study. Archives of 
Neurology 2004; 61(8): 1290-1293. 
 
58. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Del Parigi A, Caselli RJ et al. Incident 
occurrence of depressive symptoms among patients with mild cognitive impairment the 
Italian Longitudinal Study on Aging. Dementia and Geriatric Cognitive Disorders 2007; 
24(1): 55-64. 
 
59. Winkler AM, Kochunov P, Blangero J, Almasy L, Zilles K, Fox PT et al. Cortical thickness or 
grey matter volume? The importance of selecting the phenotype for imaging genetics 
studies. Neuroimage 2010; 53(3): 1135-1146. 
 
60. Marosi K, Mattson MP. BDNF mediates adaptive brain and body responses to energetic 
challenges. Trends in Endocrinology and Metabolism 2014; 25(2): 89-98. 
 
61. Szuhany KL, Bugatti M, Otto MW. A meta-analytic review of the effects of exercise on 
brain-derived neurotrophic factor. Journal of Psychiatric Research 2015; 60: 56-64. 
 
62. Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T et al. Exercise 
promotes the expression of brain derived neurotrophic factor (BDNF) through the action of 
the ketone body beta-hydroxybutyrate. Elife 2016; 5. 
 
63. Halagappa VKM, Guo ZH, Pearson M, Matsuoka Y, Cutler RG, LaFerla FM et al. 
Intermittent fasting and caloric restriction ameliorate age-related behavioral deficits in the 
triple-transgenic mouse model of Alzheimer's disease. Neurobiology of Disease 2007; 
26(1): 212-220. 
 
64. Hegerl U SP. Subdiagnostic depression. Are there treatments with clinically relevant 












STATEMENT OF AUTHORSHIP 
I confirm that, to the best of my knowledge, the doctoral dissertation represents my 
own work and was prepared independently without any impermissible help or sources. I 
assure that third parties have not received indirect or direct monetary incentives for work in 
connection the contents of the present dissertation, and that the doctoral dissertation 
contains no material which has been presented for the award of any other degree or diploma 
in any other university, tertiary education institution, and national or foreign examination 
board. I certify that to the best of my knowledge and belief, this doctoral dissertation contains 
no material previously published or written by another person, except where due reference 
has been made in the text. All persons directly involved in the present work have been 
indicated by name. The current legal standards with regard to clinical studies, animal 
welfare, genetic engineering as well as data protection regulations have not been violated. 
I assure to know and to adhere to the regulations of good scientific practice of the University 
of Leipzig. 
Erklärung über die eigenständige Abfassung der Arbeit 
Hiermit erkläre ich, dass ich die vorliegende Arbeit selbstständig und ohne unzulässige Hilfe oder Benutzung 
anderer als der angegebenen Hilfsmittel angefertigt habe. Ich versichere, dass Dritte von mir weder unmittelbar 
noch mittelbar eine Vergütung oder geldwerte Leistungen für Arbeiten erhalten haben, die im Zusammenhang 
mit dem Inhalt der vorgelegten Dissertation stehen, und dass die vorgelegte Arbeit weder im Inland noch im 
Ausland in gleicher oder ähnlicher Form einer anderen Prüfungsbehörde zum Zweck einer Promotion oder 
eines anderen Prüfungsverfahrens vorgelegt wurde. Alles aus anderen Quellen und von anderen Personen 
übernommene Material, das in der Arbeit verwendet wurde oder auf das direkt Bezug genommen wird, wurde 
als solches kenntlich gemacht. Insbesondere wurden alle Personen genannt, die direkt an der Entstehung der 
vorliegenden Arbeit beteiligt waren. Die aktuellen gesetzlichen Vorgaben in Bezug auf die Zulassung der 
klinischen Studien, die Bestimmungen des Tierschutzgesetzes, die Bestimmungen des Gentechnikgesetzes 
und die allgemeinen Datenschutzbestimmungen wurden eingehalten. Ich versichere, dass ich die Regelungen 











Name                           Polyakova Maryna 
Date of birth               November, 23rd, 1984 
Place of birth              Khmelnytskyi, Ukraine 
 
Work Experience 
Since 12/2012           Max Planck Institute for Human Cognitive and Brain Sciences, 
                                     Leipzig, Germany, Research group Cognitive Neuropsychiatry 
                                     University Clinic for psychiatry and Psychotherapy, Leipzig 
                                     University, Leipzig, Germany 
                                      Doctoral student 
06/2011-11/2012      Vienna medical University, Vienna, Austria 
                                      Neuroproteomics laboratory of Prof. Gert Lubec 
                                      Research Fellow                                                
02/2011 – 05/2011   Khmelnytskyi Regional Psychiatric Hospital, Khmelnytskyi,                                                               
                                     Ukraine 
                                     Psychiatrist  
 
Education 
08/2009 – 01/2011   Juschenko Winnytsya Regional Psychiatric Hospital,  
                                     Winnytsya, Ukraine 
                                     Specialization in Psychiatry 
09/2003 – 06/2009  Winnytsya National Medical University named after M. Pyrogov, 
                                     Winnytsya, Ukraine 
                                     Medicine 
09/2000 – 06/2003   Khmelnytskyi Medical College, Khmelnytskyi, Ukraine 
                                      Nursing 
09/1996 – 05/2000   Khmelnytskyi Gymnasium #1 , Khmelnytskyi, Ukraine 







1. Polyakova M, Sonnabend N, Sander C, Mergl R, Schroeter ML, Schroeder J et al. 
Prevalence of minor depression in elderly persons with and without mild cognitive 
impairment: A systematic review. Journal of Affective Disorders 2014; 152: 28-38. 
 
2. Polyakova M, Stuke K, Schuemberg K, Mueller K, Schoenknecht P, Schroeter ML. 
BDNF as a biomarker for successful treatment of mood disorders: A systematic & 
quantitative meta-analysis. Journal of Affective Disorders 2015; 174: 432-440. 
 
3. Polyakova M, Schroeter ML, Elzinga BM, Holiga S, Schoenknecht P, de Kloet ER et 
al. Brain-Derived Neurotrophic Factor and Antidepressive Effect of Electroconvulsive 
Therapy: Systematic Review and Meta-Analyses of the Preclinical and Clinical Literature. 
Plos One 2015; 10(11). 
 
4. Molendijk M, Polyakova M. The utility of a regression weight versus that of an F-
value. European Archives of Psychiatry and Clinical Neuroscience 2015; 265(4): 357-358. 
 
5. Schumberg K, Polyakova M, Steiner J, Schroeter ML. Serum S100B Is Related to 
Illness Duration and Clinical Symptoms in Schizophrenia - A Meta-Regression Analysis. 
Frontiers in Cellular Neuroscience 2016; 10. 
 
6. Polyakova M, Schlogl H, Sacher J, Schmidt-Kassow M, Kaiser J, Stumvoll M et al. 
Stability of BDNF in Human Samples Stored Up to 6 Months and Correlations of Serum 




7. Polyakova M, Sander C, Arelin K, Lampe L, Luck T, Luppa M et al. First evidence 
for glial pathology in late life minor depression: MOB is increased in males with minor 
depression. Frontiers in Cellular Neuroscience 2015; 9. 
 
8. Polyakova M, Mueller K, Sander C, Beyer F, Witte V, Lampe L et al. No Changes in 
Gray Matter Density or Cortical Thickness in Late-Life Minor Depression. The Journal of 
clinical psychiatry 2018; 79(2). 
 
9. Schroeter ML, Pawelke S, Bisenius S, Kynast J, Schuemberg K, Polyakova M et al. 
A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal 




1. Exploring the neural correlates of minor depression: a combined serum marker, 
VBM, DWI and resting state MRI study. M. Polyakova K. Mueller, C.Sander, 
N.Sonnabend, N.Mauche, R.Mergl, P. Schoenknecht and M. L.Schroeter IMPRS 
summer school, Leipzig 2013 
2. Computer - assisted volumetry of mammillary bodies in vivo using high resolution 7 
Tesla MRI in major depression and bipolar disorder S. Schindler, M. Polyakova, M. 
Kleinsorge, N. Freund, M. Strauß, P.-L. Bazin, U. Hegerl, R. Turner, S. Geyer, P. 
Schönknecht, DGPPN Congress, Berlin 2013 
3. Brain Derived Neurotrophic factor in mood disorders: meta-analysis of serum and 
plasma studies M.Polyakova, K.Stucke, K.Mueller, P.Schoenknecht and 
M.Schroeter, Research Festival, Medical Faculty of the Leipzig University, Leipzig 
2014 
4. Brain Derived Neurotrophic factor in mood disorders: meta-analysis of serum and 
plasma studies M.Polyakova, K.Stucke, K.Mueller, P.Schoenknecht and 
M.Schroeter, DGPPN Congress, Berlin, 2014 
5. Prevalence of minor depression in elderly persons with and without 
mild cognitive impairment: a systematic review M. Polyakova, N. Dreimueller, C. 
Sander, R. Mergl, ML Schroeter, J. Schroeder, P. Schoenknecht, European 
Psychiatry Association Congress (EPA), Munich, 2014 
133
6. Brain-derived neurotrophic factor and antidepressive effect of electroconvulsive 
therapy: systematic review and meta-analyses of the preclinical and clinical 
literature M. Polyakova, M. L. Schroeter, B. M. Elzinga, S. Holiga, P. Schoenknecht, 
E. R. De Kloet, M. L. Molendijk, DGPPN Congress, Berlin  2015 
7. Serum neuron-specific enolase is increased in mild neurocognitive disorder / mild 
cognitive impairment and related to white matter hyperintensities M. Polyakova, C. 
Sander, K. Arelin, L. Lampe, T. Luck, M. Luppa, J. Kratzsch, KT. Hoffmann, 
S.Riedel-Heller, A. Villringer, P. Schoenknecht and ML. Schroeter, FTLD 10th 
International Conference on Frontotemporal Dementias, Munich, 2016 
8. First evidence for glial pathology in late life minor depression: S100B is increased in 
males with minor depression M. Polyakova, C. Sander, K. Arelin, L. Lampe, T. 
Luck, M. Luppa, J. Kratzsch, KT. Hoffmann, S.Riedel-Heller, A. Villringer, P. 
Schoenknecht and ML. Schroeter, EPA Congress, Madrid, 2016 
9. Insufficient evidence for structural gray matter alterations in late life minor 
depression: results from LIFE-adult study. Maryna Polyakova, Christian Sander, 
Karsten Mueller, Katrin Arelin, Leonie Lampe, Karl-Titus Hoffmann, Arno Villringer, 
Matthias L. Schroeter, Peter Schoenknecht,  Deutsche Gesellschaft für Klinische 
Neurophysiologie und Funktionelle Bildgebung (DGKN), Leipzig, 2017 
10. First evidence for glial pathology in late life minor depression: S100B is increased in 
males with minor depression. Results from LIFE-adult study. Maryna Polyakova, 
Christian Sander, Katrin Arelin, Leonie Lampe, Tobias Luck, Melanie Luppa, Jürgen 
Kratzsch, Karl-Titus Hoffmann, Steffi Riedel-Heller, Arno Villringer, Peter 
Schoenknecht and Matthias L. Schroeter, Deutsche Gesellschaft für Klinische 
Neurophysiologie und Funktionelle Bildgebung (DGKN), Leipzig, 2017 
11. Does the DSM-5 neglect unaware patients with neurocognitive disorder? Maryna 
Polyakova, Jana Kynast, Francisca Then, Tobias Luck, Steffi Riedel-Heller, Arno 
Villringer, Peter Schoenknecht, Matthias L. Schroeter, 24th  International 
Symposium on Current Isues and Controversies in Psychiatry, "Crisis in 
Psychiatry?", Barcelona, 2017 
 
Awards 
1. A stipend from the Medical University of Vienna for the project “Protein kinases 
and phosphatases network in Alzheimer’s Disease”, Vienna, Austria 2011 
2. IMPRS NEUROCOM stipend for the PhD thesis “Neural correlates of lte life 
minor depression|, Leipzig, Germany, 2012  
134
3. Poster Prize for the Poster “Brain Derived Neurotrophic factor in mood 
disorders: meta-analysis of serum and plasma studies” Research Festival, 
Medical Faculty of the Leipzig University, Leipzig 2014 
4. Second Poster Prize for the Poster  “Does the DSM-5 neglect unaware patients 
with neurocognitive disorder?” 24th  International Symposium on Current Isues 





I want to thank people directly involved into this work, and those who supported me on 
the way to PhD. 
First of all to my supervisors. To Prof. Peter Schoenknecht, for choosing my CV from 
many others, for his support and optimism, despite obstacles. To Prof. Matthias Schroeter 
for guiding me during my work, for his attention to details and being responsive to my needs. 
I’m appreciate to Prof. Karsten Mueller for his methodological advice, openness and sharing 
his knowledge. I further thank Steffanie Schindler for always being critical and honest, 
listening to and commenting on my presentations. I thank my collaborator Dr. Marc 
Molendijk, for scientific discussions and joint projects.  
I thank all the people involved in LIFE project: Dr. Christian Sander and Dr. Roland 
Mergl; Dr. Veronica Witte, Frauke Beyer and Dr. Leonie Lample; Dr. Franzisca Then and 
Dr. Tobias Luck. As well as its permanent leaders Prof. Arno Villringer, Prof. Steffi Riedel-
Heller and Prof. Marcus Loeffler. I thank our research coordinators Dr. Antje Niven and Dr. 
Veronika Krieghoff, their advice and support. I also thank our research group members, the 
very encouraging environment of Max Planck Institute. Finally, I thank LIFE study 
participants for giving their time for the science. Many theses would not be possible without 
their help 
I am also very appreciate my family members for their support. First of all, to my 
husband for sharing all my worries, being my closest reviewer and advisor, and especially 
for taking care of our three little girls, when I was out for work. I thank my girls for inspiration; 
my mom, for giving me the education and providing space for dreams. And one last thank 
goes to my granddads,both examples of striving for knowledge men, who would be very 
happy to know that I have earned a doctorate. 
136
